<SEC-DOCUMENT>0000950170-24-007011.txt : 20240124
<SEC-HEADER>0000950170-24-007011.hdr.sgml : 20240124
<ACCEPTANCE-DATETIME>20240124163411
ACCESSION NUMBER:		0000950170-24-007011
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240122
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240124
DATE AS OF CHANGE:		20240124

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adicet Bio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38359
		FILM NUMBER:		24556928

	BUSINESS ADDRESS:	
		STREET 1:		200 BERKELEY STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		200 BERKELEY STREET
		STREET 2:		19TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	resTORbio, Inc.
		DATE OF NAME CHANGE:	20171024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>acet-20240122.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2024-01-24T16:05:14.5985+00:00 --><!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:acet="http://www.adicetbio.com/20240122" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_ef6ac5f9-f947-419d-a79c-4a18c68aaec1" name="dei:EntityCentralIndexKey" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca">0001720580</ix:nonNumeric><ix:nonNumeric id="F_b1c22b03-07f2-4268-8025-4cfce751c269" name="dei:AmendmentFlag" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca">false</ix:nonNumeric><ix:nonNumeric id="F_ef9b0e89-4d0c-4ea2-9a83-6aad9cfc0ace" name="dei:SecurityExchangeName" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca">NONE</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="acet-20240122.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-22</xbrli:startDate><xbrli:endDate>2024-01-22</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_39a2f78b-e8bc-4c38-8d3b-ec9e37b81e6b" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_8762b3e1-eb0e-4837-9bd9-531c79826349" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">January 22, 2024</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e3407cdd-bb3b-4476-9eb6-787e85ffefa0" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;"></td>
    <td style="width:1%;"></td>
    <td style="width:20%;"></td>
    <td style="width:18%;"></td>
    <td style="width:41%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_744e1d8f-b70c-4163-bce9-b4a5a302e9a4" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8370a4dc-5593-4a8c-8902-cda19f3ff01a" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-38359</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e041e51c-67c4-496e-8193-1bb3964fbe19" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">81-3305277</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction<br />of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3215cc56-b691-4326-b9ba-aad107bc9287" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">200 Berkeley Street, 19th Floor</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0341c563-d9e6-4669-9827-54da3b03ba81" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_6322aa18-a71f-40b1-85b9-244f77f38a48" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8991945f-dc3c-4e23-8fc9-5e1da0f2160e" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02116</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_0fc4a147-7ce3-4901-aaf1-29b5b7af99f1" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(650)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_f3b1b3db-68ba-466d-919f-a99836d3fb6f" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">503-9095</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7f26dad5-cd96-4e4d-a290-7f7d8a65f1fc" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Not applicable</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4af4b675-8b1d-426d-bcf4-fa3640b0881d" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f58ee7a4-a1e0-4788-9f16-942fd6bd5a03" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be0008b7-c378-4974-948f-987d302eb4bf" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2b192a8b-819e-43d4-9aa3-bf0e40aaeed7" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"></td>
    <td style="width:1%;"></td>
    <td style="width:15%;"></td>
    <td style="width:1%;"></td>
    <td style="width:45%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br />Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading<br />Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br />Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_bda3cfe4-c305-4189-bf26-8dcf0e7c0364" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0bb7303b-eb88-474e-8b6e-7f0e9a80e3c1" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ACET</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_ef9b0e89-4d0c-4ea2-9a83-6aad9cfc0ace;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Global Market</span></span></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x202f;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x202f;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_6a3b1a99-9a76-442e-8f2d-c404ae733b3a" contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1.01 Entry into a Material Definitive Agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 22, 2024, Adicet Bio, Inc. (the &#x201c;Company&#x201d;) entered into an Underwriting Agreement (the &#x201c;Underwriting Agreement&#x201d;) with Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters listed on Schedule A thereto (the &#x201c;Underwriters&#x201d;), related to an underwritten public offering (the &#x201c;Offering&#x201d;) of 27,054,667 shares (the &#x201c;Shares&#x201d;) of common stock of the Company, par value $0.0001 per share (the &#x201c;Common Stock&#x201d;), and, in lieu of Common Stock to an investor, pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase 8,445,333 shares of Common Stock (the &#x201c;Warrant Shares&#x201d;). The Shares are being sold at a public offering price of $2.40 per share and the Pre-Funded Warrants are being sold at a public offering price of $2.3999 per underlying share, which represents the per share public offering price of each share of common stock minus the $0.0001 per share exercise price for each pre-funded warrant. The purchase price to be paid by the Underwriters to the Company will be $2.256 per Share and $2.2559 per Pre-Funded Warrant, representing a discount to the Underwriters of 6.0%. In addition, the Company granted the Underwriters an option exercisable for 30 days from the date of the Underwriting Agreement to purchase, at the public offering price less underwriting discounts and commissions, up to an additional 5,325,000 shares of Common Stock. On January 23, 2024, the Underwriters exercised this option in full. The Company estimates net proceeds from the Offering, after deducting the underwriting discount and commissions and other estimated offering expenses, will be approximately $91.8 million. The Company may receive nominal proceeds, if any, from the exercise of the Pre-Funded Warrants. The Offering is expected to close on January 25, 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each Pre-Funded Warrant has an exercise price of $0.0001 per share. The exercise price and the number of shares of Common Stock issuable upon exercise of each Pre-Funded Warrant is subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock. Each Pre-Funded Warrant is exercisable from the date of issuance by means of a cashless exercise. Under the Pre-Funded Warrants, the Company may not effect the exercise of any Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Pre-Funded Warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of shares of Common Stock beneficially owned by the holder (together with its affiliates) to exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of the Company&#x2019;s securities beneficially owned by the holder (together with its affiliates) to exceed 9.99% of the combined voting power of all of the Company&#x2019;s securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants, unless such percentage is increased upon at least 61 days&#x2019; prior notice, but not in excess of 19.99%.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in certain circumstances, upon a fundamental transaction, a holder of Pre-Funded Warrants will be entitled to receive, upon exercise of the Pre-Funded Warrants, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Pre-Funded Warrants immediately prior to the fundamental transaction; provided, however, that in the event of a fundamental transaction where the consideration consists solely of cash, solely of marketable securities or a combination thereof, each Pre-Funded Warrant will be deemed to be exercised in full in a cashless exercise effective immediately prior to and contingent upon the consummation of such fundamental transaction.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company made certain customary representations, warranties and covenants concerning the Company and the registration statement in the Underwriting Agreement and also agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The Offering was made pursuant to the Company&#x2019;s shelf registration statement on Form S-3 (File No. 333-263587), filed with the Securities and Exchange Commission (the &#x201c;Commission&#x201d;) on March 15, 2022, as amended, and declared effective by the Commission on May 9, 2022, as supplemented by a final prospectus supplement, dated January 22, 2024 and filed with the Commission on January 24, 2024 (the &#x201c;Prospectus Supplement&#x201d;). This Current Report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy any of the shares of Common Stock or the Pre-Funded Warrants.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The foregoing description of certain terms of the Underwriting Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Underwriting Agreement, which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated by reference herein.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The foregoing description of certain terms of the form of Pre-Funded Warrant does not purport to be a complete statement of the rights and obligations of the parties thereto and the transactions contemplated thereby, and is qualified in its entirety by reference to the form of Pre-Funded Warrant, which is filed as Exhibit 4.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A copy of the legal opinion of Goodwin Procter LLP, relating to the legality of the issuance and sale of the shares of Common Stock and the Pre-Funded Warrants in this Offering, is filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated by reference herein.</span></p>
  <hr style="page-break-after:always;" />
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Offering, on January 22, 2024, the Company filed a preliminary prospectus supplement, which contained certain information regarding the Company&#x2019;s results of operations or financial condition for the year ended December 31, 2023. As disclosed in the preliminary prospectus supplement, as of December 31, 2023, the Company had $159.7 million of cash and cash equivalents.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This financial data as of December 31, 2023 is preliminary and may change, and is based on information available to management as of the filing date of the Prospectus Supplement and is subject to completion by management of the Company&#x2019;s financial statements as of and for the fiscal quarter and year ended December 31, 2023. There can be no assurance that the Company&#x2019;s final cash position as of December 31, 2023 will not differ from these estimates, including as a result of review adjustments and any such changes could be material. This preliminary estimate has been prepared by, and is the responsibility of, the Company&#x2019;s management and is based on a number of assumptions. The Company&#x2019;s independent registered public accountants have not audited, reviewed, compiled or performed any procedures with respect to such preliminary financial data as of and for the three months and the year ended December 31, 2023 and accordingly do not express an opinion or any other form of assurance with respect to this preliminary amount. These results could change as a result of further review. Complete results will be included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The information under Item 2.02 of this Current Report on Form 8-K is intended to be furnished and shall not be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8.01 Other Events.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 22, 2024, the Company issued a press release announcing the Offering. On January 22, 2024, the Company issued a press release announcing that it had priced the Offering. A copy of both press releases are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated by reference herein.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As disclosed in the Prospectus Supplement, as of December 31, 2023, the Company had $159.7 million of cash and cash equivalents. Since September 30, 2023, the Company has sold an aggregate of 6,350,000 shares of Common Stock in a series of &#x201c;at-the-market&#x201d; offerings in accordance with the Capital On Demand&#153; Sales Agreement, by and between the Company and JonesTrading Institutional Services, LLC, as sales agent, at an average price of $3.13 per share, resulting in aggregate net proceeds of approximately $19.3 million, after deducting sales agent commissions, but before deducting any expenses related to such sales.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cautionary Note Regarding Forward Looking Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Current Report on Form 8-K and certain of the materials filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the Offering. The words &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;plan,&#34; &#34;anticipate,&#34; &#34;intend,&#34; &#34;believe,&#34; &#34;expect,&#34; &#34;estimate,&#34; &#34;seek,&#34; &#34;predict,&#34; &#34;future,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;continue,&#34; &#34;target&#34; and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements, such as those related to the anticipated closing of the Offering and the potential exercise of the Pre-Funded Warrants, are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Current Report on Form 8-K or the materials furnished or filed herewith, including, without limitation, uncertainties related to market conditions and the completion of the Offering on the anticipated terms or at all. These and other risks and uncertainties are described in greater detail in the section entitled &#34;Risk Factors&#34; in the Company&#x2019;s most recent annual report on Form 10-K and its periodic reports on Form 10-Q and Form 8-K filed with the Commission, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Commission, including those contained or incorporated by reference in the Prospectus Supplement and accompanying prospectus related to the Offering filed with the Commission. In addition, any forward-looking statements represent the Company&#x2019;s views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <hr style="page-break-after:always;" />
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.04%;"></td>
    <td style="width:2.3%;"></td>
    <td style="width:90.66%;"></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="acet-ex1_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Underwriting Agreement, dated as of January 22, 2024, by and among the Company and Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters listed on Schedule A thereto</span></a></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="acet-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Pre-Funded Warrant</span></a></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.1</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="acet-ex5_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Opinion of Goodwin Procter LLP regarding the issue of Common Stock being registered</span></a></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="acet-ex5_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Goodwin Procter LLP (included in Exhibit 5.1)</span></a></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="acet-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press release announcing the Offering, dated January 22, 2024</span></a></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.2</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="acet-ex99_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press release announcing the pricing of the Offering, dated January 22, 2024</span></a></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL Document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:43.24%;"></td>
    <td style="width:2.76%;"></td>
    <td style="width:13.14%;"></td>
    <td style="width:40.86%;"></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td colspan="2" style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ADICET BIO, INC.</span></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: January 24, 2024</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Nick Harvey</span></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Name:</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Nick Harvey</span></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Title:</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Financial Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>acet-ex1_1.htm
<DESCRIPTION>EX-1.1
<TEXT>
<html>
 <head>
  <title>EX-1.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">27,054,667 Shares</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">And</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pre-Funded Warrants to Purchase 8,445,333 Shares</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">UNDERWRITING AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">January 22, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">JEFFERIES LLC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">GUGGENHEIM SECURITIES, LLC</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>As Representatives of the <br>several Underwriters named <br>in Schedule A attached hereto<br>	<br>c/o JEFFERIES LLC <br>520 Madison Avenue<br>New York, New York 10022</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">c/o </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Guggenheim Securities, LLC</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">330 Madison Avenue</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">New York, New York 10017</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Ladies and Gentlemen:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Introductory.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Adicet Bio, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), proposes to issue and sell to the several underwriters named in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Underwriters</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) (i) an aggregate of 27,054,667 shares (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of its common stock, par value $0.0001 per share (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and (ii) pre-funded warrants of the Company (in the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit C</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">) to purchase an aggregate of 8,445,333 shares of Common Stock at an exercise price equal to $0.0001 per share (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pre-Funded Warrants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  The Shares and the Pre-Funded Warrants to be sold by the Company are called the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Firm Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d;  In addition, the Company has granted to the Underwriters an option to purchase up to an additional 5,325,000 shares of Common Stock as provided in &#x200e;Section 2.  The additional Shares to be sold by the Company pursuant to such option are collectively called the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Optional Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d;  The Firm Securities and, if and to the extent such option is exercised, the Optional Shares are collectively called the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Offered Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d; Jefferies LLC (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Jefferies</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Guggenheim Securities, LLC (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Guggenheim</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) have agreed to act as representatives of the several Underwriters (in such capacity, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Representatives</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) in connection with the offering and sale of the Offered Securities.  To the extent there are no additional underwriters listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, the term &#x201c;Representatives&#x201d; as used herein shall mean you, as Underwriters, and the term &#x201c;Underwriters&#x201d; shall mean either the singular or the plural, as the context requires. As used herein, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company has prepared and filed with the Securities and Exchange Commission (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Commission</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) a shelf registration statement on Form S-3, File No. 333&#x2011;263587, including a base prospectus (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Base Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to be used in connection with the public offering and sale of the Offered Securities.  Such registration statement, as amended, including the financial statements, exhibits and schedules thereto, in the form in which it became effective under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), including all documents incorporated or deemed to be incorporated by reference therein and any</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">information deemed to be a part thereof at the time of effectiveness pursuant to Rule 430A or 430B under the Securities Act, is called the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d;  Any registration statement filed by the Company pursuant to Rule 462(b) under the Securities Act in connection with the offer and sale of the Offered Securities is called the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Rule 462(b) Registration Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">,&#x201d; and from and after the date and time of filing of any such Rule 462(b) Registration Statement the term &#x201c;Registration Statement&#x201d; shall include the Rule 462(b) Registration Statement.  The preliminary prospectus supplement dated January 22, 2024 describing the Offered Securities and the offering thereof (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Preliminary Prospectus Supplement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), together with the Base Prospectus, is called the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Preliminary Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">,&#x201d; and the Preliminary Prospectus and any other prospectus supplement to the Base Prospectus in preliminary form that describes the Offered Securities and the offering thereof and is used prior to the filing of the Prospectus (as defined below), together with the Base Prospectus, is called a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">preliminary prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d;  As used herein, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean the final prospectus supplement to the Base Prospectus that describes the Offered Securities and the offering thereof (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Final Prospectus Supplement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), together with the Base Prospectus, in the form first used by the Underwriters to confirm sales of the Offered Securities</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act.  References herein to the Preliminary Prospectus, any preliminary prospectus and the Prospectus shall refer to both the prospectus supplement and the Base Prospectus components of such prospectus.  As used herein, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Applicable Time</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; is 7:00 pm (New York City time) on January 22, 2024.  As used herein, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">free writing prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; has the meaning set forth in Rule 405 under the Securities Act, and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Time of Sale Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Preliminary Prospectus, as amended or supplemented immediately prior to the Applicable Time, together with the free writing prospectuses, if any, identified in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> hereto.  As used herein, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Road Show&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> means a &#x201c;road show&#x201d; (as defined in Rule 433 under the Securities Act) relating to the offering of the Offered Securities contemplated hereby that is a &#x201c;written communication&#x201d; (as defined in Rule 405 under the Securities Act).  As used herein, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 5(d) Written Communication</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means each written communication (within the meaning of Rule 405 under the Securities Act) that is made in reliance on Section 5(d) of the Securities Act by the Company or any person authorized to act on behalf of the Company to one or more potential investors that are qualified institutional buyers (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">QIBs</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and/or institutions that are accredited investors (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">IAIs</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), as such terms are respectively defined in Rule 144A and Rule 501(a) under the Securities Act, to determine whether such investors might have an interest in the offering of the Offered Securities; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 5(d) Oral Communication</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means each oral communication, if any, made in reliance on Section 5(d) of the Securities Act by the Company or any person authorized to act on behalf of the Company made to one or more QIBs and/or one or more IAIs to determine whether such investors might have an interest in the offering of the Offered Securities; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Marketing Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Offered Securities, including any roadshow or investor presentations made to investors by the Company (whether in person or electronically); and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Section 5(d) Communication</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Section 5(d) Written Communication(s) and Marketing Materials listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule C</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> hereto.</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">All references in this Agreement to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus and the Prospectus shall include the documents incorporated or deemed to be incorporated by reference therein.  All references in this Agreement to financial statements and schedules and other information which are &#x201c;contained,&#x201d; &#x201c;included&#x201d; or &#x201c;stated&#x201d; in, or &#x201c;part of&#x201d; the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, and all other references of like import, shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be.  All references in this Agreement to amendments or supplements to the Registration Statement, the Preliminary Prospectus, any preliminary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus shall be deemed to mean and include the filing of any document under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) that is or is deemed to be incorporated by reference in the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, or the Prospectus, as the case may be.  All references in this Agreement to (i) the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus or the Prospectus, any amendments or supplements to any of the foregoing, or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EDGAR</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and (ii) the Prospectus shall be deemed to include any &#x201c;electronic Prospectus&#x201d; provided for use in connection with the offering of the Offered Securities as contemplated by Section 3(n) of this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In the event that the Company has only one subsidiary, then all references herein to &#x201c;subsidiaries&#x201d; of the Company shall be deemed to refer to such single subsidiary, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">mutatis</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">mutandis</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company hereby confirms its agreement with the Underwriters as follows:</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Representations and Warranties of the Company.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Representations and Warranties of the Company</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company hereby represents, warrants and covenants to each Underwriter, as of the date of this Agreement, as of the First Closing Date (as hereinafter defined) and as of each Option Closing Date (as hereinafter defined), if any, as follows:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compliance with Registration Requirements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Registration Statement has become effective under the Securities Act.  The Company has complied, to the Commission&#x2019;s satisfaction, with all requests of the Commission for additional or supplemental information, if any.  No stop order suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission.  At the time the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2022 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Annual Report</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) was filed with the Commission, or, if later, at the time the Registration Statement was originally filed with the Commission, the Company met the then-applicable requirements for use of Form S-3 under the Securities Act.  The Company meets the requirements for use of Form S-3 under the Securities Act specified in FINRA Conduct Rule 5110(B)(7)(C)(i). The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus, at the time they were or hereafter are filed with the Commission, or became effective under the Exchange Act, as the case may be, complied and will comply in all material respects with the requirements of the Exchange Act.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disclosure</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Each preliminary prospectus and the Prospectus when filed complied in all material respects with the Securities Act and, if filed by electronic transmission pursuant to EDGAR, was identical (except as may be permitted by Regulation S&#x2011;T under the Securities Act) to the copy thereof delivered to the Underwriters for use in connection with the offer and sale of the Offered Securities.  Each of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective, complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.  As of the Applicable Time, the Time of Sale Prospectus did not, and at the First Closing Date (as defined in &#x200e;Section 2) and at each applicable Option Closing Date (as defined in Section 2), will not, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.  The Prospectus, as of its date, did not, and at the First Closing Date and at each applicable Option Closing Date, will not, contain any untrue statement of a material fact or omit to state </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.  The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement or any post-effective amendment thereto, or the Prospectus or the Time of Sale Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with written information relating to any Underwriter furnished to the Company in writing by the Representatives expressly for use therein, it being understood and agreed that the only such information consists of the information described in &#x200e;Section 9(b) below.  There are no contracts or other documents required to be described in the Time of Sale Prospectus or the Prospectus or to be filed as an exhibit to the Registration Statement which have not been described or filed as required. The statements set forth in the Time of Sale Prospectus and Prospectus under the caption &#x201c;Description of Capital Stock&#x201d;, insofar as it purports to constitute a summary of the terms of the Common Stock, and under the captions &#x201c;Risk Factors&#x201d; and &#x201c;Underwriting,&#x201d; insofar as they purport to describe the provisions of the laws and documents referred to therein, are accurate and complete in all material respects.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Free Writing Prospectuses; Road Show</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  As of the determination date referenced in Rule 164(h) under the Securities Act, the Company was not, is not or will not be (as applicable) an &#x201c;ineligible issuer&#x201d; in connection with the offering of the Offered Securities pursuant to Rules 164, 405 and 433 under the Securities Act.  Each free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act.  Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of Rule 433 under the Securities Act, including timely filing with the Commission, retention and legending, as applicable, and each such free writing prospectus, as of its issue date and at all subsequent times through the completion of the public offer and sale of the Offered Securities did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Prospectus or any preliminary prospectus unless such information has been superseded or modified as of such time.  Except for the free writing prospectuses, if any, identified in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, and electronic road shows, if any, furnished to you before first use, the Company has not prepared, used or referred to, and will not, without your prior written consent, prepare, use or refer to, any free writing prospectus.  Each Road Show, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the immediately preceding sentence do not apply to statements made in reliance upon and in conformity with written information relating to any Underwriter furnished to the Company in writing by the Representatives expressly for use therein, it being understood and agreed that the only such information consists of the information described in Section 9(b) below.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distribution of Offering Material By the Company</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Prior to the later of (i) the expiration or termination of the option granted to the several Underwriters in &#x200e;Section 2, and (ii) the completion of the Underwriters&#x2019; distribution of the Offered Securities</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> the Company has not distributed and will not distribute any offering material in connection with the offering and sale of the Offered Securities other than the Registration Statement, the Time of Sale Prospectus, the Prospectus or any free writing prospectus reviewed and consented to by the Representative, the free writing prospectuses, if any, identified on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> hereto.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Underwriting Agreement</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  This Agreement has been duly authorized, executed and delivered by the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Authorization of the Offered Securities</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Shares to be delivered on the First Closing Date and any Option Closing Date, if any, have been duly authorized and, when issued and delivered in accordance with this Agreement, will be validly issued, fully paid and non-assessable</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">will have been issued </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">in compliance with all applicable state, federal and foreign securities laws and will not have been issued in violation of or subject to any preemptive or similar right that entitles any person to acquire any Relevant Security (as defined below) from the Company.  The Common Stock and the Shares conform to the descriptions thereof contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus.  Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the Company has no outstanding warrants, options to purchase, or any preemptive rights or other rights to subscribe for or to purchase, or any contracts or commitments to issue or sell, any Relevant Security.  No holder of any Relevant Security has any rights to require registration under the Securities Act of any Relevant Security in connection with the offer and sale of the Shares contemplated hereby, except for any such rights that have either been fully complied with by the Company or effectively waived by the holders thereof. The Warrant Shares have been duly authorized and validly reserved for issuance upon exercise of the Pre-Funded Warrants in a number sufficient to meet the current exercise requirements. The Warrant Shares, when issued and delivered upon exercise of the Pre-Funded Warrants in accordance therewith, will be validly issued, fully paid and nonassessable, and the issuance of the Warrant Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Warrant Shares.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Material Adverse Change</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Subsequent to the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus or the Prospectus, except as disclosed therein, (i) the Company has not declared or paid any dividends, or made any other distribution of any kind, on or in respect of its capital stock, (ii) there has not been any material change in the capital stock or long-term or short-term debt of the Company or its subsidiaries listed on Exhibit 21.1 of its most recent Annual Report on Form 10-K (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subsidiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), (iii) there have been no transactions entered into by the Company or the Subsidiaries which are material with respect to the Company and the Subsidiaries, taken as a whole, other than in the ordinary course of business, (iv) neither the Company nor any Subsidiary has sustained any material loss or interference with its business or properties from fire, explosion, flood, earthquake, hurricane, accident or other calamity, whether or not covered by insurance, or from any labor dispute or any legal or governmental proceeding, and (v) there has not been any material adverse change, or any development involving a prospective material adverse change, whether or not arising from transactions in the ordinary course of business, in or affecting the business, management, condition (financial or otherwise), results of operations, stockholders&#x2019; equity, properties or prospects of the Company and the Subsidiaries, taken as a whole (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Material Adverse Change</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Since the date of the latest balance sheet included, or incorporated by reference, in the Registration Statement, the Time of Sale Prospectus or the Prospectus, neither the Company nor any Subsidiary has incurred or undertaken any liabilities or obligations, whether direct or indirect, liquidated or contingent, matured or unmatured, or entered into any transactions, including any acquisition or disposition of any business or asset, which are material to the Company and the Subsidiaries, taken as a whole, except for liabilities, obligations and transactions which are disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Independent Accountants</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  KPMG LLP, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus or the Prospectus, is (i) an independent registered public accounting firm as required by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">PCAOB</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the Securities Act and (iii) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Statements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The financial statements, including the notes thereto, and the supporting schedules included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus present fairly in all material respects the consolidated financial position as of the dates indicated and the cash flows and results of operations for the periods specified of the Company and </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the Subsidiaries; said financial statements have been prepared in conformity with United States generally accepted accounting principles (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">GAAP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) applied on a consistent basis throughout the periods involved; and the supporting schedules, if any, included in the Registration Statement, the Time of Sale Prospectus and the Prospectus present fairly in all material respects in accordance with GAAP the information required to be stated therein.  No other historical or pro forma financial statements or supporting schedules are required to be included in the Registration Statement, the Time of Sale Prospectus or the Prospectus by the Securities Act, the Exchange Act or the  rules and regulations promulgated thereunder.  The other financial and statistical information included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus present fairly in all material respects the information included therein and have been prepared on a basis consistent with that of the financial statements that are included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus and the books and records of the respective entities presented therein.  All disclosures contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus, or incorporated by reference therein, regarding &#x201c;non-GAAP financial measures&#x201d; (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#x2019;s rules and guidelines applicable thereto.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company&#x2019;s Accounting System</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company and the Subsidiaries maintain a system of internal accounting and other controls sufficient to provide reasonable assurances that (i) transactions are executed in accordance with management&#x2019;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets, (iii) access to assets is permitted only in accordance with management&#x2019;s general or specific authorization, (iv) the recorded accounting for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#x2019;s rules and guidelines applicable thereto. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Exchange Act) that comply with the requirements of the Exchange Act; such disclosure controls and procedures have been designed to ensure that material information relating to the Company and the Subsidiaries is made known to the Company&#x2019;s principal executive officer and principal financial officer by others within those entities; and such disclosure controls and procedures are effective. The Company maintains a system of internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) that complies with the requirements of the Exchange Act and has been designed by the Company&#x2019;s principal executive officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.  The Company&#x2019;s internal control over financial reporting is effective and, except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the Company is not aware of any material weaknesses in its internal control over financial reporting.  Since the date of the latest audited financial statements included or incorporated by reference in the Time of Sale Prospectus, there has been no change in the Company&#x2019;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">6</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incorporation and Good Standing of the Company</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">and its Subsidiaries</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company and each Subsidiary has been duly organized and validly exists as a corporation, partnership or limited liability company (as the case may be) in good standing under the laws of its jurisdiction of organization and has corporate, partnership or limited liability company power and authority (as the case may be) to own or lease its property and conduct its business as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus.  The Company and each Subsidiary is qualified to do business and is in good standing as a foreign corporation, partnership or limited liability company (as the case may be) in each jurisdiction in which the character or location of its properties (owned, leased or licensed) or the nature or conduct of its business makes such qualification necessary, except for those failures to be so qualified or in good standing which (individually and in the aggregate) could not reasonably be expected to have a material adverse effect on (i) the business, management, condition (financial or otherwise), results of operations, stockholders&#x2019; equity, properties or prospects of the Company and the Subsidiaries, taken as a whole; or (ii) the ability of the Company to consummate the Offering or any other transaction contemplated by this Agreement or the Registration Statement, the Time of Sale Prospectus and the Prospectus (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Material Adverse Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  The certificate or articles of incorporation, by-laws, partnership agreement, limited liability company agreement or other constitutive and organizational documents (as the case may be) of the Company and the Subsidiaries comply with the requirements of applicable law and are in full force and effect.  The Subsidiaries are the only &#x201c;subsidiaries&#x201d; of the Company (within the meaning of Rule 405 under the Securities Act.) </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(m)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Capitalization and Other Capital Stock Matters</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company has an authorized capitalization as set forth in the Time of Sale Prospectus and the Prospectus, and all of the issued and outstanding shares of capital stock of the Company are fully paid and non-assessable and have been duly authorized and validly issued, in compliance with all applicable state, federal and foreign securities laws and not in violation of or subject to any preemptive or similar right that entitles any person to acquire from the Company or the Subsidiaries any Common Stock or other security of the Company or any security convertible into, or exercisable or exchangeable for, Common Stock or any other such security of the Company (any &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Relevant Security</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), except for such rights as may have been fully satisfied or waived prior to the effectiveness of the Registration Statement.  All of the issued shares of capital stock of or other ownership interests in the Subsidiaries owned, directly or indirectly, by the Company have been duly authorized and validly issued and are fully paid and non-assessable and are owned directly or indirectly by the Company free and clear of any lien, charge, mortgage, pledge, security interest, claim, equity, trust or other encumbrance, preferential arrangement, defect or restriction of any kind whatsoever (any &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lien</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(n)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Exchange Listing</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The shares of Common Stock are registered pursuant to Section 12(b) or 12(g) of the Exchange Act and have been approved for listing on the Nasdaq Global Market ( &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Nasdaq</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), subject to completion of the issuance of the Shares pursuant to this Agreement, and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Shares under the Exchange Act or delisting the Shares from Nasdaq, nor has the Company received any notification that the Commission or Nasdaq is contemplating terminating such registration or listing.  To the Company&#x2019;s knowledge, it is in compliance with all applicable listing requirements of Nasdaq.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(o)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Contravention of Existing Instruments; No Further Authorizations or Approvals Required</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Neither the Company nor any Subsidiary (i) is in violation of its certificate or articles of incorporation, by-laws, certificate of formation, limited liability company agreement, partnership agreement or other organizational documents, (ii) is in default under, and no event has occurred which, with notice or lapse of time or both, would constitute a default under or result in the creation or imposition of any Lien upon any property or assets of the Company or the Subsidiaries pursuant to, any indenture, mortgage, deed of trust, note, lease, loan agreement or other agreement or instrument to which it is a party or by which it is bound or to which any of its property or assets is subject, or (iii) is in violation of any statute, law, rule, regulation, ordinance, directive, judgment, writ, decree or order of any court or judicial, regulatory or other </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">7</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">legal or governmental agency or body, foreign or domestic, having jurisdiction over the Company or the Subsidiaries except (in the case clauses (ii) and (iii) above) for violations or defaults that could not (individually or in the aggregate) reasonably be expected to have a Material Adverse Effect. The Company and the Subsidiaries have all requisite power and authority, and all necessary consents, approvals, authorizations, orders, registrations, qualifications, licenses, filings and permits of, with and from all judicial, regulatory and other legal or governmental agencies and bodies and all third parties, foreign and domestic (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Consents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), to own, lease and operate its properties and conduct its business as it is now being conducted and as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, and each such Consent is valid and in full force and effect, except in each case as could not reasonably be expected to have a Material Adverse Effect.  Neither the Company nor any Subsidiary has received notice of any investigation or proceedings which, if decided adversely to the Company or the Subsidiaries, could reasonably be expected to result in the revocation of, or imposition of a materially burdensome restriction on, any such Consent. The issue and sale of the Offered Securities (including the use of proceeds from the sale of the Offered Securities as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus), the compliance by the Company with this Agreement and the consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus do not and will not (i) conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default (or an event which with notice or lapse of time, or both, would constitute a default) under, or result in the creation or imposition of any Lien upon any property or assets of the Company or the Subsidiaries pursuant to, any indenture, mortgage, deed of trust, note, lease, loan agreement or other agreement, instrument, franchise, license or permit to which the Company or any Subsidiary is a party or by which the Company or the Subsidiaries or their respective properties, operations or assets may be bound, (ii) violate or conflict with any provision of the certificate or articles of incorporation, by-laws, certificate of formation, limited liability company agreement, partnership agreement or other organizational documents (as the case may be) of the Company or the Subsidiaries, or (iii) violate or conflict with any statute, law, rule, regulation, ordinance, directive, judgment, writ, decree or order of any court or judicial, regulatory, administrative or other legal or governmental agency or body (including, without limitation, the U.S. Food and Drug Administration (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">FDA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), domestic or foreign, having jurisdiction over the Company or the Subsidiaries, except (in the case of clauses (i) and (iii) above) as could not reasonably be expected to have a Material Adverse Effect. No Consent is required for the execution, delivery and performance by the Company of this Agreement, the issue and sale of the Shares (including the use of proceeds from the sale of the Shares as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus) and the consummation by the Company of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus, except the registration under the Securities Act of the Shares, such Consents as may be required by Nasdaq in regards to the listing of the Shares and under applicable state securities or blue sky laws and such other Consents as have been obtained.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(p)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compliance with Laws.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company and the Subsidiaries (i) are in material compliance with all statutes, rules and regulations applicable to the testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by the Company or the Subsidiaries (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Applicable Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) except where such noncompliance could not reasonably be expected to have a Material Adverse Effect, (ii) have not received any Form 483 from the FDA, notice of adverse finding, warning letter, or other written correspondence or notice from the FDA, the European Medicines Agency (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EMA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the U.K. Medicines and Healthcare Products Regulatory Agency (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">MHRA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the German </font><font style="color:#333333;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Federal Institute for Drugs and Medical Devices (the &#x201c;</font><font style="color:#333333;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">BfArM</font><font style="color:#333333;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;),</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> or any other federal, state, local or foreign governmental or regulatory authority alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Authorizations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), that could, individually or in the aggregate, result in a Material Adverse Effect; (iii) possess all material Authorizations and such Authorizations are valid and in </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">8</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">full force and effect and neither the Company nor any Subsidiary is in material violation of any term of any such Authorizations except where such nonpossession, failure or noncompliance could not reasonably be expected to have a Material Adverse Effect; (iv) have not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA, the EMA, the MHRA, the BfArM, or any other federal, state, local or foreign governmental or regulatory authority or third party alleging that any Company product, operation or activity is in material violation of any Applicable Laws or Authorizations which noncompliance could reasonably be expected to have a Material Adverse Effect and has no knowledge that the FDA, the EMA, the MHRA, the BfArM, or any other federal, state, local or foreign governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding against the Company; (v) have not received written notice that the FDA, EMA, the MHRA, the BfArM, or any other federal, state, local or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations that could reasonably be expected to have a Material Adverse Effect and has no knowledge that the FDA, EMA, the MHRA, the BfArM, or any other federal, state, local or foreign governmental or regulatory authority is considering such action; and (vi) have filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations, except whether the failure to file, obtain, maintain or submit such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments could not result in a Material Adverse Effect, and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission) except such incompletions and incorrections as could not reasonably be expected to result in a Material Adverse Effect.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(q)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Material Actions or Proceedings</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  There is no judicial, regulatory, arbitral or other legal or governmental proceeding or other litigation or arbitration, domestic or foreign, pending to which the Company or any Subsidiary is a party or of which any property, operations or assets of the Company or the Subsidiaries is the subject which, individually or in the aggregate, if determined adversely to the Company or any Subsidiary, could reasonably be expected to have a Material Adverse Effect on the consummation of the transactions contemplated in this Agreement or the performance by the Company of its obligations hereunder; to the Company&#x2019;s knowledge, no such proceeding, litigation or arbitration is threatened or contemplated; and the defense of all such proceedings, litigation and arbitration against or involving the Company or any Subsidiary could not reasonably be expected to have a Material Adverse Effect.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(r)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual Property Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Company and its Subsidiaries own or possess, or can acquire on reasonable terms, adequate patents, patent rights, licenses, approvals, inventions, copyrights, domain names, technology, trade secrets, know-how (including unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names or other intellectual property and similar rights, including registrations and applications for registration thereof (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) necessary or material to the conduct of the business now conducted or proposed in the Registration Statement, the Time of Sale Prospectus and the Prospectus to be conducted by them, and the failure to own, possess or acquire such Intellectual Property Rights and the expected expiration of any such Intellectual Property Rights would not, individually or in the aggregate, have a Material Adverse Effect. To the Company&#x2019;s knowledge, none of the patents and patent applications owned or licensed by the Company or its Subsidiaries is invalid or unenforceable, in whole or in part. To the Company&#x2019;s knowledge, none of the Intellectual Property Rights owned or licensed by the Company or its Subsidiaries, other than patents and patent applications, are invalid or unenforceable, in whole or in part. To the knowledge of the Company, there are no unreleased liens or security interests which have been filed against any of the Intellectual Property Rights owned or licensed by the Company. Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, (i) the Company is not obligated to pay a material royalty, grant a license or provide other material consideration to any third party in </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">9</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">connection with the Intellectual Property Rights owned by or licensed to the Company; (ii) to the Company&#x2019;s knowledge, there are no rights of third parties to any of the Intellectual Property Rights owned by or licensed to the Company or its Subsidiaries, in any field of use, other than the respective licensor to the Company of such Intellectual Property Rights; (iii) to the Company&#x2019;s knowledge, there is no material infringement, misappropriation breach, default or other violation, or the occurrence of any event that with notice or the passage of time would constitute any of the foregoing, by the Company or its Subsidiaries of any third party Intellectual Property Rights or third parties of any of the Intellectual Property Rights of the Company or its Subsidiaries; (iv) there is no pending or, to the Company&#x2019;s knowledge, threatened action, suit, proceeding or claim by others against the Company or its Subsidiaries or, to the Company&#x2019;s knowledge against any person or entity, (a) challenging the Company&#x2019;s or any of its Subsidiaries&#x2019; rights in or to, or the violation of any of the terms of, any of their Intellectual Property Rights; (b) challenging the validity, enforceability or scope of any such Intellectual Property Rights; or (c) that alleges the Company or any of its Subsidiaries infringes, misappropriates or otherwise violates or conflicts with any Intellectual Property Rights or other proprietary rights of others, and, in each case, the Company is unaware of any facts which would form a reasonable basis for any such claim; (v) none of the Intellectual Property Rights owned by or licensed to the Company or its Subsidiaries in their businesses has been obtained or is being used by the Company or its Subsidiaries in violation of any contractual obligation binding on the Company or any of its Subsidiaries in violation of the rights of any persons; and (vi) to the Company&#x2019;s knowledge, no employee or consultant of the Company or any of its Subsidiaries is in or has ever been in violation of any term of any employment or consulting contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer or consultant where the basis of such violation relates to such employee&#x2019;s employment with or such consultant&#x2019;s services to the Company or any of its Subsidiaries or actions undertaken by the employee or consultant while employed with or providing services to the Company or any of its Subsidiaries. To the knowledge of the Company and as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, (1) neither the commercial development nor the sale of any of the proposed products or processes of the Company, as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, infringes, misappropriates or otherwise violates, or would, upon the commercialization of such proposed products or processes, infringe, misappropriate or otherwise violate, any Intellectual Property Rights of any third party; and (2) each current and former employee and consultant of the Company (a) has executed an inventions assignment and confidentiality agreement with the Company, on or about the respective date of hire, and signed copies of such agreements have been made available to the Underwriters and their counsel; and (b) has signed or agreed to assign to the Company any and all Intellectual Property Rights he or she may possess or may have possessed that are related to the Company&#x2019;s business, as currently conducted and as proposed to be conducted, as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus. All patents and patent applications owned by or licensed to the Company or under which the Company has rights have, to the knowledge of the Company, been duly and properly filed and maintained; to the knowledge of the Company, the parties prosecuting such applications have complied with their duty of candor and disclosure to the U.S. Patent and Trademark Office (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">USPTO</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and any similar office or agency in the world in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO or similar office or agency that were not disclosed and which would preclude the grant of a patent in connection with any such application or could form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(s)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Title to Properties</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company and its Subsidiaries do not own any real property and have good title to all other properties owned by them, free and clear of any and all Liens except such as (A) are described in the Registration Statement, the Time of Sale Prospectus and the Prospectus or (B) do not (individually or in the aggregate) materially affect the value of such property or materially interfere with the use made or proposed to be made of such property by the Company and the Subsidiaries; and any real property and buildings held under lease or sublease by the Company and the Subsidiaries are held by them </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">10</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">under valid, subsisting and enforceable leases with such exceptions as are not material to, and do not materially interfere with, the use made and proposed to be made of such property and buildings by the Company and the Subsidiaries.  Neither the Company nor any Subsidiary has received any notice of any claim adverse to its ownership of any real or personal property or of any claim against the continued possession of any real property, whether owned or held under lease or sublease by the Company or the Subsidiaries.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(t)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Tax Law Compliance</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Except as would not reasonably be expected to result in a Material Adverse Effect, the Company and each Subsidiary has accurately prepared and timely filed all federal, state, foreign and other tax returns that are required to be filed by it or have been granted extensions thereof and has paid or made provision for the payment of all taxes, assessments, governmental or other similar charges, including without limitation, all sales and use taxes and all taxes which the Company or any Subsidiary is obligated to withhold from amounts owing to employees, creditors and third parties, with respect to the periods covered by such tax returns (whether or not such amounts are shown as due on any tax return).  Except as would not reasonably be expected to result in a Material Adverse Effect, no  deficiency assessment with respect to a proposed adjustment of the Company&#x2019;s or the Subsidiaries&#x2019; federal, state, local or foreign taxes is pending or, to the Company&#x2019;s knowledge, threatened.  The accruals and reserves on the books and records of the Company and the Subsidiaries in respect of tax liabilities for any taxable period not finally determined are adequate to meet any assessments and related liabilities for any such period and, since December 31, 2020, except as would not reasonably be expected to have a Material Adverse Effect, the Company and the Subsidiaries have not incurred any liability for taxes other than in the ordinary course of its business.  There is no tax lien, whether imposed by any federal, state, foreign or other taxing authority, outstanding against the assets, properties or business of the Company or the Subsidiaries, other than any such tax lien arising automatically under applicable law with respect to taxes not yet due and payable or being contested in good faith.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(u)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Insurance</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company and the Subsidiaries maintain insurance in such amounts and covering such risks as the Company reasonably considers adequate for the conduct of its business and the value of its properties and as is customary for companies engaged in similar businesses in similar industries, all of which insurance is in full force and effect, except where the failure to maintain such insurance could not reasonably be expected to have a Material Adverse Effect.  There are no material claims by the Company or the Subsidiaries under any such policy or instrument as to which any insurance company is denying liability or defending under a reservation of rights clause.  The Company reasonably believes that it will be able to renew its existing insurance as and when such coverage expires or will be able to obtain replacement insurance adequate for the conduct of the business and the value of its properties at a cost that could not have a Material Adverse Effect.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compliance with Environmental Laws</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  There has been no storage, generation, transportation, handling, use, treatment, disposal, discharge, emission, contamination, release or other activity involving any kind of hazardous, toxic or other wastes, pollutants, contaminants, petroleum products or other hazardous or toxic substances, chemicals or materials (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Hazardous Substances</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) by, due to, on behalf of, or caused by the Company or the Subsidiaries (or, to the Company&#x2019;s knowledge, any other entity for whose acts or omissions the Company is or may be liable) upon any property now or previously owned, operated, used or leased by the Company or the Subsidiaries, or upon any other property, which would be a violation of or give rise to any liability under any applicable law, rule, regulation, order, judgment, decree or permit, common law provision or other legally binding standard relating to pollution or protection of human health and the environment (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Environmental Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), except for violations and liabilities which, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect.  There has been no disposal, discharge, emission, contamination or other release of any kind at, onto or from any such property or into the environment surrounding any such property of any Hazardous Substances with respect to which the Company or any Subsidiary has knowledge, except as could not, individually or in the </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">11</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">aggregate, reasonably be expected to have a Material Adverse Effect. To the Company&#x2019;s knowledge, there are no events or circumstances that would reasonably be expected to form the basis for an order for cleanup or remedial action, except as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.  There is no pending or, to the Company&#x2019;s knowledge, threatened administrative, regulatory or judicial action, claim or notice of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any Subsidiary, except in each case which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.  No property of the Company or any Subsidiary is subject to any Lien under any Environmental Law.  Neither the Company nor any Subsidiary is subject to any order, decree, agreement or other individualized legal requirement related to any Environmental Law.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(w)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Labor and Employment Matters.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> No labor disturbance by the employees of the Company or the Subsidiaries exists or, to the Company&#x2019;s knowledge, is imminent and the Company is not aware of any existing or imminent labor disturbances by the employees of any of its or the Subsidiaries&#x2019; principal suppliers, manufacturers&#x2019;, customers or contractors, which, in either case (individually or in the aggregate), could reasonably be expected to have a Material Adverse Effect.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(x)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ERISA Compliance</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, (i) each &#x201c;employee benefit plan&#x201d; (within the meaning of Section 3(3) of the Employee Retirement Security Act of 1974, as amended (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ERISA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)) for which the Company or any member of its &#x201c;Controlled Group&#x201d; (defined as any organization which is a member of a controlled group of corporations within the meaning of Section 414 of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)) would have any liability (each a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) has been maintained in compliance with its terms and with the requirements of all applicable statutes, rules and regulations including ERISA and the Code; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan excluding transactions effected pursuant to a statutory or administrative exemption; (iii) with respect to each Plan subject to Title IV of ERISA (A) no &#x201c;reportable event&#x201d; (within the meaning of Section 4043(c) of ERISA) has occurred or is reasonably expected to occur, (B) no &#x201c;accumulated funding deficiency&#x201d; (within the meaning of Section 302 of ERISA or Section 412 of the Code), whether or not waived, has occurred or is reasonably expected to occur, (C) the fair market value of the assets under each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan), and (D) neither the Company or any member of its Controlled Group has incurred, or reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guaranty Corporation in the ordinary course and without default) in respect of a Plan (including a &#x201c;multiemployer plan&#x201d;, within the meaning of Section 4001(c)(3) of ERISA); and (iv) each Plan that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(y)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company Not an &#x201c;Investment Company.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company is not and, at all times up to and including consummation of the transactions contemplated by this Agreement, and after giving effect to application of the net proceeds of the Offering as described in the Time of Sale Prospectus and the Prospectus, will not be, required to register as an &#x201c;investment company&#x201d; under the Investment Company Act of 1940, as amended, and is not and will not be an entity &#x201c;controlled&#x201d; by an &#x201c;investment company&#x201d; within the meaning of such act.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(z)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Price Stabilization or Manipulation; Compliance with Regulation M</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Neither the Company nor any of its affiliates (within the meaning of Rule 144 under the Securities Act) has taken, directly or indirectly, any action which constitutes or is designed to cause or result in, or which could reasonably be expected to constitute, cause or result in, the stabilization or manipulation of the price of any </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">12</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">security to facilitate the sale or resale of the Offered Securities or to result in a violation of Regulation M under the Exchange Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Regulation M</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(aa)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Related-Party Transactions</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> To the Company&#x2019;s knowledge, no relationship, direct or indirect, exists between or among any of the Company or any affiliate of the Company, on the one hand, and any director, officer, shareholder, customer or supplier of the Company or any affiliate of the Company, on the other hand, which is required by the Securities Act or the Exchange Act to be described in the Registration Statement or the Prospectus that is not so described as required.  There are no outstanding loans, advances (except normal advances for business expenses in the ordinary course of business) or guarantees or indebtedness by the Company to or for the benefit of any of the officers or directors of the Company or any of their respective family members.  The Company has not, in violation of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated in connection therewith (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sarbanes-Oxley Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), directly or indirectly, including through any affiliate of the Company, extended or maintained credit, arranged for the extension of credit, or renewed an extension of credit, in the form of a personal loan to or for any director or executive officer of the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(bb)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">FINRA Matters</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  All of the information provided to the Underwriters or to counsel for the Underwriters by the Company and, to the Company&#x2019;s knowledge, its officers, directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Offered Securities is true, complete and correct in all material respects and compliant with Financial Industry Regulatory Authority, Inc.&#x2019;s (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">FINRA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) rules and, to the Company&#x2019;s knowledge, any letters, filings or other supplemental information provided to FINRA pursuant to FINRA rules or NASD Conduct Rules is true, complete and correct in all material respects.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(cc)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Parties to Lock-Up Agreements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company has furnished to the Underwriters a letter agreement in the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lock-up Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) from each of the persons listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Such </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> lists under an appropriate caption the directors and executive officers of the Company.  If any additional persons shall become directors or executive officers of the Company prior to the end of the Company Lock-up Period (as defined below), the Company shall cause each such person, prior to or contemporaneously with their appointment or election as a director or executive officer of the Company, to execute and deliver to the Representatives a Lock-up Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(dd)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Statistical and Market-Related Data</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  All statistical, demographic and market&#x2011;related data included in the Registration Statement, the Time of Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material respects.  To the extent required, the Company has obtained the written consent to the use of such data from such sources.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(ee)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sarbanes-Oxley Act.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> There is and has been no failure on the part of the Company or any of the Company&#x2019;s directors or executive officers, in their capacities as such, to comply in all material respects with any applicable provision of the Sarbanes-Oxley Act, including Section 402 related to loans and Sections 302 and 906 related to certifications.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(ff)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Unlawful Contributions or Other Payments</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Neither the Company nor any of its subsidiaries nor, to the best of the Company&#x2019;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any applicable law or of the character required to be disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(gg)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anti-Corruption and Anti-Bribery Laws</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Neither the Company nor any of its subsidiaries, nor any director, officer or employee of the Company or any of its subsidiaries nor, to the knowledge of the </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">13</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i) made, offered, promised or authorized any unlawful contribution, gift, entertainment or other unlawful expense (or taken any act in furtherance thereof); (ii) made, offered, promised or authorized any direct or indirect unlawful payment; or (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or the rules and regulations thereunder, the Bribery Act 2010 of the United Kingdom or any other applicable anti-corruption, anti-bribery or related law, statute or regulation (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Anti-Corruption Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); the Company and its subsidiaries have conducted their businesses in compliance with Anti-Corruption Laws and have instituted and maintained and will continue to maintain policies and procedures reasonably designed to promote and achieve compliance with such laws and with the representations and warranties contained herein; neither the Company nor any of its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of Anti-Corruption Laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(hh)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Money Laundering Laws</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with the requirements of applicable anti-money laundering laws, including, but not limited to, the Bank Secrecy Act of 1970, as amended by the USA PATRIOT ACT of 2001, and the rules and regulations promulgated thereunder, and the anti-money laundering laws of the various jurisdictions in which the Company and its subsidiaries conduct business, (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Money Laundering Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sanctions</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Neither the Company nor any of its subsidiaries, nor any director, officer or employee of the Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is (i) currently the subject or the target of any sanctions administered or enforced by the U.S. Government, including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">OFAC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), or the U.S. Department of State and including, without limitation, the designation as a &#x201c;specially designated national&#x201d; or &#x201c;blocked person,&#x201d; the European Union, His Majesty&#x2019;s Treasury, the United Nations Security Council, or other relevant sanctions authority (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sanctions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), (ii) organized or resident in a country or territory that is the subject or target of comprehensive Sanctions (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sanctioned Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any unlawful activities of or business with any person that, at the time of such funding, is the subject or the target of Sanctions, or in any country or territory, that, at the time of such funding, is a Sanctioned Jurisdiction or (ii) in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions; neither the Company nor any of its subsidiaries is knowingly engaged in, or has, at any time in the past five years, knowingly engaged in, any dealings or transactions with or involving any individual or entity that was or is, as applicable, at the time of such dealing or transaction, the subject or target of Sanctions or with any country or territory that was or is, as applicable, at the time of such dealing or transaction, a Sanctioned Jurisdiction; the Company and its subsidiaries have instituted, and maintain, policies and procedures designed to promote and achieve continued compliance with Sanctions.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(jj)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Brokers</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  There are no contracts, agreements or understandings between the Company and any person that would give rise to a valid claim against the Company or any Underwriter for a brokerage commission, finder&#x2019;s fee or other like payment in connection with the transactions contemplated by this Agreement or, to the Company&#x2019;s knowledge, any arrangements, agreements, understandings, payments or </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">14</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">issuance with respect to the Company or any of its officers, directors, shareholders, partners, employees, subsidiaries or affiliates that may affect the Underwriters&#x2019; compensation, as determined by FINRA Rule 5110.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(kk)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Material Lending Relationships.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Company (i) does not have any material lending or other relationship with any bank or lending affiliate of any Underwriter and (ii) does not intend to use any of the proceeds from the sale of the Shares to repay any outstanding debt owed to any affiliate of any Underwriter.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(ll)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Forward-Looking Statements.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Each financial or operational projection or other &#x201c;forward-looking statement&#x201d; (as defined by Section 27A of the Securities Act or Section 21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus (i) was so included by the Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii) is accompanied by meaningful cautionary statements identifying those factors that could cause actual results to differ materially from those in such forward&#x2011;looking statement.  No such statement was made with the knowledge of an executive officer or director of the Company that it was false or misleading.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(mm)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cybersecurity</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Company and its subsidiaries&#x2019; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">IT Systems</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, to the knowledge of the Company, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards designed to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including &#x201c;Personal Data,&#x201d; used in connection with their businesses. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Personal Data</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, as applicable, (i) a natural person&#x2019;s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver&#x2019;s license number, passport number, credit card number, bank information, or customer or account number; (ii) any information which would qualify as &#x201c;personally identifying information&#x201d; under the Federal Trade Commission Act, as amended; (iii) &#x201c;personal data&#x201d; as defined by the European Union General Data Protection Regulation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">GDPR</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); (iv) any information which would qualify as &#x201c;protected health information&#x201d; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">HIPAA&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">); and (v) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&#x2019;s health or sexual orientation. To the knowledge of the Company, there have been no material breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(nn)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compliance with Data Privacy Laws</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> To the knowledge of the Company, the Company and its subsidiaries are, and for the past three years were, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May 25, 2018, have been and currently are in compliance with, GDPR (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Privacy </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">15</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Policies</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Company and its subsidiaries have made all disclosures to users or customers required by applicable Privacy Laws, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. To the knowledge of the Company, neither it nor any subsidiary: (i) has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(oo)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging Growth Company Status.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  From the time of initial confidential submission of the Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged in any Section 5(d) Written Communication or any Section 5(d) Oral Communication) through the date hereof, the Company has been and is an &#x201c;emerging growth company,&#x201d; as defined in Section 2(a) of the Securities Act (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(pp)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Communications.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company (i) has not alone engaged in communications with potential investors in reliance on Section 5(d) of the Securities Act other than Permitted Section 5(d) Communications with the consent of the Representatives with entities that are QIBs or IAIs and (ii) has not authorized anyone other than the Representatives to engage in such communications; the Company reconfirms that the Representatives have been authorized to act on its behalf in undertaking Marketing Materials, Section 5(d) Oral Communications and Section 5(d) Written Communications; as of the Applicable Time, each Permitted Section 5(d) Communication, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time, include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading; and each Permitted Section 5(d) Communication, if any, does not, as of the date hereof, conflict with the information contained in the Registration Statement, the Preliminary Prospectus and the Prospectus; and the Company has filed publicly on EDGAR at least 15 calendar days prior to any &#x201c;road show&#x201d; (as defined in Rule 433 under the Act), any confidentially submitted registration statement and registration statement amendments relating to the offer and sale of the Offered Securities. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(qq)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Data and Regulatory Compliance.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The pre-clinical and clinical studies (as applicable) conducted by, on behalf of or sponsored by the Company or its Subsidiaries, or in which the Company or its Subsidiaries or their product candidates participated, including, to the knowledge of the Company, such studies conducted by Novartis International Pharmaceutical Ltd. or its affiliates, were and, if still pending are being, conducted in all material respects in accordance with standard medical and scientific research procedures and with all applicable local, state and federal laws, rules and regulations, including, without limitation, the Federal Food, Drug and Cosmetic Act and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312; the descriptions of the results of such studies contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus are accurate and complete in all material respects and fairly present the data derived from such studies; the Company is not aware of any studies, the results of which are inconsistent with or otherwise call into question the study results described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; and neither the FDA nor any applicable foreign regulatory agency has commenced, or, to the knowledge of the Company, threatened to initiate, any action to place a hold order on, or otherwise terminate, delay or suspend, any proposed or ongoing pre-clinical studies or clinical investigations conducted or proposed to be conducted by or on behalf of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">16</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(rr)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compliance Programs. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company has established and administers a compliance program applicable to the Company, to assist the Company and the directors, officers and employees of the Company in complying with applicable regulatory guidelines (including, without limitation, those administered by the FDA, the EMA, the MHRA, the BfArM, and any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA or EMA); except where such noncompliance could not reasonably be expected to have a Material Adverse Effect.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(ss)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compliance with Health Care Laws</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Company and each of its Subsidiaries has operated and currently is in compliance in all material respects with all applicable Health Care Laws (as defined below), including, without limitation, the rules and regulations of the FDA, the U.S. Department of Health and Human Services Office of Inspector General, the Centers for Medicare &amp; Medicaid Services, the Office for Civil Rights, the Department of Justice or any other governmental agency or body having jurisdiction over the Company or any of its activities, and has not engaged in activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state or federal health care program. For purposes of this Agreement, &#x201c;Health Care Laws&#x201d; shall mean the federal Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b(b)), the Physician Payment Sunshine Act (42 U.S.C. &#167; 1320a-7h), the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the criminal False Claims Act (42 U.S.C. &#167; 1320a-7b(a)), all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under HIPAA, the exclusion laws (42 U.S.C. &#167; 1320a-7), the civil monetary penalties law (42 U.S.C. &#167; 1320a-7a), HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. &#167;&#167; 17921 et seq.), the patient privacy, data security and breach notification provisions under HIPAA, the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), the Public Health Service Act (42 U.S.C. &#167;&#167; 262 et seq.), Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act), the regulations promulgated pursuant to such laws, and any other similar local, state or federal law and regulations. The Company has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence, communication or notice from the FDA or any other governmental or regulatory authority alleging or asserting noncompliance with any Health Care Laws applicable to the Company. The Company is not a party to nor has any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any governmental or regulatory authority. Neither the Company, its Subsidiaries nor any of their respective employees, officers, directors or, to the Company&#x2019;s knowledge, consultants has been excluded, suspended or debarred from participation in any U.S. state or federal health care program or human clinical research or, to the Company&#x2019;s knowledge, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Any certificate signed by any officer of the Company or any of its subsidiaries and delivered to any Underwriter or to counsel for the Underwriters in connection with the offering, or the purchase and sale, of the Offered Securities shall be deemed a representation and warranty by the Company (and not by any such officer in his or her personal capacity) to each Underwriter as to the matters covered thereby.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company has a reasonable basis for making each of the representations set forth in this Section 1.  The Company acknowledges that the Underwriters and, for purposes of the opinions to be delivered pursuant to &#x200e;Section 6 hereof, counsel to the Company and counsel to the Underwriters, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Purchase, Sale and Delivery of the Offered Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Firm Securities</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Upon the terms herein set forth, the Company agrees to issue and sell to the several Underwriters an aggregate of 27,054,667 Shares and an aggregate of 8,445,333 Pre-Funded Warrants.  On </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">17</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.533%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Underwriters agree, severally and not jointly, to purchase from the Company the respective number of Firm Securities set forth opposite their names on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The purchase price per Firm Securities to be paid by the several Underwriters to the Company shall be $2.256 per Share and $2.2559 per Pre-Funded Warrant.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The First Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Delivery of the Firm Securities to be purchased by the Underwriters and payment therefor shall be made at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (or such other place as may be agreed to by the Company and the Representatives) at 9:00 a.m. New York City time, on January 25, 2024, or such other time and date not later than 1:30 p.m. New York City time, on January 25, 2024 as the Representatives shall designate by notice to the Company (the time and date of such closing are called the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">First Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  The Company hereby acknowledges that circumstances under which the Representatives may provide notice to postpone the First Closing Date as originally scheduled include, but are not limited to, any determination by the Company or the Representatives to recirculate to the public copies of an amended or supplemented Prospectus or a delay as contemplated by the provisions of Sections 11 and 19.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Optional Shares; Option Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  In addition, on the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Company hereby grants an option to the several Underwriters to purchase, severally and not jointly, up to an aggregate of 5,325,000 Optional Shares from the Company at the purchase price per share to be paid by the Underwriters for the Shares, less an amount per share equal to any dividend or distribution declared by the Company and payable on the Shares but not payable on Optional Shares.  The option granted hereunder may be exercised at any time and from time to time in whole or in part upon notice by the Representatives to the Company, which notice may be given at any time within 30 days from the date of this Agreement.  Such notice shall set forth the aggregate number of Optional Shares as to which the Underwriters are exercising the option and (ii) the time, date and place at which certificates for the Optional Shares will be delivered (which time and date may be simultaneous with, but not earlier than, the First Closing Date; and in the event that such time and date are simultaneous with the First Closing Date, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">First Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall refer to the time and date of delivery of certificates for the Firm Securities and such Optional Shares).  Any such time and date of delivery, if subsequent to the First Closing Date, is called an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Option Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">,&#x201d; and shall be determined by the Representatives and shall not be earlier than two or later than five full business days after delivery of such notice of exercise.  If any Optional Shares are to be purchased, each Underwriter agrees, severally and not jointly, to purchase the number of Optional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine) that bears the same proportion to the total number of Optional Shares to be purchased as the number of Shares set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> opposite the name of such Underwriter bears to the total number of Shares. The Representatives may cancel the option at any time prior to its expiration by giving written notice of such cancellation to the Company.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Public Offering of the Offered Securities</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Representatives hereby advise the Company that the Underwriters intend to offer for sale to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, their respective portions of the Offered Securities as soon after this Agreement has been executed as the Representatives, in their sole judgment, have determined is advisable and practicable. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Payment for the Offered Securities</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Payment for the Offered Securities shall be made at the First Closing Date (and, if applicable, at each Option Closing Date) by wire transfer of immediately available funds to the order of the Company.  </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">18</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">It is understood that the Representatives have been authorized, for their own accounts and the accounts of the several Underwriters, to accept delivery of and receipt for, and make payment of the purchase price for, the Firm Securities and any Optional Shares the Underwriters have agreed to purchase.  Each of Jefferies and Guggenheim, individually and not as the Representatives of the Underwriters, may (but shall not be obligated to) make payment for any Offered Securities to be purchased by any Underwriter whose funds shall not have been received by the Representatives by the First Closing Date or the applicable Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delivery of the Offered Securities</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company shall (i) deliver, or cause to be delivered through the facilities of Depositary Trust Company (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">DTC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) unless the Representatives shall otherwise instruct, to the Representatives for the accounts of the several Underwriters the Shares, and (ii) deliver, or cause to be delivered, to the purchasers thereof the Pre-Funded Warrants in accordance with the Underwriters&#x2019; instructions to be sold by them at the First Closing Date, against release of a wire transfer of immediately available funds for the amount of the purchase price therefor. The Company shall also deliver, or cause to be delivered through the facilities of DTC unless the Representatives shall otherwise instruct, to the Representatives for the accounts of the several Underwriters, the Optional Shares the Underwriters have agreed to purchase from them at the First Closing Date or the applicable Option Closing Date, as the case may be, against the release of a wire transfer of immediately available funds for the amount of the purchase price therefor. If the Representatives so elect, delivery of the Shares may be made by credit to the accounts designated by the Representatives through DTC&#x2019;s full fast transfer or DWAC programs. If the Representatives so elect, the Shares shall be registered in such names and denominations as the Representatives shall have requested at least two full business days prior to the First Closing Date (or the applicable Option Closing Date, as the case may be) and shall be made available for inspection on the business day preceding the First Closing Date (or the applicable Option Closing Date, as the case may be) at a location in New York City as the Representatives may designate; provided, however, that if the Company, upon the instruction of the Representatives, registers the Pre-Funded Warrants in the name of any person or entity to whom any Underwriter intends to sell such Pre-Funded Warrants, then such Underwriter shall have the right to thereafter request the re-registration of such Pre-Funded Warrants (and the Company shall be required to re-register such Pre-Funded Warrants) in the name of any other person or entity (it being understood that such re-registration is intended to permit an Underwriter to resell such Pre-Funded Warrants in the event that the person or entity to whom such Underwriter originally intended to sell such Pre-Funded Warrants shall fail to pay the purchase price of such Pre-Funded Warrants). Time shall be of the essence, and delivery at the time and place specified in this Agreement is a further condition to the obligations of the Underwriters.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Additional Covenants.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company further covenants and agrees with each Underwriter as follows:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delivery of Registration Statement, Time of Sale Prospectus and Prospectus.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Company shall furnish to you in New York City, without charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during the period when a prospectus relating to the Offered Securities is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Securities, as many copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement as you may reasonably request.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Representatives&#x2019; Review of Proposed Amendments and Supplements.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> During the period when a prospectus relating to the Offered Securities is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), the Company </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">19</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(i) will furnish to the Representatives for review, a reasonable period of time prior to the proposed time of filing of any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and (ii) will not amend or supplement the Registration Statement (including any amendment or supplement through incorporation of any report filed under the Exchange Act) without the Representatives&#x2019; prior written consent.  Prior to amending or supplementing any preliminary prospectus, the Time of Sale Prospectus or the Prospectus (including any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the time of filing or use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement.  The Company shall not file or use any such proposed amendment or supplement without the Representatives&#x2019; prior written consent.  The Company shall file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Free Writing Prospectuses.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Company shall furnish to the Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto prepared by or on behalf of, used by, or referred to by the Company, and the Company shall not file, use or refer to any proposed free writing prospectus or any amendment or supplement thereto without the Representatives&#x2019; prior written consent.  The Company shall furnish to each Underwriter, without charge, as many copies of any free writing prospectus prepared by or on behalf of, used by or referred to by the Company as such Underwriter may reasonably request.  If at any time when a prospectus is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Securities (but in any event if at any time through and including the First Closing Date) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict or so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, as the case may be; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus, and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the Representatives&#x2019; prior written consent.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Filing of Underwriter Free Writing Prospectuses.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Company shall not take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that such Underwriter otherwise would not have been required to file thereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amendments and Supplements to Time of Sale Prospectus.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> If the Time of Sale Prospectus is being used to solicit offers to buy the Offered Securities at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement, or if, in the reasonable opinion of counsel for the </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">20</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company shall (subject to Section 3(b) and Section 3(c) hereof) promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Certain Notifications and Required Actions</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  After the date of this Agreement, the Company shall promptly advise the Representatives in writing of:  (i) the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii) the time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus; (iii) the time and date that any post-effective amendment to the Registration Statement becomes effective; and (iv) the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus or the Prospectus or of any order preventing or suspending the use of any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes.  If the Commission shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest practicable time.  Additionally, the Company agrees that it shall comply with all applicable provisions of Rule 424(b), Rule 433 and Rule 430B under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433 were received in a timely manner by the Commission. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amendments and Supplements to the Prospectus and Other Securities Act Matters.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  If any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading, or if in the reasonable opinion of the Representatives or counsel for the Underwriters it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, the Company agrees (subject to Section 3(b) and Section 3(c)) hereof to promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law.  Neither the Representatives&#x2019; consent to, nor delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&#x2019;s obligations under Section 3(b) or Section 3(c).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Blue Sky Compliance</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company shall cooperate with the Representatives and counsel for the Underwriters to qualify or register the Offered Securities for sale under (or obtain exemptions from the application of) the state securities or blue sky laws (or other foreign laws) of those jurisdictions reasonably designated by the Representatives, shall use commercially reasonable efforts to comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">21</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">distribution of the Offered Securities.  The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation.  The Company will advise the Representatives promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Offered Securities for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof at the earliest practicable moment.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Proceeds</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company shall apply the net proceeds from the sale of the Offered Securities sold by it in the manner described under the caption &#x201c;Use of Proceeds&#x201d; in the Registration Statement, the Time of Sale Prospectus and the Prospectus.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Transfer Agent</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Earnings Statement</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company will make generally available to its security holders and to the Representatives as soon as practicable an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company commencing after the date of this Agreement that will satisfy the provisions of Section 11(a) of the Securities Act and the rules and regulations of the Commission thereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Continued Compliance with Securities Laws</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company will comply with the Securities Act and the Exchange Act so as to permit the completion of the distribution of the Offered Securities as contemplated by this Agreement</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the Registration Statement, the Time of Sale Prospectus and the Prospectus.  Without limiting the generality of the foregoing, the Company will, during the period when a prospectus relating to the Offered Securities is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), file on a timely basis with the Commission and Nasdaq all reports and documents required to be filed under the Exchange Act. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(m)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Listing</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company will use its best efforts to list, subject to notice of issuance, the Shares and Warrant Shares on Nasdaq.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(n)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company to Provide Copy of the Prospectus in Form That May be Downloaded from the Internet</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  If requested by the Representatives, the Company shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement, to the Representatives an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">electronic Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; to be used by the Underwriters in connection with the offering and sale of the Offered Securities.  As used herein, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">electronic Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a form of Prospectus, and any amendment or supplement thereto, that meets each of the following conditions: (i) it shall be encoded in an electronic format, satisfactory to the Representatives, that may be transmitted electronically by the Representatives and the other Underwriters to offerees and purchasers of the Offered Securities; (ii) it shall disclose the same information as the paper Prospectus, except to the extent that graphic and image material cannot be disseminated electronically, in which case such graphic and image material shall be replaced in the electronic Prospectus with a fair and accurate narrative description or tabular representation of such material, as appropriate; and (iii) it shall be in or convertible into a paper format or an electronic format, satisfactory to the Representatives, that will allow investors to store and have continuously ready access to the Prospectus at any future time, without charge to investors (other than any fee charged for subscription to the Internet as a whole and for on-line time).  The Company hereby confirms that it has included or will include in the Prospectus filed pursuant to EDGAR or otherwise with the Commission and in the Registration Statement at the time it was declared effective an undertaking that, upon receipt of a request by an investor </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">22</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">or his or her representative, the Company shall transmit or cause to be transmitted promptly, without charge, a paper copy of the Prospectus.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(o)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreement Not to Offer or Sell Additional Shares</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  During the period commencing on and including the date hereof and continuing through and including the 90th day following the date of the Prospectus (such period, as extended as described below, being referred to herein as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lock-up Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the Company will not, without the prior written consent of the Representatives (which consent may be withheld in their sole discretion), directly or indirectly:  (i) sell, offer to sell, contract to sell or lend any Shares or Related Securities (as defined below); (ii) effect any short sale, or establish or increase any &#x201c;put equivalent position&#x201d; (as defined in Rule 16a-1(h) under the Exchange Act) or liquidate or decrease any &#x201c;call equivalent position&#x201d; (as defined in Rule 16a&#x2011;1(b) under the Exchange Act) of any Shares or Related Securities; (iii) pledge, hypothecate or grant any security interest in any Shares or Related Securities; (iv) in any other way transfer or dispose of any Shares or Related Securities; (v) enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of any Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi) announce the offering of any Shares or Related Securities; (vii) submit or file any registration statement under the Securities Act in respect of any Shares or Related Securities (other than as contemplated by this Agreement with respect to the Offered Securities); (viii) effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Shares;</font><font style="color:#1f497d;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">or (ix) publicly announce the intention to do any of the foregoing; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, that the Company may (A) effect the transactions contemplated hereby and (B) issue Shares or options to purchase Shares, or issue Shares upon exercise of options, pursuant to any stock option, stock bonus or other stock plan or arrangement described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, but only, in the case of directors or executive officers, if the holders of such Shares or options agree in writing with the Underwriters not to sell, offer, dispose of or otherwise transfer any such Shares or options during such Lock-up Period without the prior written consent of the Representatives (which consent may be withheld in its sole discretion).  For purposes of the foregoing, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Related Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into, Shares.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(p)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future Reports to the Representatives.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">During the period of five years hereafter, the Company will furnish to the Representatives, c/o Jefferies, at 520 Madison Avenue, New York, New York 10022, Attention: Global Head of Syndicate, and c/o Guggenheim at 330 Madison Avenue, New York New York, Attention: Head of Equity Capital Markets: (i) as soon as practicable after the end of each fiscal year, copies of the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income, stockholders&#x2019;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">equity and cash flows for the year then ended and the opinion thereon of the Company&#x2019;s independent public or certified public accountants; (ii) as soon as practicable after the filing thereof, copies of each proxy statement, Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other report filed by the Company with the Commission, FINRA or any securities exchange; and (iii) as soon as available, copies of any report or communication of the Company furnished or made available generally to holders of its capital stock; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> that the requirements of this Section 3(p) shall be satisfied to the extent that such reports, statement, communications, financial statements or other documents are available on EDGAR.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(q)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investment Limitation</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company shall not invest or otherwise use the proceeds received by the Company from its sale of the Offered Securities in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">23</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(r)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Stabilization or Manipulation; Compliance with Regulation M</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company will not take, and will ensure that no affiliate of the Company will take, directly or indirectly, any action designed to or that would reasonably be expected to cause or result in stabilization or manipulation of the price of the Shares or any reference security with respect to the Shares, whether to facilitate the sale or resale of the Offered Securities or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(s)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Enforce Lock-Up Agreements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  During the Lock-up Period, the Company will enforce all agreements between the Company and any of its securityholders that restrict or prohibit, expressly or in operation, the offer, sale or transfer of Shares or Related Securities or any of the other actions restricted or prohibited under the terms of the form of Lock-up Agreement.  In addition, the Company will direct the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such &#x201c;lock-up&#x201d; agreements for the duration of the periods contemplated in such agreements, including, without limitation, &#x201c;lock-up&#x201d; agreements entered into by the Company&#x2019;s officers and directors and securityholders pursuant to &#x200e;Section 6(l) hereof.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(t)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company to Provide Interim Financial Statements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Prior to the First Closing Date and each applicable Option Closing Date, the Company will furnish the Underwriters, as soon as they have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company for any period subsequent to the period covered by the most recent financial statements appearing in the Registration Statement and the Prospectus.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(u)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Shares Reserved</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The Company shall, at all times while any Pre-Funded Warrants are outstanding, reserve and keep available out of its authorized but unissued and otherwise unreserved shares of Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of such  Pre-Funded Warrants, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of the then-outstanding Pre-Funded Warrants.  </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	The Representatives, on behalf of the several Underwriters, may, in their sole discretion, waive in writing the performance by the Company of any one or more of the foregoing covenants or extend the time for their performance.</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Payment of Expenses.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i) all expenses incident to the issuance and delivery of the Offered Securities (including all printing and engraving costs), (ii) all fees and expenses of the registrar and transfer agent of the Shares, (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Offered Securities to the Underwriters, (iv) all fees and expenses of the Company&#x2019;s counsel, independent public or certified public accountants and other advisors, (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Time of Sale Prospectus, the Prospectus, each free writing prospectus prepared by or on behalf of, used by, or referred to by the Company, and each preliminary prospectus, and all amendments and supplements thereto, and this Agreement, (vi) all filing fees, reasonable and documented attorneys&#x2019; fees and expenses incurred by the Company or the Underwriters in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Offered Securities for offer and sale under the state securities or blue sky laws, and, if requested by the Representatives, preparing and printing a &#x201c;Blue Sky Survey&#x201d; or memorandum and a &#x201c;Canadian wrapper&#x201d;, and any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, (vii) the costs, fees and expenses incurred by the Underwriters in connection with determining their compliance with the rules and regulations of FINRA related to the Underwriters&#x2019; participation in the offering and distribution of the Offered </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">24</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Securities, including any related filing fees and the legal fees of, and disbursements by, counsel to the Underwriters, in an amount not to exceed $15,000, (viii) the costs and expenses of the Company relating to investor presentations on any &#x201c;road show&#x201d;, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and any such consultants, and the cost of any aircraft chartered in connection with the road show, (ix) the fees and expenses associated with listing the Offered Securities on the Nasdaq, and (x) all other fees, costs and expenses of the nature referred to in Item 14 of Part II of the Registration Statement. Except as provided in this &#x200e;Section 4 or in &#x200e;Section 7, &#x200e;Section 9 or &#x200e;Section 10 hereof, the Underwriters shall pay their own expenses, including the fees and disbursements of their counsel.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Covenant of the Underwriters.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Each Underwriter severally and not jointly covenants with the Company not to take any action that would result in the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not, but for such actions, be required to be filed by the Company under Rule 433(d).</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Conditions of the Obligations of the Underwriters.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The respective obligations of the several Underwriters hereunder to purchase and pay for the Offered Securities as provided herein on the First Closing Date and, with respect to the Optional Shares, each Option Closing Date, shall be subject to the accuracy of the representations and warranties on the part of the Company set forth in &#x200e;Section 1 hereof as of the date hereof and as of the First Closing Date as though then made and, with respect to the Optional Shares, as of each Option Closing Date as though then made, to the timely performance by the Company of its covenants and other obligations hereunder, and to each of the following additional conditions:</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comfort Letter</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  On the date hereof, the Representatives shall have received from KPMG LLP, independent registered public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance satisfactory to the Representatives, containing statements and information of the type ordinarily included in accountant&#x2019;s &#x201c;comfort letters&#x201d; to underwriters, delivered according to Statement of Auditing Standards No. 72 (or any successor bulletin), with respect to the audited and unaudited financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus, and each free writing prospectus, if any. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compliance with Registration Requirements; No Stop Order; No Objection from FINRA.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company shall have filed the Prospectus with the Commission (including the information previously omitted from the Registration Statement pursuant to Rule 430B under the Securities Act) in the manner and within the time period required by Rule 424(b) under the Securities Act; or the Company shall have filed a post&#x2011;effective amendment to the Registration Statement containing the information previously omitted from the Registration Statement pursuant to Rule 430B under the Securities Act, and such post-effective amendment shall have become effective;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment to the Registration Statement shall be in effect, and no proceedings for such purpose shall have been instituted or, to the knowledge of the Company, threatened by the Commission; and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">25</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If a filing has been made with FINRA, FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Material Adverse Change or Ratings Agency Change</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  For the period from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">in the judgment of the Representatives, there shall not have occurred any Material Adverse Change; and</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#x201c;nationally recognized statistical rating organization&#x201d; as that term is used in Rule 15c3-1(c)(2)(vi)(F) under the Exchange Act.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Opinion of Counsel for the Company</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  On each of the First Closing Date and each Option Closing Date the Representatives shall have received the opinion and negative assurance letter of Goodwin Procter LLP, counsel for the Company, dated as of such date, in the form and substance satisfactory to the Representatives. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Opinion of Intellectual Property Counsel for the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">On each of the First Closing Date and each Option Closing Date, the Representatives shall have received the opinion of Squire Patton Boggs, counsel for the Company with respect to certain intellectual property matters, dated as of such date, in the form and substance satisfactory to the Representatives.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Opinion of Counsel for the Underwriters</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  On each of the First Closing Date and each Option Closing Date the Representatives shall have received the opinion and negative assurance letter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel for the Underwriters in connection with the offer and sale of the Offered Securities, in form and substance satisfactory to the Underwriters, dated as of such date. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Officers&#x2019; Certificate</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  On each of the First Closing Date and each Option Closing Date, the Representatives shall have received a certificate executed by the Chief Executive Officer or President of the Company and the Chief Financial Officer of the Company, on behalf of the Company and not in their individual capacities, dated as of such date, to the effect set forth in &#x200e;Section 6(b)(ii) and further to the effect that:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">for the period from and including the date of this Agreement through and including such date, there has not occurred any Material Adverse Change;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the representations, warranties and covenants of the Company set forth in Section 1 of this Agreement are true and correct with the same force and effect as though expressly made on and as of such date; and</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the Company has complied with all the agreements hereunder and satisfied all the conditions on its part to be performed or satisfied hereunder at or prior to such date.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bring-down Comfort Letter</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  On each of the First Closing Date and each Option Closing Date the Representatives shall have received from KPMG LLP, independent registered public accountants for the Company, a letter dated such date, in form and substance satisfactory to the Representatives, which </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">26</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">letter shall:  (i) reaffirm the statements made in the letter furnished by them pursuant to &#x200e;Section 6(a), except that the specified date referred to therein for the carrying out of procedures shall be no more than three business days prior to the First Closing Date or the applicable Option Closing Date, as the case may be; and (ii) cover certain financial information contained in the Prospectus.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lock-Up Agreements.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  On or prior to the date hereof, the Company shall have furnished to the Representatives an agreement in the form of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> hereto from each of the persons listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> hereto, and each such agreement shall be in full force and effect on each of the First Closing Date and each Option Closing Date.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rule 462(b) Registration Statement</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> In the event that a Rule 462(b) Registration Statement is filed in connection with the offering contemplated by this Agreement, such Rule 462(b) Registration Statement shall have been filed with the Commission on the date of this Agreement and shall have become effective automatically upon such filing.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">CFO Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. On each of the First Closing Date and each Option Closing Date, the Representatives shall have received a certificate executed by the Chief Financial Officer of the Company, on behalf of the Company and not in his individual capacity, dated as of such date, in form and substance satisfactory to the Underwriters. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Form of Warrants.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> On the Closing Date, the Pre-Funded Warrants shall be delivered to those persons and entities as directed by the Representative in form and substance as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibits C</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> hereto, dated as of such date.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(m)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional Documents</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  On or before each of the First Closing Date and each Option Closing Date, the Representatives and counsel for the Underwriters shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the issuance and sale of the Offered Securities as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Offered Securities as contemplated herein and in connection with the other transactions contemplated by this Agreement shall be satisfactory in form and substance to the Representatives and counsel for the Underwriters.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If any condition specified in this &#x200e;Section 6 is not satisfied when and as required to be satisfied, this Agreement may be terminated by the Representatives by notice from the Representatives to the Company at any time on or prior to the First Closing Date and, with respect to the Optional Shares, at any time on or prior to the applicable Option Closing Date, which termination shall be without liability on the part of any party to any other party, except that &#x200e;Section 4, &#x200e;Section 7, &#x200e;Section 9 and &#x200e;Section 10 shall at all times be effective and shall survive such termination.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Reimbursement of Underwriters&#x2019; Expenses. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> If this Agreement is terminated by the Representatives pursuant to &#x200e;Section 6, &#x200e;Section 11, or if the sale to the Underwriters of the Offered Securities on the First Closing Date is not consummated because of any refusal, inability or failure on the part of the Company to perform any agreement herein or to comply with any provision hereof, the Company agrees to reimburse the Representatives and the other Underwriters (or such Underwriters as have terminated this Agreement with respect to themselves), severally, upon demand for all  documented out-of-pocket expenses that shall have been reasonably incurred by the Representatives and the Underwriters in connection with the proposed purchase and the offering and sale of the Offered Securities, including, but not limited to, fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">27</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effectiveness of this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  This Agreement shall become effective upon the execution and delivery hereof by the parties hereto. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indemnification.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification of the Underwriters</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Offered Securities have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii) any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any Marketing Material or the Prospectus (or any amendment or supplement to the foregoing), or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading; and to reimburse each Underwriter and each such affiliate, director, officer, employee, agent and controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by such Underwriter or such affiliate, director, officer, employee, agent or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company by the Representatives in writing expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any such free writing prospectus, any Marketing Material or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information consists of the information described in &#x200e;Section 9(b) below. The indemnity agreement set forth in this &#x200e;Section 9(a) shall be in addition to any liabilities that the Company may otherwise have.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification of the Company, its Directors and Officers</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act, against any loss, claim, damage, liability or expense, as incurred, to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii) any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433 of the Securities Act or the Prospectus (or any such amendment or supplement) or the omission or alleged omission </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">28</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, such preliminary prospectus, the Time of Sale Prospectus, such free writing prospectus or the Prospectus (or any such amendment or supplement), in reliance upon and in conformity with information relating to such Underwriter furnished to the Company by the Representatives in writing expressly for use therein; and to reimburse the Company, or any such director, officer or controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action.  The Company hereby acknowledges that the only information that the Representatives have furnished to the Company expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement to the foregoing) are the statements set forth in</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the first paragraph under the heading &#x201c;Underwriting&#x2014;Commissions and Expenses&#x201d;, the first paragraph under the heading &#x201c;Underwriting&#x2014;Stabilization,&#x201d; and the information under the heading &#x201c;Underwriting&#x2014;Electronic Distributions,&#x201d; in each case contained in the Preliminary Prospectus Supplement and the Final Prospectus Supplement. The indemnity agreement set forth in this &#x200e;Section 9(b) shall be in addition to any liabilities that each Underwriter may otherwise have.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Notifications and Other Indemnification Procedures</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Promptly after receipt by an indemnified party under this &#x200e;Section 9 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this &#x200e;Section 9, notify the indemnifying party in writing of the commencement thereof, but the omission to so notify the indemnifying party will not relieve the indemnifying party from any liability which it may have to any indemnified party to the extent the indemnifying party is not materially prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may have otherwise than on account of this indemnity agreement.  In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, that if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties.  Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#x2019;s election to so assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this &#x200e;Section 9 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i) the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the Representatives (in the case of counsel for the indemnified parties referred to in Section 9(a) above) or by the Company (in the case of counsel for the indemnified parties referred to in &#x200e;Section 9(b) above)) or (ii) the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">29</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">commencement of the action or (iii) the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Settlements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The indemnifying party under this &#x200e;Section 9 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment.  Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by &#x200e;Section 9(c) hereof, the indemnifying party shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement.  No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such indemnified party.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Contribution.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  If the indemnification provided for in &#x200e;Section 9 is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Offered Securities pursuant to this Agreement or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations.  The relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Offered Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the Offered Securities pursuant to this Agreement (before deducting expenses) received by the Company, and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth on the front cover page of the Prospectus, bear to the aggregate initial public offering price of the Offered Securities as set forth on such cover.  The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Underwriters, on the other hand, and the parties&#x2019; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in &#x200e;Section 9(c), any documented legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim.  The provisions set forth in &#x200e;Section 9(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this &#x200e;Section 10;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">30</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> that no additional notice shall be required with respect to any action for which notice has been given under &#x200e;Section 9(c) for purposes of indemnification.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this &#x200e;Section 10 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this &#x200e;Section 10.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the provisions of this &#x200e;Section 10, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Offered Securities underwritten by it and distributed to the public.  No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.  The Underwriters&#x2019; obligations to contribute pursuant to this &#x200e;Section 10 are several, and not joint, in proportion to their respective underwriting commitments as set forth opposite their respective names on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  For purposes of this &#x200e;Section 10, each affiliate, director, officer, employee and agent of an Underwriter and each person, if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company.</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Default of One or More of the Several Underwriters</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  If, on the First Closing Date or any Option Closing Date any one or more of the several Underwriters shall fail or refuse to purchase Offered Securities that it or they have agreed to purchase hereunder on such date, and the aggregate number of Offered Securities which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Offered Securities to be purchased on such date, the Representatives may make arrangements satisfactory to the Company for the purchase of such Offered Securities by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions that the number of Firm Securities set forth opposite their respective names on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> bears to the aggregate number of Firm Securities set forth opposite the names of all such non-defaulting Underwriters, or in such other proportions as may be specified by the Representatives with the consent of the non-defaulting Underwriters, to purchase the Offered Securities which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date. If, on the First Closing Date or any Option Closing Date any one or more of the Underwriters shall fail or refuse to purchase Offered Securities and the aggregate number of Offered Securities with respect to which such default occurs exceeds 10% of the aggregate number of Offered Securities to be purchased on such date, and arrangements satisfactory to the Representatives and the Company for the purchase of such Offered Securities are not made within 48 hours after such default, this Agreement shall terminate without liability of any party to any other party except that the provisions of &#x200e;Section 4, &#x200e;Section 7, &#x200e;Section 9 and &#x200e;Section 10 shall at all times be effective and shall survive such termination.  In any such case either the Representatives or the Company shall have the right to postpone the First Closing Date or the applicable Option Closing Date, as the case may be, but in no event for longer than seven days in order that the required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As used in this Agreement, the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Underwriter</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall be deemed to include any person substituted for a defaulting Underwriter under this &#x200e;Section 11.  Any action taken under this &#x200e;Section 11 shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">31</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Termination of this Agreement</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Prior to the purchase of the Firm Securities by the Underwriters on the First Closing Date, this Agreement may be terminated by the Representatives by notice given to the Company if at any time: (i) trading or quotation in any of the Company&#x2019;s securities shall have been suspended or limited by the Commission or by the Nasdaq, or trading in securities generally on either the Nasdaq or the NYSE shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges; (ii) a general banking moratorium shall have been declared by any of federal or New York, authorities; (iii) there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#x2019; or international political, financial or economic conditions, as in the judgment of the Representatives is material and adverse and makes it impracticable to market the Offered Securities in the manner and on the terms described in the Time of Sale Prospectus or the Prospectus or to enforce contracts for the sale of securities; (iv) in the judgment of the Representatives there shall have occurred any Material Adverse Change; or (v) the Company shall have sustained a loss by strike, fire, flood, earthquake, accident or other calamity of such character as in the judgment of the Representatives may interfere materially with the conduct of the business and operations of the Company regardless of whether or not such loss shall have been insured.  Any termination pursuant to this &#x200e;Section 12 shall be without liability on the part of (a) the Company to any Underwriter, except that the Company shall be obligated to reimburse the expenses of the Representatives and the Underwriters pursuant to &#x200e;Section 4 or &#x200e;Section 7 hereof or (b) any Underwriter to the Company; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> that the provisions of &#x200e;Section 9 and &#x200e;Section 10 shall at all times be effective and shall survive such termination.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Advisory or Fiduciary Relationship.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company acknowledges and agrees that (a) the purchase and sale of the Offered Securities pursuant to this Agreement, including the determination of the public offering price of the Offered Securities and any related discounts and commissions, is an arm&#x2019;s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b) in connection with the offering contemplated hereby and the process leading to such transaction, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or the Company&#x2019;s other stockholders, or its creditors, employees or any other party, (c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other matters) and no Underwriter has any obligation to the Company with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and (e) the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Representations and Indemnities to Survive Delivery</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> The respective indemnities, agreements, representations, warranties and other statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of any Underwriter or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Offered Securities sold hereunder and any termination of this Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">32</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notices.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows:</font></div></div>
  <p style="margin-left:3.333%;text-indent:6.897%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If to the Representatives:	Jefferies LLC</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	520 Madison Avenue<br>	New York, New York 10022<br>	Attention: General Counsel</font></p>
  <p style="text-indent:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Guggenheim Securities, LLC</font></p>
  <p style="text-indent:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">330 Madison Avenue</font></p>
  <p style="text-indent:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">New York, New York 10017</font></p>
  <p style="text-indent:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Attention: Head of Equity Capital Markets</font></p>
  <p style="text-indent:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">with a copy to:	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.<br>	One Financial Center<br>	Boston, MA 02111<br>	Attention: William C. Hicks, Esq.<br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If to the Company:	Adicet Bio, Inc.<br>	1000 Bridge Parkway<br>	Redwood City, CA 94065<br>	Attention:  Chen Schor and Nick Harvey</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">with a copy to:	Goodwin Procter LLP<br>	100 Northern Avenue<br>	Boston, MA 02210</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Attention: Danielle Lauzon and Gabriela Morales-Rivera</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Any party hereto may change the address for receipt of communications by giving written notice to the others.</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Successors</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  This Agreement will inure to the benefit of and be binding upon the parties hereto, including any substitute Underwriters pursuant to &#x200e;Section 11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred to in &#x200e;Section 9 and &#x200e;Section 10, and in each case their respective successors, and no other person will have any right or obligation hereunder.  The term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">successors</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall not include any purchaser of the Offered Securities as such from any of the Underwriters merely by reason of such purchase.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Partial Unenforceability.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof.  If any section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Recognition of the U.S. Special Resolution Regimes.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">33</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this Agreement, (A) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">BHC Act Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; has the meaning assigned to the term &#x201c;affiliate&#x201d; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k); (B) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Covered Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any of the following: (i) a &#x201c;covered entity&#x201d; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#x201c;covered bank&#x201d; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii) a &#x201c;covered FSI&#x201d; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b); (C) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Default Right</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and (D) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">U.S. Special Resolution Regime</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 19.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Governing Law Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state.  Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Related Proceedings</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Specified Courts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Related Judgment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding.  Service of any process, summons, notice or document by mail to such party&#x2019;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court.  The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.   </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">With respect to any Related Proceeding, each party irrevocably waives, to the fullest extent permitted by applicable law, all immunity (whether on the basis of sovereignty or otherwise) from jurisdiction, service of process, attachment (both before and after judgment) and execution to which it might otherwise be entitled in the Specified Courts, and with respect to any Related Judgment, each party waives any such immunity in the Specified Courts or any other court of competent jurisdiction, and will not raise or claim or cause to be pleaded any such immunity at or in respect of any such Related Proceeding or Related Judgment, including, without limitation, any immunity pursuant to the United States Foreign Sovereign Immunities Act of 1976, as amended.</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">Section 20.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">General Provisions.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof.  This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.  The words &#x201c;execution,&#x201d; &#x201c;signed,&#x201d; </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">34</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;signature,&#x201d; &#x201c;delivery,&#x201d; and words of like import in or relating to this Agreement or any document to be signed in connection with this Agreement shall be deemed to include electronic signatures, deliveries or the keeping of records in electronic form. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, and the parties hereto consent to conduct the transactions contemplated hereunder by electronic means.  This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit.  The section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of &#x200e;Section 9 and the contribution provisions of &#x200e;Section 10, and is fully informed regarding said provisions.  Each of the parties hereto further acknowledges that the provisions of &#x200e;Section 9 and &#x200e;Section 10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and its business in order to assure that adequate disclosure has been made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as contemplated by the Securities Act and the Exchange Act.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">35</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms.</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Very truly yours,</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ADICET BIO, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">/s/ Chen Schor	</font></p>
  <p style="margin-left:44.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name: Chen Schor</font></p>
  <p style="margin-left:44.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:   President and Chief Executive Officer,</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">       Secretary and Treasurer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[Signature Page to Underwriting Agreement]</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representatives in New York, New York as of the date first above written.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">JEFFERIES LLC</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">GUGGENHEIM SECURITIES, LLC</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Acting individually and as Representatives</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of the several Underwriters named in</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the attached </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">JEFFERIES LLC</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">/s/ Michael Brinkman		</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Name: Michael Brinkman</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Title:   Managing Director</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">GUGGENHEIM SECURITIES, LLC</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">/s/ Shiv Taylor		</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Name: Shiv Taylor</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Title:   Senior Managing Director</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[Signature Page to Underwriting Agreement]</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;" id="scheda"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.66%;"></td>
    <td style="width:1.58%;"></td>
    <td style="width:16.26%;"></td>
    <td style="width:16.26%;"></td>
    <td style="width:20.24%;"></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Underwriters</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</font></p><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">to be Purchased</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Pre-Funded Warrants</font></p><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">to be Purchased</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jefferies LLC</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;text-align:left;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,768,781</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;text-align:left;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,673,720</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Guggenheim Securities, LLC</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;text-align:left;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,063,314</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;text-align:left;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,829,187</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Truist Securities, Inc.</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;text-align:left;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,976,013</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;text-align:left;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">928,987</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Wedbush Securities Inc.</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;text-align:left;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,893,826</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;text-align:left;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">591,173</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">JMP Securities LLC</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;text-align:left;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,352,733</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;text-align:left;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">422,266</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="text-indent:-36pt;padding-left:36pt;font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Total</font></p></td>
    <td style="padding-left:0.05in;vertical-align:top;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.05in;vertical-align:top;border-bottom:2.25pt double;padding-right:0.05in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,054,667</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.05in;vertical-align:top;border-bottom:2.25pt double;padding-right:0.05in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,445,333</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-left:0.05in;vertical-align:top;border-bottom:2.25pt double #ffffff03;padding-right:0.05in;"><p style="font-size:11pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:2.7pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule A</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;" id="schedc"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">B</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Free Writing Prospectuses Included in the Time of Sale Prospectus</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[None]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule B</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule C</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="exha"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Section 5(d) Communications</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[None]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule C</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Form of Lock-up Agreement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="exhd"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">January ___, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Jefferies LLC<br>Guggenheim Securities, LLC</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As Representatives of the Several Underwriters</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>c/o Jefferies LLC<br>520 Madison Avenue<br>New York, New York 10022<br><br>c/o Guggenheim Securities, LLC</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">330 Madison Avenue</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">New York, New York 10017</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">RE:  Adicet Bio, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Ladies &amp; Gentlemen:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned is an owner of shares of common stock, par value $.0001 per share, of the Company (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) or of securities convertible into or exchangeable or exercisable for Shares.  The Company proposes to conduct a public offering of Shares (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Offering</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) for which Jefferies LLC (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Jefferies</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Guggenheim Securities, LLC (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Guggenheim</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) will act as the representatives of the underwriters (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Representatives</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  The undersigned recognizes that the Offering will benefit each of the Company and the undersigned.  The undersigned acknowledges that you are relying on the representations and agreements of the undersigned contained in this letter agreement in conducting the Offering and, at a subsequent date, in entering into an underwriting agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Underwriting Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and other underwriting arrangements with the Company with respect to the Offering.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Annex A sets forth definitions for capitalized terms used in this letter agreement that are not defined in the body of this agreement.  Those definitions are a part of this agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby agrees that, during the Lock-up Period, the undersigned will not (and will cause any Family Member not to), without the prior written consent of the Representatives, which may withhold their consent in their sole discretion:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sell or Offer to Sell any Shares or Related Securities currently or hereafter owned either of record or beneficially (as defined in Rule 13d-3 under the Exchange Act) by the undersigned or such Family Member,</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">enter into any Swap,</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and sale of any Shares or Related Securities, or cause to be filed a registration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">publicly announce any intention to do any of the foregoing.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The foregoing will not apply to the registration of the offer and sale of the Shares, and the sale of the Shares to you, in each case as contemplated by the Underwriting Agreement.  In addition, the foregoing restrictions shall not apply to the transfer of Shares or Related Securities:</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(i) by gift, (ii) by will or intestate succession, (iii) to a Family Member or (iv) to a trust whose direct or indirect beneficiaries consist exclusively of one or more of the undersigned and/or a Family Member; </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">by operation of law, including pursuant to a domestic order, divorce settlement, divorce decree, separation agreement or pursuant to an order of a court of competent jurisdiction enforcing such agreement;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to a charitable trust; </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to a corporation, limited liability company or partnership wholly owned by the undersigned and/or one or more Family Members;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the Company as forfeitures to satisfy tax withholding obligations of the undersigned in connection with the vesting or exercise of equity awards by the undersigned existing as of the date of the Prospectus (in each case used herein, as defined in the Underwriting Agreement) and described or incorporated by reference in the Prospectus or pursuant to arrangements under which the Company has the option to repurchase such shares or a right of first refusal with respect to transfer of such shares, provided that (i) any required filing under Section 16 of the Exchange Act made during the Lock-Up Period shall clearly indicate in the footnotes thereto that (A) the filing relates to the circumstances described above and (B) no Related Securities were sold by the reporting person other than such transfers to the Company as described above and (ii) the undersigned does not otherwise voluntarily effect any other public filing or report regarding such transfers during the Lock-Up Period;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">pursuant to a &#x201c;net exercise&#x201d; or &#x201c;cashless exercise&#x201d; (to satisfy exercise price or related withholding obligations) by the undersigned of equity awards existing as of the date of the Prospectus and described or incorporated by reference in the Prospectus, provided that any Shares acquired upon the net exercise or cashless exercise of equity awards described in this clause shall be subject to the restrictions set forth in this agreement, provided that (i) any required filing under Section 16 of the Exchange Act made during the Lock-Up Period shall clearly indicate in the footnotes thereto that (A) the filing relates to the circumstances described above and (B) no Related Securities were sold by the reporting person other than such transfers to the Company as described above and (ii) the undersigned does not otherwise voluntarily effect any other public filing or report regarding such transfers during the Lock-Up Period;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">distributions of Related Securities to limited partners, limited liability company members or stockholders of the undersigned;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">transactions relating to Related Securities acquired in the Offering or in open market transactions after the closing of the Offering;</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the undersigned&#x2019;s affiliates or to any investment fund or other entity controlled or managed by or on behalf of the undersigned or one or more of its affiliates; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">pursuant to a bona fide third-party tender offer for all outstanding shares of the Company, merger, consolidation or other similar transaction made to all holders of the Company&#x2019;s securities involving a change of control of the Company (including, without limitation, the entering into of any lock-up, voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of Related Securities in connection with such transaction, or vote any Related Securities in favor of any transaction), provided that in the event that such tender offer, merger, consolidation or other such transaction is not completed, such securities held by the undersigned shall remain subject to the provisions of this agreement.</font></div></div>
  <p style="text-indent:-13.293%;padding-left:11.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In any such case, it shall be a condition to such transfer that:</font></p>
  <p style="text-indent:-13.293%;padding-left:11.733%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">with respect to any transfer or distribution pursuant to each of the preceding clauses (a) through (d), (g) and (i),  (A) any such transfer shall not involve a disposition for value and (B) each transferee or donee executes and delivers to the Representatives an agreement in form and substance satisfactory to the Representatives stating that such transferee is receiving and holding such Shares and/or Related Securities subject to the provisions of this letter agreement and agrees not to Sell or Offer to Sell such Shares and/or Related Securities, engage in any Swap or engage in any other activities restricted under this letter agreement except in accordance with this letter agreement (as if such transferee had been an original signatory hereto); and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">with respect to any transfer or distribution pursuant to each of the preceding clauses (a) through (d), and (g) through (i), prior to the expiration of the Lock-up Period, no public disclosure or filing under the Exchange Act by any party to the transfer (donor, donee, transferor or transferee) shall be required, or made voluntarily, reporting a reduction in beneficial ownership of Shares.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In addition, the restrictions described in this agreement shall not apply to the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act, provided that no transfers occur under such plan during the Lock-Up Period and no public announcement or filing shall be required or voluntarily made by any person in connection therewith other than general disclosure in Company periodic reports to the effect that the Company directors and officers may enter into such trading plans from time to time.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#x2019;s transfer agent and registrar against the transfer of Shares or Related Securities held by the undersigned and the undersigned's Family Members, if any, except in compliance with the foregoing restrictions.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">With respect to the Offering only, the undersigned waives any registration rights relating to registration under the Securities Act of the offer and sale of any Shares and/or any Related Securities owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned confirms that the undersigned has not, and has no knowledge that any Family Member has, directly or indirectly, taken any action designed to or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale of the Shares.  The undersigned will not, and will cause any Family Member not to take, directly or indirectly, any such action.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned acknowledges and agrees that the underwriters have not provided any recommendation or investment advice nor have the underwriters solicited any action from the undersigned with respect to the Offering and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">It is understood that if (i) the Company notifies the Underwriters that it does not intend to proceed with the Offering, (ii) the Underwriting Agreement does not become effective on or prior to January 31, 2024, (iii) the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Shares, or (iv) the closing of the Offering pursuant to the Underwriting Agreement has not occurred by January 31, 2024, the undersigned will be released from its obligations under this Agreement. Whether or not the Offering occurs as currently contemplated or at all depends on market conditions and other factors.  The Offering will only be made pursuant to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and you.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned hereby represents and warrants that the undersigned has full power, capacity and authority to enter into this letter agreement.  This letter agreement is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This letter agreement shall be governed by, and construed in accordance with, the laws of the State of New York.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Signature</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Printed Name of Person Signing</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Title</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[Signature Page to Lock-up Agreement]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Certain Defined Terms<br>Used in Lock-up Agreement<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For purposes of the letter agreement to which this Annex A is attached and of which it is made a part:</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Call Equivalent Position</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">shall have the meaning set forth in Rule 16a-1(b) under the Exchange Act.</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">shall mean the Securities Exchange Act of 1934, as amended.</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Family Member</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean any relationship by blood, domestic partnership, marriage or adoption not more remote than first cousin, the spouse of the undersigned, an immediate family member of the undersigned or an immediate family member of the undersigned's spouse, in each case living in the undersigned's household or whose principal residence is the undersigned's household (regardless of whether such spouse or family member may at the time be living elsewhere due to educational activities, health care treatment, military service, temporary internship or employment or otherwise).  &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Immediate family member</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; as used above shall have the meaning set forth in Rule 16a-1(e) under the Exchange Act.</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lock-up Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean the period beginning on the date hereof and continuing through the close of trading on the date that is 90 days after the date of the Prospectus (as defined in the Underwriting Agreement).</font></p>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Put Equivalent Position</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall have the meaning set forth in Rule 16a-1(h) under the Exchange Act.</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Related Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible into Shares.</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean the Securities Act of 1933, as amended.</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sell or Offer to Sell</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean to:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:13.333%;text-indent:-4%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x2013;	sell, offer to sell, contract to sell or lend,</font></p>
  <p style="margin-left:13.333%;text-indent:-4%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x2013;	effect any short sale or establish or increase a Put Equivalent Position or liquidate or decrease any Call Equivalent Position</font></p>
  <p style="margin-left:13.333%;text-indent:-4%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x2013;	pledge, hypothecate or grant any security interest in, or</font></p>
  <p style="margin-left:13.333%;text-indent:-4%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x2013;	in any other way transfer or dispose of,</font></p>
  <p style="margin-left:6.667%;text-indent:3.571%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">in each case whether effected directly or indirectly.</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Swap</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Capitalized terms not defined in this Annex A shall have the meanings given to them in the body of this lock-up agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Directors and Executive Officers </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>           Signing Lock-up Agreement</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">            </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Directors:</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Chen Schor</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Jeffrey Chodakewitz</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Steve Dubin</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Carl L. Gordon</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Aya Jakobovits</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Andrew Sinclair</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Michael Kauffman</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Katie Peng</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Executive Officers:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Nick Harvey</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Francesco Galimi</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Blake Aftab</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Don Healey</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Stockholders:</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Abingworth Bioventures 8 LP</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	OrbiMed Private Investments V, LP</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	OrbiMed Private Investments VI, LP</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	OrbiMed Israel Partners Limited Partnership</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	OrbiMed Israel Partners II, L.P.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit C</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Form of Pre-Funded Warrant</font></p>
  <p style="margin-left:0.013%;text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.95pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADICET BIO, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.013%;text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.8pt;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WARRANT TO PURCHASE COMMON STOCK</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-0.094%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.537%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares: [_________] (subject to adjustment)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.55pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant No. [___] 	 Original Issue Date: January [___], 2024</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.669%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5.45pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [___________] or its registered assigns (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Holder</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [______] shares of common stock, $0.0001 par value per share (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), of the Company (each such share, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant Share</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and all such shares, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) at an exercise price per share equal to $0.0001 per share (as adjusted from time to time as provided in Section 9 herein, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) at any time and from time to time on or after the date hereof (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Original Issue Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), subject to the following terms and conditions:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.669%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.1pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. For purposes of this Warrant, the following terms shall have the following meanings:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.472%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.1pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(a) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:13.333%;text-indent:-0.112%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.1pt;margin-right:2.898%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(b) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Commission</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the United States Securities and Exchange Commission.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.731%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.1pt;margin-right:2.898%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(c) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Closing Sale Price</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national securities exchange or other trading market on the relevant date, the last quoted bid price for the security in the over-the-counter market on the relevant date as reported by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors&#x2019; determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:-0.094%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.537%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(d) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Marketable Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means securities meeting all of the following requirements:</font></p>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.35pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and is then current in its filing of all required reports and other information under the Securities Act and the Exchange Act; (ii) the class and</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit C</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.35pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">series of shares or other security of the issuer that would be received by Holder in connection with the Fundamental Transaction (as defined below) were Holder to exercise this Warrant on or prior to the closing thereof is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market, and (iii) following the closing of such Fundamental Transaction, the Holder would not be restricted from publicly re-selling all of the issuer&#x2019;s shares and/or other securities that would be received by the Holder in such Fundamental Transaction were the Holder to exercise or convert this Warrant in full on or prior to the closing of such Fundamental Transaction.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:13.1pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Principal Trading Market</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the national securities exchange or other trading market on which the Common Stock is primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Market.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:13.2pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Company&#x2019;s Registration Statement on Form S-3 (File No. 333-263587), as amended, that became effective on May 9, 2022. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.95pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as amended.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:13.3pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Trading Day</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any weekday on which the Principal Trading Market is open for trading. If the Common Stock is not listed or admitted for trading, &#x201c;Trading Day&#x201d; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City are authorized or required by law or other governmental action to close.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.45pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Transfer Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Computershare Trust Company, N.A., the Company&#x2019;s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.1pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issuance of Securities; Registration of Warrants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Warrant, as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or an exchange meeting the requirements of Section 3(a)(9) of the Exchange Act as in effect on the Original Issue Date, the Warrant Shares, are not &#x201c;restricted securities&#x201d; under Rule 144 promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant Register</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0.15pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Registration of Transfers</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">New Warrant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EN-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">NY\5662481.1</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0.15pt;min-width:6.667%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company&#x2019;s own expense any New Warrant under this Section 3. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.2pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exercise and Duration of Warrants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.45pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">All or any part of this Warrant shall be exercisable by the registered Holder in the manner set forth in Section 10 at any time and from time to time on or after the Original Issue Date. </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.5pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Holder may exercise this Warrant by delivering to the Company an exercise notice, in the form attached as Schedule 1 hereto (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), completed and duly signed. The date on which such exercise notice is delivered to the Company (as determined in accordance with the notice provisions hereof) is an </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Exercise Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.2pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delivery of Warrant Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Upon exercise of this Warrant, the Company shall promptly (but in no event later than three (3) Trading Days after the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder&#x2019;s or its designee&#x2019;s balance account with The Depository Trust Company (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">DTC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities Transfer Program or if the certificates are required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company&#x2019;s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&#x2019;s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be.  </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If by the close of the third (3rd) Trading Day after the Exercise Date, the Company fails to deliver to the Holder a certificate representing the required number of Warrant Shares in the manner required pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 5(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> or fails to credit the Holder&#x2019;s DTC account for such number of Warrant Shares to which the Holder is entitled, and if after such third (3rd) Trading Day and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EN-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">NY\5662481.1</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">which the Holder anticipated receiving upon such exercise (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Buy-In</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then the Company shall, within three (3) Trading Days after the Holder&#x2019;s request promptly honor its obligation to deliver to the Holder a certificate or certificates representing such Warrant Shares and pay cash to the Holder in an amount equal to the excess (if any) of Holder&#x2019;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the Buy-In less the product of (A) the number of shares of Common Stock purchased in the Buy-In, times (B) the Closing Sale Price of a share of Common Stock on the Exercise Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.35pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To the extent permitted by law and subject to Section 5(b), the Company&#x2019;s obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in Section 11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to Section 5(b), nothing herein shall limit the Holder&#x2019;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#x2019;s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Charges, Taxes and Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.2pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Replacement of Warrant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&#x2019;s obligation to issue the New Warrant.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reservation of Warrant Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Company covenants that it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EN-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">NY\5662481.1</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:6.667%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Certain Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Number of Warrant Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) are subject to adjustment from time to time as set forth in this Section 9.  </font></div></div>
  <div style="margin-left:1.333%;text-indent:13.513%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.5138394802720265%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Stock Dividends and Splits</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock that is payable in shares of Common Stock, (ii) subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii) combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv) issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company, then in each such case the Number of Warrant Shares shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately after such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately before such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Number of Warrant Shares shall be recomputed accordingly as of the close of business on such record date and thereafter the Number of Warrant Shares shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination.</font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pro Rata Distributions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security (including Common Stock), or (iv) cash or any other asset (in each case, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Distribution</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), other than a reclassification as to which Section 9(c) applies, then in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the ownership limitation set forth in Section 11(a) hereof) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the participation in such Distribution;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, to the extent that the Holder&#x2019;s right to participate in any such Distribution would result in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof, then the Holder shall not be entitled to participate in such </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EN-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">NY\5662481.1</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Distribution to such extent (or in the beneficial ownership of any Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as the delivery to such Holder of such portion would not result in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0.25pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Fundamental Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity, (ii) the Company effects any sale to another Person of all or substantially all of its assets in one transaction or a series of related transactions, (iii) pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv) the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 9(a) above) (in any such case, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Fundamental Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the Number of Warrant Shares (in the case of clause (iii) above, assuming it had tendered, and the offeror had accepted, such Warrant Shares) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Alternate Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i) the Alternate Consideration is solely cash and the Company provides for the simultaneous &#x201c;cashless exercise&#x201d; of this Warrant pursuant to Section 10 below or (ii) prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. Notwithstanding the foregoing, in the event of a </font></div></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Fundamental Transaction where the consideration payable to holders of Common Stock consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities, then this</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.55pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant shall automatically be deemed to be exercised in full in a &#x201c;cashless exercise&#x201d; pursuant to Section 10 below effective immediately prior to and contingent upon the consummation of such Fundamental Transaction.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EN-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">6</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">NY\5662481.1</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.5pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Simultaneously with any adjustment to the Number of Warrant Shares pursuant to Section 9 the Exercise Price shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased Number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common Stock then in effect.  </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.45pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Calculations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. All calculations under this Section 9 shall be made to the nearest one-hundredth of one cent or the nearest whole share, as applicable. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notice of Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company&#x2019;s transfer agent.  </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.25pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notice of Corporate Events</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by Section 9(c), other than a Fundamental Transaction under clause (iii) of Section 9(c), then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10) days prior to the date such Fundamental Transaction is consummated.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:5.45pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cashless Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding anything contained herein to the contrary, this Warrant may only be exercised through a &#x201c;cashless exercise.&#x201d; Upon exercise, the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section 3(a)(9) of the Securities Act as determined as follows:  </font></div></div>
  <p style="margin-left:13.333%;text-indent:-0.281%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:53.417%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">X = Y [(A-B)/A] where:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EN-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">7</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">NY\5662481.1</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:-0.128%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.1pt;margin-right:13.593%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;X&#x201d; equals the number of Warrant Shares to be issued to the Holder; &#x201c;Y&#x201d; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:13.333%;text-indent:-0.108%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;A&#x201d; equals the Closing Sale Price per share of Common Stock as of the</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:-0.108%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.4pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Trading Day on the date immediately preceding the Exercise Date; and</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:13.333%;text-indent:-0.114%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.5pt;margin-right:4.676%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;B&#x201d; equals the Exercise Price per Warrant Share then in effect on the Exercise Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.669%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.5pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in such a &#x201c;cashless exercise&#x201d; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.35pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In no event will the exercise of this Warrant be settled in cash.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.2pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Limitations on Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.7pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares if, upon giving effect to such exercise, (i) immediately prior to the exercise, the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act, beneficially owns an aggregate number of shares of Common Stock greater than 9.99% (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Maximum Percentage</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of the total number of issued and outstanding shares of Common Stock of the Company without taking into account any Warrant Shares, or (ii) immediately following exercise, the combined voting power of the securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act would be greater than 9.99% of the combined voting power of all of the securities of the Company then outstanding following such exercise without taking into account any Warrant Shares. Any portion of an exercise that would result in the issuance of shares in excess of the Maximum Percentage shall be treated as null and void ab initio. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company&#x2019;s most recent Form 10-Q or Form 10-K, as the case may be, filed with the Commission prior to the date hereof, (y) a more recent public announcement by the Company or (z) any other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three (3) Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage specified not in excess of 19.99% specified in such notice; provided that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Company. For purposes of this Section 11(a), the aggregate number of shares of Common Stock or voting </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EN-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">8</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">NY\5662481.1</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.7pt;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x) exercise of the remaining unexercised and non-cancelled portion of this Warrant by the Holder and (y) exercise or conversion of the unexercised, non-converted or non-cancelled portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="margin-left:6.667%;text-indent:16.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:15.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.0017892921046148%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Section 11 shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section 9(c) of this Warrant.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Fractional Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional shares.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:5.55pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via confirmed email prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed e-mail on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses and e-mail addresses for such communications shall be:  </font></div></div>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5.35pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If to the Company:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">200 Berkeley Street, 19th Floor</font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Boston, Massachusetts</font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Attention: Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Telephone:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Email:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-0.106%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.55pt;margin-right:5.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If to the Holder, to its address or e-mail address set forth herein or on the books and records of the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.602%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.6pt;margin-right:0.435%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Or, in each of the above instances, to such other address or e-mail address as the recipient party has specified by written notice given to each other party at least five (5) days prior to the effectiveness of such change.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EN-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">9</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">NY\5662481.1</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.204%;text-indent:6.887%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.85346501921567%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10) days&#x2019; notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#x2019;s last address as shown on the Warrant Register.  </font></div></div>
  <div style="margin-left:3.204%;text-indent:6.887%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.65pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.85346501921567%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Miscellaneous</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Rights as a Stockholder</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Holder, solely in such Person&#x2019;s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&#x2019;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.25pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Authorized Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant, and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.65pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EN-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">10</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">NY\5662481.1</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.65pt;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Amendment and Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.45pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Acceptance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein. </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Governing Law; Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.  </font></div></div>
  <div style="margin-left:16.269%;text-indent:15.924%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:24.05pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.5450549975516834%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof. </font></div></div>
  <div style="margin-left:16.269%;text-indent:15.924%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.5450549975516834%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.  </font></div></div>
  <p style="margin-left:8.96%;text-indent:-0.113%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.15pt;margin-right:8.574%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EN-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">11</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">NY\5662481.1</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:8.96%;text-indent:-0.113%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.15pt;margin-right:8.574%;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:36pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10.8pt;margin-right:6.398%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ADICET BIO, INC.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-0.098%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.481%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:________________________________</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:8.96%;text-indent:-0.103%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.15pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">      Name:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:8.96%;text-indent:-0.104%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.15pt;margin-right:1.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">      Title:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EN-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">12</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">NY\5662481.1</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.013%;text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.95pt;margin-right:0.028%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SCHEDULE 1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.013%;text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.95pt;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FORM OF EXERCISE NOTICE</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:10.747%;text-indent:-0.105%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[To be executed by the Holder to purchase shares of Common Stock under the Warrant]</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-0.098%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.343%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ladies and Gentlemen:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0.25pt;margin-right:4.398%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The undersigned is the Holder of Warrant No. ___ (the &#x201c;Warrant&#x201d;) issued by Adicet Bio, Inc., a Delaware corporation (the &#x201c;Company&#x201d;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.343%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:13.35pt;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.667%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The undersigned hereby exercises its right to purchase ___________ Warrant Shares pursuant to the Warrant.</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11.5pt;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.667%;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Holder intends that payment of the Exercise Price shall be made as a &#x201c;Cashless Exercise&#x201d; under Section 10 of the Warrant.</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:5.55pt;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.667%;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number:</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:36pt;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.667%;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a) of the Warrant to which this notice relates.</font></div></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.45pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dated:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:11.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.3pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-7.711%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:74.111%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Name of Holder:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.25pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.25pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Name:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Title:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.947%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EN-</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">13</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">NY\5662481.1</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.013%;text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.95pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Form of Pre-Funded Warrant</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.013%;text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.95pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADICET BIO, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.013%;text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.8pt;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WARRANT TO PURCHASE COMMON STOCK</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-0.094%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.537%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares: [_________] (subject to adjustment)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.55pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant No. [___] 	 Original Issue Date: January [___], 2024</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.669%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5.45pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [___________] or its registered assigns (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Holder</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [______] shares of common stock, $0.0001 par value per share (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), of the Company (each such share, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant Share</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and all such shares, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) at an exercise price per share equal to $0.0001 per share (as adjusted from time to time as provided in Section 9 herein, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) at any time and from time to time on or after the date hereof (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Original Issue Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), subject to the following terms and conditions:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.669%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.1pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. For purposes of this Warrant, the following terms shall have the following meanings:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.472%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.1pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(a) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:13.333%;text-indent:-0.112%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.1pt;margin-right:2.898%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(b) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Commission</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the United States Securities and Exchange Commission.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.731%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.1pt;margin-right:2.898%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(c) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Closing Sale Price</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national securities exchange or other trading market on the relevant date, the last quoted bid price for the security in the over-the-counter market on the relevant date as reported by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors&#x2019; determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:-0.094%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.537%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(d) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Marketable Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means securities meeting all of the following requirements:</font></p>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.35pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and is then current in its filing of all required reports and other information under the Securities Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.35pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Fundamental Transaction (as defined below) were Holder to exercise this Warrant on or prior to the closing thereof is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market, and (iii) following the closing of such Fundamental Transaction, the Holder would not be restricted from publicly re-selling all of the issuer&#x2019;s shares and/or other securities that would be received by the Holder in such Fundamental Transaction were the Holder to exercise or convert this Warrant in full on or prior to the closing of such Fundamental Transaction.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:13.1pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Principal Trading Market</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the national securities exchange or other trading market on which the Common Stock is primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Market.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:13.2pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Company&#x2019;s Registration Statement on Form S-3 (File No. 333-263587), as amended, that became effective on May 9, 2022. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.95pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as amended.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:13.3pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(m)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Trading Day</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any weekday on which the Principal Trading Market is open for trading. If the Common Stock is not listed or admitted for trading, &#x201c;Trading Day&#x201d; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City are authorized or required by law or other governmental action to close.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.45pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(n)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Transfer Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Computershare Trust Company, N.A., the Company&#x2019;s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.1pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issuance of Securities; Registration of Warrants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Warrant, as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or an exchange meeting the requirements of Section 3(a)(9) of the Exchange Act as in effect on the Original Issue Date, the Warrant Shares, are not &#x201c;restricted securities&#x201d; under Rule 144 promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant Register</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0.15pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Registration of Transfers</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">New Warrant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0.15pt;min-width:6.667%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company&#x2019;s own expense any New Warrant under this Section 3. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.2pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exercise and Duration of Warrants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.45pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">All or any part of this Warrant shall be exercisable by the registered Holder in the manner set forth in Section 10 at any time and from time to time on or after the Original Issue Date. </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.5pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Holder may exercise this Warrant by delivering to the Company an exercise notice, in the form attached as Schedule 1 hereto (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), completed and duly signed. The date on which such exercise notice is delivered to the Company (as determined in accordance with the notice provisions hereof) is an </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Exercise Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.2pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delivery of Warrant Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Upon exercise of this Warrant, the Company shall promptly (but in no event later than three (3) Trading Days after the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder&#x2019;s or its designee&#x2019;s balance account with The Depository Trust Company (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">DTC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities Transfer Program or if the certificates are required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company&#x2019;s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&#x2019;s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be.  </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If by the close of the third (3rd) Trading Day after the Exercise Date, the Company fails to deliver to the Holder a certificate representing the required number of Warrant Shares in the manner required pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 5(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> or fails to credit the Holder&#x2019;s DTC account for such number of Warrant Shares to which the Holder is entitled, and if after such third (3rd) Trading Day and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) shares </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Buy-In</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then the Company shall, within three (3) Trading Days after the Holder&#x2019;s request promptly honor its obligation to deliver to the Holder a certificate or certificates representing such Warrant Shares and pay cash to the Holder in an amount equal to the excess (if any) of Holder&#x2019;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the Buy-In less the product of (A) the number of shares of Common Stock purchased in the Buy-In, times (B) the Closing Sale Price of a share of Common Stock on the Exercise Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.35pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To the extent permitted by law and subject to Section 5(b), the Company&#x2019;s obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in Section 11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to Section 5(b), nothing herein shall limit the Holder&#x2019;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#x2019;s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Charges, Taxes and Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.2pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Replacement of Warrant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&#x2019;s obligation to issue the New Warrant.  </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reservation of Warrant Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Company covenants that it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Certain Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Number of Warrant Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) are subject to adjustment from time to time as set forth in this Section 9.  </font></div></div>
  <div style="margin-left:1.333%;text-indent:13.513%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.5138394802720265%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Stock Dividends and Splits</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock that is payable in shares of Common Stock, (ii) subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii) combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv) issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company, then in each such case the Number of Warrant Shares shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately after such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately before such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Number of Warrant Shares shall be recomputed accordingly as of the close of business on such record date and thereafter the Number of Warrant Shares shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination.</font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pro Rata Distributions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security (including Common Stock), or (iv) cash or any other asset (in each case, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Distribution</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), other than a reclassification as to which Section 9(c) applies, then in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the ownership limitation set forth in Section 11(a) hereof) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the participation in </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">such Distribution;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, to the extent that the Holder&#x2019;s right to participate in any such Distribution would result in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as the delivery to such Holder of such portion would not result in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0.25pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Fundamental Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity, (ii) the Company effects any sale to another Person of all or substantially all of its assets in one transaction or a series of related transactions, (iii) pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv) the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 9(a) above) (in any such case, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Fundamental Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the Number of Warrant Shares (in the case of clause (iii) above, assuming it had tendered, and the offeror had accepted, such Warrant Shares) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Alternate Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i) the Alternate Consideration is solely cash and the Company provides for the simultaneous &#x201c;cashless exercise&#x201d; of this Warrant pursuant to Section 10 below or (ii) prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. Notwithstanding the foregoing, in the event of a </font></div></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Fundamental Transaction where the consideration payable to holders of Common Stock consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities, then this</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.55pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant shall automatically be deemed to be exercised in full in a &#x201c;cashless exercise&#x201d; pursuant to Section 10 below effective immediately prior to and contingent upon the consummation of such Fundamental Transaction.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.5pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Simultaneously with any adjustment to the Number of Warrant Shares pursuant to Section 9 the Exercise Price shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased Number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common Stock then in effect.  </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.45pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Calculations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. All calculations under this Section 9 shall be made to the nearest one-hundredth of one cent or the nearest whole share, as applicable. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notice of Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company&#x2019;s transfer agent.  </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.25pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notice of Corporate Events</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by Section 9(c), other than a Fundamental Transaction under clause (iii) of Section 9(c), then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10) days prior to the date such Fundamental Transaction is consummated.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:5.45pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">19.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cashless Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding anything contained herein to the contrary, this Warrant may only be exercised through a &#x201c;cashless exercise.&#x201d; Upon exercise, the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section 3(a)(9) of the Securities Act as determined as follows:  </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:-0.281%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:53.417%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">X = Y [(A-B)/A] where:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:13.333%;text-indent:-0.128%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.1pt;margin-right:13.593%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;X&#x201d; equals the number of Warrant Shares to be issued to the Holder; &#x201c;Y&#x201d; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:13.333%;text-indent:-0.108%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;A&#x201d; equals the Closing Sale Price per share of Common Stock as of the</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:-0.108%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.4pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Trading Day on the date immediately preceding the Exercise Date; and</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:13.333%;text-indent:-0.114%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.5pt;margin-right:4.676%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;B&#x201d; equals the Exercise Price per Warrant Share then in effect on the Exercise Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.669%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.5pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in such a &#x201c;cashless exercise&#x201d; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.35pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In no event will the exercise of this Warrant be settled in cash.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.2pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Limitations on Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.7pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares if, upon giving effect to such exercise, (i) immediately prior to the exercise, the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act, beneficially owns an aggregate number of shares of Common Stock greater than 9.99% (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Maximum Percentage</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of the total number of issued and outstanding shares of Common Stock of the Company without taking into account any Warrant Shares, or (ii) immediately following exercise, the combined voting power of the securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act would be greater than 9.99% of the combined voting power of all of the securities of the Company then outstanding following such exercise without taking into account any Warrant Shares. Any portion of an exercise that would result in the issuance of shares in excess of the Maximum Percentage shall be treated as null and void ab initio. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company&#x2019;s most recent Form 10-Q or Form 10-K, as the case may be, filed with the Commission prior to the date hereof, (y) a more recent public announcement by the Company or (z) any other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three (3) Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.7pt;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage specified not in excess of 19.99% specified in such notice; provided that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Company. For purposes of this Section 11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x) exercise of the remaining unexercised and non-cancelled portion of this Warrant by the Holder and (y) exercise or conversion of the unexercised, non-converted or non-cancelled portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="margin-left:6.667%;text-indent:16.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:15.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.0017892921046148%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Section 11 shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section 9(c) of this Warrant.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Fractional Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional shares.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:5.55pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via confirmed email prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed e-mail on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses and e-mail addresses for such communications shall be:  </font></div></div>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5.35pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If to the Company:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">200 Berkeley Street, 19th Floor</font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Boston, Massachusetts</font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Attention: Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Telephone: (650) 503-9095</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Email: [_]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-0.106%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.55pt;margin-right:5.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If to the Holder, to its address or e-mail address set forth herein or on the books and records of the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.602%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.6pt;margin-right:0.435%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Or, in each of the above instances, to such other address or e-mail address as the recipient party has specified by written notice given to each other party at least five (5) days prior to the effectiveness of such change.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="margin-left:3.204%;text-indent:6.887%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.85346501921567%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10) days&#x2019; notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#x2019;s last address as shown on the Warrant Register.  </font></div></div>
  <div style="margin-left:3.204%;text-indent:6.887%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.65pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.85346501921567%;text-indent:0;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Miscellaneous</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Rights as a Stockholder</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Holder, solely in such Person&#x2019;s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&#x2019;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.25pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Authorized Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant, and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.  </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.65pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Amendment and Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.45pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Acceptance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein. </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Governing Law; Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.  </font></div></div>
  <div style="margin-left:16.269%;text-indent:15.924%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:24.05pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.5450549975516834%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof. </font></div></div>
  <div style="margin-left:16.269%;text-indent:15.924%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.5450549975516834%;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:16.269%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <p style="margin-left:8.96%;text-indent:-0.113%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.15pt;margin-right:8.574%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:8.96%;text-indent:-0.113%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.15pt;margin-right:8.574%;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:36pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10.8pt;margin-right:6.398%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ADICET BIO, INC.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-0.098%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.481%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:________________________________</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:8.96%;text-indent:-0.103%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.15pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">      Name:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:8.96%;text-indent:-0.104%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.15pt;margin-right:1.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">      Title:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.013%;text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.95pt;margin-right:0.028%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SCHEDULE 1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.013%;text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.95pt;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FORM OF EXERCISE NOTICE</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:10.747%;text-indent:-0.105%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[To be executed by the Holder to purchase shares of Common Stock under the Warrant]</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-0.098%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.343%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ladies and Gentlemen:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0.25pt;margin-right:4.398%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The undersigned is the Holder of Warrant No. ___ (the &#x201c;Warrant&#x201d;) issued by Adicet Bio, Inc., a Delaware corporation (the &#x201c;Company&#x201d;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.343%;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:13.35pt;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.667%;display:inline-flex;justify-content:flex-start;">(6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The undersigned hereby exercises its right to purchase ___________ Warrant Shares pursuant to the Warrant.</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11.5pt;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.667%;display:inline-flex;justify-content:flex-start;">(7)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Holder intends that payment of the Exercise Price shall be made as a &#x201c;Cashless Exercise&#x201d; under Section 10 of the Warrant.</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:5.55pt;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.667%;display:inline-flex;justify-content:flex-start;">(8)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number:</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:36pt;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.667%;display:inline-flex;justify-content:flex-start;">(9)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a) of the Warrant to which this notice relates.</font></div></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.45pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dated:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:11.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.3pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-7.711%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:74.111%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Name of Holder:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.25pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.25pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Name:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Title:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.947%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>acet-ex4_1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<html>
 <head>
  <title>EX-4.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="margin-top:48.0px;"></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.013%;text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.95pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Form of Pre-Funded Warrant</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.013%;text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.95pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADICET BIO, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.013%;text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.8pt;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WARRANT TO PURCHASE COMMON STOCK</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-0.094%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.537%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares: [_________] (subject to adjustment)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-0.094%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.537%;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"></td>
    <td style="width:50%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrant No. [___]</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Original Issue Date: January [___], 2024</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.55pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">                                                                </font></p>
  <p style="text-indent:6.669%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5.45pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [___________] or its registered assigns (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Holder</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [______] shares of common stock, $0.0001 par value per share (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), of the Company (each such share, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant Share</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and all such shares, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) at an exercise price per share equal to $0.0001 per share (as adjusted from time to time as provided in Section 9 herein, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) at any time and from time to time on or after the date hereof (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Original Issue Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), subject to the following terms and conditions:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.669%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.1pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. For purposes of this Warrant, the following terms shall have the following meanings:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.472%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.1pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(a) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:13.333%;text-indent:-0.112%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.1pt;margin-right:2.898%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(b) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Commission</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the United States Securities and Exchange Commission.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.731%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.1pt;margin-right:2.898%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(c) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Closing Sale Price</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national securities exchange or other trading market on the relevant date, the last quoted bid price for the security in the over-the-counter market on the relevant date as reported by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors&#x2019; determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:-0.094%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.537%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(d) &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Marketable Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means securities meeting all of the following requirements:</font></p>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.35pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and is then current in its filing of all</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.35pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">required reports and other information under the Securities Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Fundamental Transaction (as defined below) were Holder to exercise this Warrant on or prior to the closing thereof is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market, and (iii) following the closing of such Fundamental Transaction, the Holder would not be restricted from publicly re-selling all of the issuer&#x2019;s shares and/or other securities that would be received by the Holder in such Fundamental Transaction were the Holder to exercise or convert this Warrant in full on or prior to the closing of such Fundamental Transaction.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:13.1pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Principal Trading Market</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the national securities exchange or other trading market on which the Common Stock is primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Market.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:13.2pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Company&#x2019;s Registration Statement on Form S-3 (File No. 333-263587), as amended, that became effective on May 9, 2022. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.95pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as amended.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:13.3pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Trading Day</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any weekday on which the Principal Trading Market is open for trading. If the Common Stock is not listed or admitted for trading, &#x201c;Trading Day&#x201d; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City are authorized or required by law or other governmental action to close.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.45pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Transfer Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Computershare Trust Company, N.A., the Company&#x2019;s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.1pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issuance of Securities; Registration of Warrants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Warrant, as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or an exchange meeting the requirements of Section 3(a)(9) of the Exchange Act as in effect on the Original Issue Date, the Warrant Shares, are not &#x201c;restricted securities&#x201d; under Rule 144 promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant Register</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0.15pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Registration of Transfers</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">New Warrant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such </font></div></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0.15pt;min-width:6.667%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#x2019;s own expense any New Warrant under this Section 3. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.2pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exercise and Duration of Warrants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.45pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">All or any part of this Warrant shall be exercisable by the registered Holder in the manner set forth in Section 10 at any time and from time to time on or after the Original Issue Date. </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.5pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Holder may exercise this Warrant by delivering to the Company an exercise notice, in the form attached as Schedule 1 hereto (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), completed and duly signed. The date on which such exercise notice is delivered to the Company (as determined in accordance with the notice provisions hereof) is an </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Exercise Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.2pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delivery of Warrant Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Upon exercise of this Warrant, the Company shall promptly (but in no event later than three (3) Trading Days after the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder&#x2019;s or its designee&#x2019;s balance account with The Depository Trust Company (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">DTC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities Transfer Program or if the certificates are required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company&#x2019;s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&#x2019;s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be.  </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If by the close of the third (3rd) Trading Day after the Exercise Date, the Company fails to deliver to the Holder a certificate representing the required number of Warrant Shares in the manner required pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 5(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> or fails to credit the Holder&#x2019;s DTC account for such number of Warrant Shares to which the Holder </font></div></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">is entitled, and if after such third (3rd) Trading Day and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Buy-In</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then the Company shall, within three (3) Trading Days after the Holder&#x2019;s request promptly honor its obligation to deliver to the Holder a certificate or certificates representing such Warrant Shares and pay cash to the Holder in an amount equal to the excess (if any) of Holder&#x2019;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the Buy-In less the product of (A) the number of shares of Common Stock purchased in the Buy-In, times (B) the Closing Sale Price of a share of Common Stock on the Exercise Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.35pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To the extent permitted by law and subject to Section 5(b), the Company&#x2019;s obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in Section 11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to Section 5(b), nothing herein shall limit the Holder&#x2019;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#x2019;s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Charges, Taxes and Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.2pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Replacement of Warrant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&#x2019;s obligation to issue the New Warrant.  </font></div></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reservation of Warrant Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Company covenants that it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Certain Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Number of Warrant Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) are subject to adjustment from time to time as set forth in this Section 9.  </font></div></div>
  <div style="margin-left:1.333%;text-indent:13.513%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.5138394802720265%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Stock Dividends and Splits</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock that is payable in shares of Common Stock, (ii) subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii) combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv) issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company, then in each such case the Number of Warrant Shares shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately after such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately before such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Number of Warrant Shares shall be recomputed accordingly as of the close of business on such record date and thereafter the Number of Warrant Shares shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination.</font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pro Rata Distributions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security (including Common Stock), or (iv) cash or any other asset (in each case, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Distribution</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), other than a reclassification as to which Section 9(c) applies, then in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the ownership limitation set forth in Section 11(a) hereof) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the participation in </font></div></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">such Distribution;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, to the extent that the Holder&#x2019;s right to participate in any such Distribution would result in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as the delivery to such Holder of such portion would not result in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0.25pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Fundamental Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity, (ii) the Company effects any sale to another Person of all or substantially all of its assets in one transaction or a series of related transactions, (iii) pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv) the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 9(a) above) (in any such case, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Fundamental Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the Number of Warrant Shares (in the case of clause (iii) above, assuming it had tendered, and the offeror had accepted, such Warrant Shares) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Alternate Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i) the Alternate Consideration is solely cash and the Company provides for the simultaneous &#x201c;cashless exercise&#x201d; of this Warrant pursuant to Section 10 below or (ii) prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. Notwithstanding the foregoing, in the event of a </font></div></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Fundamental Transaction where the consideration payable to holders of Common Stock consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities, then this</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.55pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Warrant shall automatically be deemed to be exercised in full in a &#x201c;cashless exercise&#x201d; pursuant to Section 10 below effective immediately prior to and contingent upon the consummation of such Fundamental Transaction.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.5pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Simultaneously with any adjustment to the Number of Warrant Shares pursuant to Section 9 the Exercise Price shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased Number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common Stock then in effect.  </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.45pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Calculations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. All calculations under this Section 9 shall be made to the nearest one-hundredth of one cent or the nearest whole share, as applicable. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notice of Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company&#x2019;s transfer agent.  </font></div></div>
  <div style="margin-left:13.333%;text-indent:15.385%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.25pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.8465159749385585%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notice of Corporate Events</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by Section 9(c), other than a Fundamental Transaction under clause (iii) of Section 9(c), then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10) days prior to the date such Fundamental Transaction is consummated.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:5.45pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cashless Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding anything contained herein to the contrary, this Warrant may only be exercised through a &#x201c;cashless exercise.&#x201d; Upon exercise, the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section 3(a)(9) of the Securities Act as determined as follows:  </font></div></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:-0.281%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:53.417%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">X = Y [(A-B)/A] where:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:13.333%;text-indent:-0.128%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8.1pt;margin-right:13.593%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;X&#x201d; equals the number of Warrant Shares to be issued to the Holder; &#x201c;Y&#x201d; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:13.333%;text-indent:-0.108%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;A&#x201d; equals the Closing Sale Price per share of Common Stock as of the</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:-0.108%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.4pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Trading Day on the date immediately preceding the Exercise Date; and</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:13.333%;text-indent:-0.114%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.5pt;margin-right:4.676%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;B&#x201d; equals the Exercise Price per Warrant Share then in effect on the Exercise Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.669%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.5pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in such a &#x201c;cashless exercise&#x201d; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.35pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In no event will the exercise of this Warrant be settled in cash.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.2pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Limitations on Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.7pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares if, upon giving effect to such exercise, (i) immediately prior to the exercise, the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act, beneficially owns an aggregate number of shares of Common Stock greater than 9.99% (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Maximum Percentage</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of the total number of issued and outstanding shares of Common Stock of the Company without taking into account any Warrant Shares, or (ii) immediately following exercise, the combined voting power of the securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act would be greater than 9.99% of the combined voting power of all of the securities of the Company then outstanding following such exercise without taking into account any Warrant Shares. Any portion of an exercise that would result in the issuance of shares in excess of the Maximum Percentage shall be treated as null and void ab initio. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company&#x2019;s most recent Form 10-Q or Form 10-K, as the case may be, filed with the Commission prior to the date hereof, (y) a more recent public announcement by the Company or (z) any other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three (3) Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of </font></div></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.7pt;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage specified not in excess of 19.99% specified in such notice; provided that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Company. For purposes of this Section 11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x) exercise of the remaining unexercised and non-cancelled portion of this Warrant by the Holder and (y) exercise or conversion of the unexercised, non-converted or non-cancelled portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#x2019;s for purposes of Section 13(d) of the Exchange Act.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="margin-left:6.667%;text-indent:16.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:15.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:1.0017892921046148%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Section 11 shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section 9(c) of this Warrant.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Fractional Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional shares.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:5.55pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via confirmed email prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed e-mail on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses and e-mail addresses for such communications shall be:  </font></div></div>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5.35pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If to the Company:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">200 Berkeley Street, 19th Floor</font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Boston, Massachusetts</font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Attention: Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Telephone:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.25pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Email:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-0.106%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.55pt;margin-right:5.296%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If to the Holder, to its address or e-mail address set forth herein or on the books and records of the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.602%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.6pt;margin-right:0.435%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Or, in each of the above instances, to such other address or e-mail address as the recipient party has specified by written notice given to each other party at least five (5) days prior to the effectiveness of such change.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="margin-left:3.204%;text-indent:6.887%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.85346501921567%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10) days&#x2019; notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#x2019;s last address as shown on the Warrant Register.  </font></div></div>
  <div style="margin-left:3.204%;text-indent:6.887%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.65pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.85346501921567%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Miscellaneous</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Rights as a Stockholder</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Holder, solely in such Person&#x2019;s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&#x2019;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12.25pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Authorized Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant, and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.  </font></div></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.65pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Amendment and Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.45pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Acceptance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein. </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.6pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.8575102053935906%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Governing Law; Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.  </font></div></div>
  <div style="margin-left:16.269%;text-indent:15.924%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:24.05pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.5450549975516834%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof. </font></div></div>
  <div style="margin-left:16.269%;text-indent:15.924%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.5450549975516834%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any </font></div></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:16.269%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11.55pt;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <p style="margin-left:8.96%;text-indent:-0.113%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.15pt;margin-right:8.574%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:8.96%;text-indent:-0.113%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.15pt;margin-right:8.574%;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:36pt;margin-right:0.037%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10.8pt;margin-right:6.398%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ADICET BIO, INC.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-0.098%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.481%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:________________________________</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:8.96%;text-indent:-0.103%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.15pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">      Name:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:8.96%;text-indent:-0.104%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.15pt;margin-right:1.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">      Title:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.013%;text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.95pt;margin-right:0.028%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SCHEDULE 1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.013%;text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4.95pt;margin-right:0.009%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FORM OF EXERCISE NOTICE</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:10.747%;text-indent:-0.105%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[To be executed by the Holder to purchase shares of Common Stock under the Warrant]</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-0.098%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.343%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ladies and Gentlemen:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:4.398%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The undersigned is the Holder of Warrant No. ___ (the &#x201c;Warrant&#x201d;) issued by Adicet Bio, Inc., a Delaware corporation (the &#x201c;Company&#x201d;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.343%;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:13.35pt;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.667%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The undersigned hereby exercises its right to purchase ___________ Warrant Shares pursuant to the Warrant.</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11.5pt;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.667%;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Holder intends that payment of the Exercise Price shall be made as a &#x201c;Cashless Exercise&#x201d; under Section 10 of the Warrant.</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:5.55pt;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.667%;display:inline-flex;justify-content:flex-start;">(4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number:</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:36pt;min-width:2.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.667%;display:inline-flex;justify-content:flex-start;">(5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a) of the Warrant to which this notice relates.</font></div></div>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.45pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dated:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:11.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.3pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-7.711%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:74.111%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Name of Holder:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.25pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.25pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Name:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Title:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.947%;text-indent:-0.1%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.5pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:-0.093%;padding-left:0.093%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>acet-ex5_1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<html>
 <head>
  <title>EX-5.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:40.468%;"></td>
    <td style="width:32.847%;"></td>
    <td style="width:26.685%;"></td>
   </tr>
   <tr style="height:64.8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img208765579_0.jpg" alt="img208765579_0.jpg" style="width:199px;height:44px;">&#160;</p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:8pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#848a8e;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Goodwin Procter</font><font style="color:#848a8e;white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;LLP</font></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#848a8e;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">100 Northern Avenue<br>Boston, MA 02210</font></p><p style="font-size:8pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#848a8e;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">goodwinlaw.com</font></p><p style="font-size:8pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#848a8e;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">+1 617 570 1000</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">January 24, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">200 Berkeley Street, 19th Floor</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Boston, MA 02116</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	Re:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Securities Registered under Registration Statement on Form S-3</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-3 (File No. 333-263587) (as amended or supplemented, the &#x201c;Registration Statement&#x201d;) filed on March 15, 2022 with the Securities and Exchange Commission (the &#x201c;Commission&#x201d;) pursuant to the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), relating to the registration of the offer by Adicet Bio, Inc., a Delaware corporation (the &#x201c;Company&#x201d;) of up to $500,000,000 of any combination of securities of the types specified therein. The Registration Statement was declared effective by the Commission on May 9, 2022. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Reference is made to our opinion letter dated March 15, 2022 and included as Exhibit 5.1 to the Registration Statement.  We are delivering this supplemental opinion letter in connection with the prospectus supplement (the &#x201c;Prospectus Supplement&#x201d;), dated January 22, 2024, by the Company with the Commission pursuant to Rule 424 under the Securities Act.  The Prospectus Supplement relates to the offering by the Company of up to 40,825,000 shares of the Company&#x2019;s Common Stock, par value $0.0001 per share (the &#x201c;Common Stock&#x201d;), consisting of (i) 32,379,667  shares of Common Stock (the &#x201c;Shares&#x201d;), and (ii) up to 8,445,333 shares of Common Stock issuable upon the exercise of pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) and the shares issuable upon exercise of the Pre-Funded Warrants, the &#x201c;Pre-Funded Warrants Shares&#x201d;), in each case covered by the Registration Statement. The Shares include an over-allotment option granted to the underwriters of the offering to purchase up to 5,325,000 Shares. The Shares and the Pre-Funded Warrants are being sold to the several underwriters named in, and pursuant to, an underwriting agreement among the Company and such underwriters (the &#x201c;Underwriting Agreement&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinions set forth below.  We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinions set forth below, on certificates of officers of the Company.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purposes of the opinion set forth in numbered paragraph 3, we have assumed that before the Pre-Funded Warrants Shares are issued, the Company does not issue shares of Common Stock or reduce the total number of shares of Common Stock that the Company is authorized to issue under its certificate of incorporation such that the number of unissued shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <div style="margin-top:48.0px;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">January 24, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Page </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of Common Stock authorized under the Company&#x2019;s certificate of incorporation is less than the number of Pre-Funded Warrants Shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The opinions set forth below are limited to the Delaware General Corporation Law.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Based on the foregoing, we are of the opinion that:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.4671798606054303%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">When the Shares are delivered and paid for in accordance with the terms of the Underwriting Agreement, the Shares will be validly issued, fully paid and non&#x2011;assessable.</font></div></div>
  <div style="margin-left:3.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.4671798606054303%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">When the Pre-Funded Warrants are delivered and paid for in accordance with the Underwriting Agreement, assuming the due authorization, execution and delivery of such Pre-Funded Warrants by Computershare Trust Company, N.A., as warrant agent, the Pre-Funded Warrants will constitute valid and binding obligations of the Company.</font></div></div>
  <div style="margin-left:3.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.4671798606054303%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Pre-Funded Warrants Shares, when delivered and paid for upon exercise of the Pre-Funded Warrants in accordance with the respective terms of the Pre-Funded Warrants, will have been duly authorized and validly issued and will be fully paid and nonassessable.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This opinion letter and the opinions it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 Business Lawyer 815 (Summer 2019).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">We hereby consent to the inclusion of this opinion as Exhibit 5.1 to Current Report on Form 8-K and to the references to our firm under the caption &#x201c;Legal Matters&#x201d; in the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Very truly yours,</font></p>
  <p style="text-indent:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">/s/ Goodwin Procter LLP</font></p>
  <p style="text-indent:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GOODWIN PROCTER </font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>acet-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.25pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc. Announces Proposed Public Offering</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">REDWOOD CITY, Calif. &amp; BOSTON--Jan. 22, 2024-- Adicet Bio, Inc. (&#x201c;Adicet&#x201d;) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. The purchase price of each pre-funded warrant will equal the price per share at which shares of common stock are being sold to the public in this offering, minus $0.0001, which will be the per share exercise price of each pre-funded warrant. In addition, Adicet also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold at the public offering price, less underwriting discounts and commissions. All of the securities in the proposed offering are to be sold by Adicet. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Jefferies and Guggenheim Securities are acting as joint book-running managers for the proposed offering.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The securities described above are being offered by Adicet pursuant to a shelf registration statement that was previously filed with, and subsequently declared effective on May 9, 2022 by, the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;). A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC&#x2019;s website at </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">www.sec.gov</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offered securities may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@Jefferies.com or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">About Adicet</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of &#x201c;off-the-shelf&#x201d; gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This press release contains &#x201c;forward-looking statements&#x201d; of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements related to the anticipated public offering of securities. These forward-looking statements include, but are</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">not limited to, those relating to Adicet expectations regarding the completion, timing and size of the public offering and its expectations with respect to granting the underwriters a 30-day option to purchase additional shares. Any forward-looking statements in this press release are based on management&#x2019;s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties related to completion of the proposed public offering on the anticipated terms, or at all, include, but are not limited to, market conditions and the satisfaction of customary closing conditions related to the proposed public offering. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet&#x2019;s actual results to differ from those contained in the forward-looking statements, see the section entitled &#x201c;Risk Factors&#x201d; in Adicet&#x2019;s most recent annual report on Form 10-K and our periodic reports on Form 10-Q and Form 8-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Adicet&#x2019;s other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the proposed public offering to be filed with the SEC. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img94724212_0.jpg" alt="img94724212_0.jpg" style="width:1px;height:1px;">&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Investor and Media Contacts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br>Anne Bowdidge<br>abowdidge@adicetbio.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>acet-ex99_2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html>
 <head>
  <title>EX-99.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc. Announces Pricing of Public Offering</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">REDWOOD CITY, Calif. and BOSTON, January 22, 2024 &#x2013; Adicet Bio, Inc. (&#x201c;Adicet&#x201d;) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the pricing of an underwritten public offering of 27,054,667 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 8,445,333 shares of common stock. The shares of common stock are being sold at a public offering price of $2.40 per share and the pre-funded warrants are being sold at a public offering price of $2.3999 per pre-funded warrant, which represents the per share public offering price of each share of common stock minus the $0.0001 per share exercise price for each pre-funded warrant. Adicet also granted the underwriters a 30-day option to purchase up to an additional 5,325,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $85.2 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the securities in the offering are to be sold by Adicet. The offering is expected to close on or about January 25, 2024, subject to customary closing conditions.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Jefferies and Guggenheim Securities are acting as joint book-running managers for the offering. Truist Securities is also acting as a joint bookrunner. Wedbush PacGrow and JMP Securities, A Citizens Company are acting as co-managers.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The securities described above are being offered by Adicet pursuant to a shelf registration statement that was previously filed with, and subsequently declared effective on May 9, 2022 by, the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;). A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on January 22, 2024. The final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC&#x2019;s website at www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offered securities may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@Jefferies.com or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">About Adicet</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.  Adicet is advancing a pipeline of &#x201c;off-the-shelf&#x201d; gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This press release contains &#x201c;forward-looking statements&#x201d; of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, statements related to the anticipated public offering of securities. These forward-looking statements include, but are not limited to, those relating to Adicet&#x2019;s expectations regarding the anticipated closing of the public offering.  Any forward-looking statements in this press release are based on management&#x2019;s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties related to completion of the public offering on the anticipated terms, or at all, include, but are not limited to, market conditions and the satisfaction of customary closing conditions related to the public offering. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Adicet&#x2019;s actual results to differ from those contained in the forward-looking statements, see the section entitled &#x201c;Risk Factors&#x201d; in Adicet&#x2019;s most recent annual report on Form 10-K and our periodic reports on Form 10-Q and Form 8-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Adicet&#x2019;s other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the offering filed with the SEC. All information in this press release is as of the date of the release, and Adicet undertakes no duty to update this information unless required by law.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adicet Bio, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Investor and Media Contacts</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Anne Bowdidge</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">abowdidge@adicetbio.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-top:48.0px;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img94724212_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img94724212_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  !  $# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img208765579_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img208765579_0.jpg
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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M*** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ********
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M%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%%
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MGAFZMU/WB34U<KK]D:>S\S[&KC/$7QD\ ^#[H6VO>-_#FB7)) AU'5K>W<X
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MNWO[.3.RXM95DC?!(.&4D'!!'U!K^>"ZM9[&ZFM[B&2WN(7:.2*52KHP."K
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M+W3S")!M^=509)!_NL7_ #CJ_P#$W34O?"TEQMC$UK*DOF,>=A.QD7ZED/\
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M-?9'_!)CX8!8?&OQ#N8AN9DT*RDW'( VS7''H<VV#[-7YRU^ZO[*?PO;X/\
M[/\ X,\-31-!J$5DMS?)(!O6YF)EE4D==K.4!]$%<M1117<<AZW1117T[JW_
M "%+S_KL_P#Z$:\U^-'_ ""M _Z[77_H,%>E:M_R%+S_ *[/_P"A&O-?C1_R
M"M _Z[77_H,%>?1^-';4V9_/;X^_Y'OQ'_V$KG_T:U?HQ_P2/_Y$3XA?]A*V
M_P#135^<_C[_ )'OQ'_V$KG_ -&M7Z,?\$C_ /D1/B%_V$K;_P!%-7EE>J_"
M'_D$WW_7<?\ H(KRJO5?A#_R";[_ *[C_P!!%=5;X#FI_$??5?G)_P %?/\
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MHMHIE+NK+DMZ^=OVW(]OPEL#_P!1>+_T3/7TPT?K7SC^W-'M^$.GG_J,0_\
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M*UB86UH&Q))]Z1FV[CCL/E '?OQG X^NRFG&*3,*C3E='Z)?\$F?^2*^+_\
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M=<D*V5G-<E656=%.Q,G W-T4>Y(%>H^#OA_%X>Q=WS1W>IXPD:X:*#(Y(/\
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M]OC[_D>_$?\ V$KG_P!&M7Z,?\$C_P#D1/B%_P!A*V_]%-7YS^/O^1[\1_\
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MNH2&VM8UCCC4=%55  'L*NT44444R0HHHHHHHH ****W=)\8:SHD(AM-0D2
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M%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%%
M!11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !111
*11110 4445__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>acet-20240122.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-01-24T16:05:15.5393+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.adicetbio.com/20240122" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:acet="http://www.adicetbio.com/20240122" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="acet-20240122.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140291070137536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 22, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 22,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adicet Bio, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001720580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3305277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Berkeley Street, 19th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">503-9095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">Not applicable<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACET<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NONE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>acet-20240122_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="acet-20240122.xsd" xlink:type="simple"/>
    <context id="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_ef6ac5f9-f947-419d-a79c-4a18c68aaec1">0001720580</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_b1c22b03-07f2-4268-8025-4cfce751c269">false</dei:AmendmentFlag>
    <dei:SecurityExchangeName
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_ef9b0e89-4d0c-4ea2-9a83-6aad9cfc0ace">NONE</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_39a2f78b-e8bc-4c38-8d3b-ec9e37b81e6b">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_8762b3e1-eb0e-4837-9bd9-531c79826349">2024-01-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_e3407cdd-bb3b-4476-9eb6-787e85ffefa0">Adicet Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_744e1d8f-b70c-4163-bce9-b4a5a302e9a4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_8370a4dc-5593-4a8c-8902-cda19f3ff01a">001-38359</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_e041e51c-67c4-496e-8193-1bb3964fbe19">81-3305277</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_3215cc56-b691-4326-b9ba-aad107bc9287">200 Berkeley Street, 19th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_0341c563-d9e6-4669-9827-54da3b03ba81">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_6322aa18-a71f-40b1-85b9-244f77f38a48">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_8991945f-dc3c-4e23-8fc9-5e1da0f2160e">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_0fc4a147-7ce3-4901-aaf1-29b5b7af99f1">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_f3b1b3db-68ba-466d-919f-a99836d3fb6f">503-9095</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_7f26dad5-cd96-4e4d-a290-7f7d8a65f1fc">Not applicable</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_4af4b675-8b1d-426d-bcf4-fa3640b0881d">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_f58ee7a4-a1e0-4788-9f16-942fd6bd5a03">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_be0008b7-c378-4974-948f-987d302eb4bf">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_2b192a8b-819e-43d4-9aa3-bf0e40aaeed7">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_bda3cfe4-c305-4189-bf26-8dcf0e7c0364">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_0bb7303b-eb88-474e-8b6e-7f0e9a80e3c1">ACET</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_320e46ac-5697-4de7-aacf-5bd4bc8fceca"
      id="F_6a3b1a99-9a76-442e-8f2d-c404ae733b3a">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ 1(0X6)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M4$L! A0#%     @ 1(0X6&C[ ]SO    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 1(0X6)E<G",0!@  G"<
M !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " !$A#A8<L8#!H$$  !6$0  &               @($."   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 1(0X6)^@&_"Q @  X@P
M  T              ( !Q0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !$
MA#A8EXJ[',     3 @  "P              @ &A#P  7W)E;',O+G)E;'-0
M2P$"% ,4    " !$A#A8.JJBYT !   \ @  #P              @ &*$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 1(0X6"0>FZ*M    ^ $  !H
M             ( !]Q$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ 1(0X6&60>9(9 0  SP,  !,              ( !W!(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  )A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="acet-20240122.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="acet-20240122.htm">acet-20240122.htm</File>
    <File>acet-20240122.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "acet-20240122.htm": {
   "nsprefix": "acet",
   "nsuri": "http://www.adicetbio.com/20240122",
   "dts": {
    "inline": {
     "local": [
      "acet-20240122.htm"
     ]
    },
    "schema": {
     "local": [
      "acet-20240122.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_320e46ac-5697-4de7-aacf-5bd4bc8fceca",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20240122.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_320e46ac-5697-4de7-aacf-5bd4bc8fceca",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "acet-20240122.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.adicetbio.com/20240122/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0000950170-24-007011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-007011-xbrl.zip
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MS$>NXE_[Y_\\/OGYXO2DQ0[;!VTP$3NVNPRQ"C=(:7U;_]O*J%BQ2WE-1,+
M#HZ"BF'4*V3+TMBOC/+O'O"5T/WGT[/?V"(*?D#?6XL5M>5R,^PYGB8<#Q2U
M;X$5$5APZ;O"ZGF.(;K>HQ1Q3;F7?A>9?VL!4#)8%3G-F@H;-EPQ&[IKQH6/
ME=N@:,Z.3B[8V='7T[.+YX9#%UJO*R2^CK-\#%X8*U(&ECN%2 R+I1DS.MO!
M#DM#5@P$4T9]!'V6=CU&:?"QX5KV# 0+CL9:TYC#M:"7!T2!3S7PZ=)Q ;.Y
M$<&>G)FAZVW@"?4" "3FHUST<S'B&=B8TC>$WK.RZZLHC[PH!ANW7[96C:!5
M4#%1V?G?$.:[12"[ ;]XMK^!A"UA^QIFH7F9X-_Z]'\-;RS&RSP3STY!N;A2
MJ+1U(TKVKD161#Z/U8OP!&=W#]I[F%!J2!P8VG2=KE'[!S-Y%M)<1F\4?@.J
M.1/H_K/M\EIP<!=$7C!QA6&]C!Z+8*??4):+%9_3ZYJ>)0Q-@*.JV8[5TUPO
M<+6.9?@]US&[ENVN2O%])?_F2'H]6TR&53YN13=%/X [VA!&&>!K6L GV@26
MI8GD&>'Y"T_&/)LPTVQ1?/)N73C' ? 7.?*Q2O*A'LD[4)-OVPE=M0TP'<JT
M'V?Y"LO6>WX \MH#>]>V>UW-%5Y7ZSD]X73"4(1<?ZH D-'!,W$9Y1A0+2BL
MM4H5?N?BER%RGR+-[*<HE?F'!YK#RS%MK9>UUVO?27I+(+1]=,/!6$%D2MU3
M(I'QG)V/A(]ALX!%"3LN<G8PX*!ZLIVG^P\/-9<WHG&-1>,Z&K5FTZ9=8/7>
M\?SN#IP[&MC&"YC5 !C$S<<M:^OE3>RE8F^QLNK9MC ")]2\'N93C*ZE>;YP
M-<_F'6[IIG"YO1IE!<H@S<".IKS?>0'4=I".DR*;'*1!TW;%7"1&_0LQRM(K
M[.=9C=9#$?-KGHD'&*OKX4T]$-7@B>C<#@!M'=?2;.[XFN/JIN8'W'!#*PQU
M@Z\&U9^C6,#8GLB>$6VZ;FB68W7<MXXWH=N&Z!B^UNWYMF:[7:$Y!F#0 /O2
M[=JA)XPG.Y02;Q?\YECE[7QBTV='H@,XM/2.V>L]PE5<(-5[ZRK4I;FX>I)Y
M#J1LDW3&J-MI,1 9^V6<13F8]4@1,ND%9FM#G.\\)[.]*M =I,-AE&-U&4,I
MR"0';>!3PN?X[)P=#4=Q.A&9I*6FQ&$G:7LAM!8Q_1N)BMZ)@84KNK>[\%JT
MWV:UF]5N5OLP>V?CQ<IB ]/H^'ZGJWE=U]!LRX1?KL?!Y@T,O>?YKNGT5F,B
M[P=!)O)<_?D2)<)X1G5IZCK[263?1"PF[+S(A"A:S'"+ ?L<IVGV4,^G0K&Y
MSBA>7^Y9!;<L""*^-/?HEFT \UA:X(JN9G>[KN8Z9D_KV &W/-WRN&.LE'L.
MX.=I=I%>/V=8YZ<T+\!?N9U%GFOPUCT2Q5W+-#DW'(WWC%"S=<_0G([G:J9M
MA[U>:#G<=E8*=G+K3K.O67H5T:Z"EXNY_<;SG/N#<2Z*(G_- 9Q[)P*>V\B1
MDUM'\>*XKN':G5 +? M+]DU+ T)UM8XP JZ')JS_<27YR^C\*W ^C_\W&E%D
M^1DCD*9A=#=QJ_4)+BC\8U;U:P8B+AKQF!W="'^,._C8:1A&OLB?-1CS.FRB
M=QEZ H' 4"+<&EY:6'ZT22"_NZI(P^R\W[+(:4G*WW^X,77#W<O9!?B@HT&:
ME"%MJNZ)QP@RM@_ )];J/]*N7C:1>UC1>NC;W+![6L\7EF:[N@&60FAHINMU
MO!X/73=\LO."_@JN\9GMB>UN1]]9K</R!,"&EF=X5N!I7<?CZ!4&&MAQH<9=
MU[&Z@15ZW?"I@/V2 G-]1:IZ]DQC1[<T5W<[JRI)W>B$C4Y8HPAH+S2[ 0\Z
MFA^X77"R[$#CIJMKO; 7.+S;"8W07U4=3[5[_S/\$-D7<<GCTTPJ#9&)8$7%
MJ,M(]R0M&!^-8D "$.0:\_.:E9U*;+$3JCO-F+I4/E.+12'6FB:7(F#G&!YB
M7WA>J)T1JZ@^;5N;VORG0V5F]]:B-=Z7P)ZVXH.!\+_1;BS@Q2P=91'6C'CI
M#?-$G%XC.>%#I#+F:+^R$.0]F(I1SB+L(@ R*U*61\-Q7/!$I.,\GK <Q$H>
M3NA-]4+JP4)E:8#:_95-"Z;'T$_&>#(IGX6@3M)K? _#F!'68>2/-4I7 "0V
M0Q&UDT0(B5&"Q0]]S;2)K4MU0^RD[LT4<#_0?&CPAR&&>W,WEFY_N'/12[8_
MV#RTO6ZOHSF>$>#Q(:"._="&7JRNK7NZXQC!4S71O[*H !!CL<TX494C^7P\
MVTO3V.- $070Y5,6^O<?W)YM[]VE:UZ*S!0X *AU>+!1;3?EV1@L.]OL*):9
MV46)FR>WC1X[^'S&3$MO0\.IR"\/Q'@:\79?!?&&'4>('K<U;@A=LWN.HX'_
MV-5<VPR#KA=TN&X]E7C/08/Y /?D\C<0F2 WX_=+N5-8L*$"QCS9&C;7#+-&
MN8U-OQ7=VF"A4\OW2;J> $0Y7D_SK9ZCV8!VH%HGU%RG%V AOV=[3_;7OV8"
M92Z>/D3G+J >ST[#$#SW=TO" !/-KP'E3BEL@&]F;GL[]R-HV?9]DK3I&:[)
M'0_KW85F6P&0-.>6YH5 MCKG0@1/+NN9(>GC/!^+;$/8CR)L"Y"$1U/>A[!5
MVWG"7OF!%^YW./#BT?IO:H-E5?RD =GJ& P2&<K- 6CV7T'LSKIKN]Y=&P*-
MSA,[L#O/%3Q\; 'Y;%##K((:+UN[\1R1.EG@?X'G=\I3-?P!\V.>YXNB<ZL$
M)?LAI'^Z]6[J?]X;;5UD'"&B#NN;#*'Q]JI*.S:$]8X)2U+4B3J=@626**T8
MT,/0.=R9*NOO5W+\VLN,O8!;?BAL<%#UCF8;C@N&O-G5G, '>[[GZU;WR5O-
MR^-^#=,CM?-P.ED:[P;C%]!_7J3^MQ8#ZXA=\7@LV(^  UTWV B/R1V\\FWD
M:R5TUI"$=<_K63J>8NDYCF;W;*$Y7E=H/2!@ESNZL/PG%YLHQ295VNKH=__@
MZ&)#FF^#-.LPP)"$%MUH\A3R_OU.2'^$_EQJAX$[>L+S@/_)?HY3C\?L-YY]
M$\5,^&)UZ?B[#Y=\&!%]GV#*<1)@X$0P;\)\2IW"-+^!-2%HB_U,7C/*&4Q0
M 'M>8FC\,DNOBP'&7T:8Z^0Y"T08)?*0*)G9T3L+#L><GHEIL6VD_]X>%?29
MX1YE><J78#@P<$9XS!16!LA@CNEIYCT/W)SK' ,\T_=KW;=?+IPUFXM]W@-F
M7X[2CI90S1W'/.-P2\*P76YY!G==D".]KF;;)FB]T PTW]9M+GJ6Y5DK.CBF
MG/O/-/4#.?.7C\"^;8(Y#F\1-BT0,0LE5S17C#$ N21BX1<@EY*4@I?C7% K
M6*8J^<"OOT04T)3?9D#<TECQ! >_CF!HI-8$I@U/,G$5Y?!>6'W>B/L^'AN%
MC?'C. '/@EP6>P3+(J?6-J\BIW7QU;X/3SR,@)[IY+FF_[WX*Q3K5/DTR*;V
MU*60KJ[&0]  ?1Y?\TF^)[_,<S^%?^=A[,]5(;7B8/]Q(8;, *.2'>&Y9U@(
ME3+.RBH =HA*/:*M2ON7F:"D2_NY2:L&JO^,\R(*)R\CA4X3-GMZ<(O-'B;*
MMI&'Y:8$?T_I!WD9[.TP,I/)*D+ )NQWS$-=9[*^H )ILY/%;:9]DD3Z16 J
M$,V?+U\.H.> _3R^O!3)0$3#FG'4PL<MM,\R ;#)H2..Z,Q+Z9,+<"8 T^-R
M4)'E+,9(4H"Q)?SL5X#&USZVS@2L8O%<X;5JABT8+.:%K*>#15=]8T70"$0$
MZ/&4I@\+;'1WJNY.%PO3-'LMO6.WNMV>#&?DS7?.Z5[C#5]&1G*,C)0+/2BU
MQRV!DCED5O&5VMH UJB" $ABC)W7FZD%1PE N$@S& SH,1R3HKGF&2JEF=EC
M2O.S;/ OU6"Z%.@-U >H!U!:3LNV.RT+[&8%A-FA&]VJOM@,<-H,G2-YD^&"
M/4%J"\0)XP5P_BQV1F!U4-3Q1Q.,\QJDD.)PP 7S?W#'ENNZU#41BE2[-$JK
MBFTJVLUIS.DLEO9*05+99I8>@-W'LI]Y_(L;D?F@WE5': E03_-HE)"LL"/;
M [X\^,VC $T3'*+.'_BX1HG QW&,[7]$[=FE69Q7L*6;'0F6>1BWIB#!97,6
M1#D9(>48C7$! MVV_K<V""R&P02T05J-J5QBIR*8?Q6(.1V1S:) 0SE=A(NE
MLP#4)@NS=$CO!>JD^D8?33%7H^<6D@4A<R$*8]PT.Z[W4JXP)_#XU:%F(.+&
M(\5WY>) G@&KF)T6H'<)N[197;Q;I7B? T!)$8'T&A4P@/W#<1Q+(BB!""P?
M8<E8#J9B@0:@+T10 U IW&#I:'> QQR,?5H;/EVXV-FUTG5*_GDY6C %G;@9
MB21'H5^2%A5"WU"[>,)^=(VV _0?Q]!7<^Y#/@&2\@5J^B0%%L&J-[4"*L0G
MT5DMI>(3A>\%4D#V7ZX9XP<X/5]I!?QP*24O*A1T) K6P+I8MXK\UVD]':'<
MG*<+\LEX,BMI41',2F-)03,-2[V3T.X\?&^).@2.&9.P&H_2I$&P8LG,@$3S
ML?<?H%$2)[4]!#Q 4 Y) 0'K$P?09SA0MXBLX%&I7(((O;XDD)P:H",:>>7'
M;V63?!1'174%S.T!MZD6P()8C%"=/9BCQYE' '@P6FA(Z!A8:BHVFC)M&="C
MO"F_9V4V 0MWV(#:&@J>$#@Y\WD^($E<@J\MA>,RGF\J%90IZ'4+FO"<W, F
MBS0; HZS 5@.,! ),NP$A!DJNR*6\J/J"'O!_4!J-\;B3F%L7K0D)5P"AE!6
MJDFE@'/*I\K^0'2F8[!9?#[.19]M1SMR0\DEZ+!+!-:==.>)!)PF# R Q$VO
M,22J; &UI.TBO90A5C+D(XG2*$9*RW?DXE#N,K?MNG\K)>R=XZ;C@J(/)&R'
M0Q%$4NA+73.WZCHV6DAEVY%:JZ1(&/\J)2H;I==RX!INIYNP\VD<]IE6OG0^
M,,Y]I@7/DZ=!A^>22$ R8=Z#8]H=EI?E@VB$K!4(Z&181K\Q')0%Q$VT3.P+
MG^>W*$N@S808;78<VISD9X*C!4+T"V93+' ?7-<@ ZQ<,\I'0"/P"HC)%@.A
M0WP3)014>02)08#=J-@WHF(;YCP@NE1%?I3YXZ'\4'>NQ!YGZ+]PU&%@VE'0
MD_ORS4K8TB$U\^Y<:4S6Y:^R%5OSVO56U? M0N&._PW)O$5Q5HM5H+Y!620M
M7-2_L*()26_)&:56(!D]X%>BG A>D6$P:5CLB_W3N@"07*-8?@F(]JIH;@MF
M<(T1DY:<U*PQL!3*F%;+A))G20Y]R6.JY54.DP)7&>>#%@5 H56['E+V4A;3
M3L4:S)K7K0<9GTG#UE+[IL1C@-Y8H)S5*;243T,B;%[S*^&(_L%"\$E'A=Q1
MA 611;G:\7!8;9<D-"X!TAH(IN^4^'M$YN]UKK3I8P9B*J-@5O!F-FD$)LD(
M5A$6)'))5<!=Q+?0+;R>U$Q?F7Q6+D&9^"%2HX,#*>B@>'1)2(*$49P# >,M
MX@K<MS),HG!!!(=?PMQ!]Y:K -.%*L])>D75Z3.UV\MW-ZHT.)D7R S(JLW
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M+ Y5*7H=W:IN)B/#3VWDS45M>RUAB:YG$$7&&-;B>!(N8 )R:<]!F[@T]E5
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M6#W->RV-I(;6.2$QC[^@IS4?"\K5?6+HDH++L=PVFNAV(N4!* +AB_(<J"A
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MS!Z&V'PA8>[$2<KPJ7(V\J_1S=Y!&Y*F;B)AC0!P>4,) % Y_:S(]\+[*#=
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MY'MV'], 9Z9E@''-G?#XT&32%[(GZ;82)5)[J%UI/B?*[Q)+41PILKGJ[L:
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M7FG,@YR)W.!'[0C,9U@47TDM+>?&&N-HID@JW0E8AYPRA5UM(T:++:.OJEE
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M!-SH37$; 5.6T*'QP*9^G[&NM?X:[SR&9JFCE(][;"\?\PMT'M12J:\E\T'
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M"/"V;1S@/7C;-=%FQ \LBO/>IJ(<,[@#R^ >WL<,[AME(L&_9Q1U_0UCZ^9
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M(2EBOJZ)Y2(01B/1#!S>*RA5X-9^A;PPVK66SC$"+T+NI;5'T=EAL9?$065
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MNYD>P23? RY?62G:!'^)>$RZ(5"$<S$WDVCNI?L=&N!X;U7<,92HDMZ$C>9
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M\[KPXS@$N( /(XL4_PJKA<E<C,[B;05971>MQCT<E4)!IA!PLM)R'?75)=F
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M)W;7_5PP9/E*AQX*M9)VPFQ5E,85C"2' G.?)P58WS"8&IS9-NK$\22=9U!
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M\",">3FT*NK,+")SS+VT,O04KWY6O6J\X!7.!(22V>"R_0U0K3Y^5,3;GWX
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MSKYI .\F4+)/6$9%B4!&5*12(?XPG!)]G9$!A9/!7V"APCU1-T1DZL+*2L)
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MKKI*=EV;?ELQN[J]FQ>W#Q"'LL2B ?RV6!;I?G (0>0Q=E#QJY7CJKPP##1
M>T0,ID91K9\*:&+ZTX[3>I=\WTCR?96[_6&OOG_4>&W$4.N@WFR4)2'_#^__
M>M^]?U;:'TZJ?VW_BZ%"/Y4H@?V4R6SL'VUR,H_J#7<ND:GP>'M!E3QDZ^CG
M?ZC+@01RTX>/>TMNP[HF?E;WS_>\)[*:;N%S73=& F9MHY^2@,. $)SR GR%
M@N[-++^]C2Z_LJ,/Y6)IYRV6''7BN:P!R[)PR%!#"7& VU\'F)HN\SHP),8M
M]CL;BR )FRPP :I0_XR^[EL] 1K-3</[W)EOU@\_'I9DYN4)<))W KCX&%=M
MV<&#E$ZAO'!=N(&'XTU.=YDV^CE'RU'C@@[LWA+.]D:S24FWY?2&PF42#.&Z
M@S6L>@HI>H=E3^,:?S)=8.:5\IJCWZ/X;AJ,;\@E%N'-'$IP(^#X&'2H&0?.
M"9[IPC-1!#NVM9QUU844^X.5',::):H(O>6\8@07'F;!H>/F(6G91W=X$<*\
MAY&2[X G5)2R@BGA.(._REAE&"W9L".! 4)BP>TKZFJDCL,"_$B55.6<B\R@
M2QY/P>C! U@MY>8S#V4S-F><R1L^D0]*O4>[!G:/94!N'V"-&S),8<I;"O?0
M-B?]]:6JWIW:9?--QGHO;);"$D1\GP;MR#F(8";VCP[7M$P_E@G8L5\_:GUL
M-?;V]UH'QP>MX[W#EP,[-JYHL![X1GX.P GY9W(">4%ZI^ZXN+A>&A^K2,'4
M$ZSSG24^'XK\8_8Q%>XW6 /%'YT('@ !]A*-US1@,B&!X)!<%+IY$=4L POS
MM$JVF>%B&D?R52B'W=TBZ7D1@9D53N"<_-  S(\UC,]E@9LX1JTJ(#JHC%5F
MHR.3(V3(ZD9@0>0=%<4:X/R5[*XW:(G)%/)Q_?CX+Z6MYO_B_Q'.EC.<!80G
M^S=;/)15(?\SFX"<*%AZ)L[,= D6L-&NC_6#CR^U7%Y_4"03OQ.;-74,5^MX
MY-!AD:Y9CBH?_MT^&FJJZ-_<]IJ&Q-[S0F)DG$LH9+,AF$URMYSKI5%/W]8Y
MHA^?<QXH"$[!: E:L(<'C0(LYO0[W##JSGC:A+.:@T'TZ$?F]>,O<KDRE9"B
M/A>=ZR?PLJ>-40Q%@T1YY AK0TDQ,48QQ"$K7L9USPU0V%<I0X\I'RT#D7K#
MK-XE&9:&A.KAHR<_"+N0!&  C9BBR:O\87%(Z34UB],%L3_ V$/?9EYC[\/?
M<;O)'_ZF&#")=X:Y(VH>; %SJ1K1@BPL1_)N5.ZKJ)&-_%_BC0(^Y$<1+ 2A
M19^E@:O\MVKL,@$:RGX,]Z8-H'8 \O8HKA:O,4H,5A0 9*TO'!E:EBAN6CFH
M>D8(FX!(DQ#&-V2\N4"409<"G+(DCF!09H1@?P!C4= !=TLR5HZ I_*$?-)2
M,J)-&FE!Q8L9.TW8J' +2N(NT^HL/$7,2@5[/]D'<!KBYE;+RN1A9UR;ZM8.
M_+$#?VQR9$V7_'7=[_(ZKX\X2N[H6L)K'0&8)_?J6!5GNDO%Y-R&6=U(I6QK
ME#T77?,"T2L* HSK?QZ,P@GJKZ'/:QD,#;:4]"=L%+)&3;--HL@%5;.DD"^Y
MT@KGS5S39%B%?RSN/\!5 %=*Y;"1+@C::M:&BY$)4PFB#=SJH0*;Q"*.YJ%\
M@O_(P'&:2GUJOT<+60 :F2R-YZ1 B-"J:GLPY)T/4V&],DMQ#DO/"*>"!;PU
MTH?G]L 25.U9.5?\>#5.=D/1\+,;BL87,IE2/4:D(:)2\7N$)O04K3O#_K9#
M^IE)1\M.OR6QC !^I_&F&K]&,8B2V%/!>_72><@'@;TWCFF?41[,\F0J#^G/
MN(+?KI=JC*R(A*DT'9MCA)<G5X82>Q:O=$%E45$S4,@*2TD#,%]QEZ?\/<K_
M@ ,\9W"]J#/2I4UAE"Z2I2"/8,U/LQ%BF$/6 )54K303M$@,YE;ZF40$Y</O
M<#I%Q]."GBOF.$?,"BD##?5?L[><4LRS$C7SFSCCC&]E<- ^BR.N/)5DS=@D
M[VPJZ;E4CL3HLS,3A_5&<T/Z,JWZGA(X?OW,1*.^M]?X>'2\?[S?V&L>-IIK
MH 78N$[A.@!8MDEA) F00R()17W7(^\JWXYQ, $O.L#.5K9*VY3[R;8,$P$[
M;J4\%&U.0@U0R'EMEB"RL PIM:NV#'4.DHQSKLGM51AEV3/>0=JY]2;3SI>Q
M=RX$G6$U<7!SNU5&2F :VI.!5PLJ*X6 @J]&8HDK%JTBLY?B3-,P6$J[S7B1
M. V,R*VV+PR3U8U./00KUUK&,:*\QF !WJG:*# V);&->)I+6<Q?G_N6I2
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MR$-\(.7YT"E;*5LYO"&F";8-!TT9>BNZ*YT<,J'!%]0FBULCJ1_YH5Y1=F7
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ME/X(",X2PV#Q(*JD8,6TU6&28>3:)R<?4P(]7O%PM%2RMG'D,:.G,$KTU)&
MKG(-.RIB$X1TQ " .XB!M<J%!]L$XL/JSB+[@W'_S6YO]X5Q_^UGR?V+7%Y)
MSVME\^<FGFX,5S$*B?U1" ,>=2NTUW)?@:*:.3(T$Q3*%[@*,4'/5T'5KHH
MW70,SR 4'@V;,.&[Q5>1HOIXF8K.<IOW*>+;N0'[@>_OPE\1UU;WV)J<'D;N
M?X<)MD(B%.VN]V4AX^I)E$^=+4SU:Y@8&<-J7QFHB44U<@1%,&:(R<W"E(S5
MGY=FVM*=6@TW%.D&GV@0D(2@^/:QDL3JSE*6Z/U#_J)]H%*^53!1\A$AI+;G
M6;,M=@7R'D@UE.E1TRE*:&['E%)$$O0-(Z!X>Y5$@;S3'Z.92RD4Y+JUAB8%
M*S-^'22D^T&&*SAJRFIK),]=#;]ZC==[#9=LT/(_J8"T?G&C;IFL:ZXXJ93_
MD=++8,H13,;7IFE0$!>"O6!%VD$:F!7'-O/+;QBB5J$8WE(4@!58$( ;43S.
MAA11>(DVN+S:2 ?R/<CO"Q%G@OBR/6REN8:94;>!A0.OC;P H?=@ M"U%@+2
M@D1FV'E>4$VNTT@D596*".L?.),9_ZRD#4M?D)&JKBHMHQQ]TOY9,<8?:]2)
M)H3/-X,O=+<:'=9\RP#)AS/V]@KA4L]?W=MYENJ>QL?#ZWZ\;)1U]V93Q$TH
M)KW=[O;^[HOT*.YV]W?V=GN[!V]V#F".NSC-'W4P^L_ P=BWU&\8=EE?4FJ#
M-)^1XBRUC#)7E)HZ=!A3H+V"V;4@+GN;]\#\J["'W\:Q]J3G^<4?Y]$S.,X7
M1GR=^ZN:E)K12@F<$KS!128P;[$8IBWL9++Q\]P?SPB0VSO'/\B;0O(@M-14
MQX7F2R<TI088;#IL>A2Y=!W".H)03!X$5BT4OH5T7J!QHK QZ'60&VD,)QHO
MFO*M-#P%0I21.]"8.LEIP@T1%F]&.A(+]H0B#D>A05NH3I7>RO6BBG:U5]&Z
M<XY2HZ.<"$^#%3Q2EA0QM^R[5)R&,J?8#VK?0NU/ZGHP]S%[:BRM<67<JLXA
M+T(]9B:,&B_O&$]"%!D]L&IHG-AL'/C7&P)QOQTSL&L>C'6IIJ(;EXV!/X;P
M^=!A/A8ZBXQW43[ #JFI!3ND8W<WE0WXY2E;(K&4P@A3]_S,K+EU]U1#6)EH
M"A.;=0KIA'IA:2L<<VLI6$ ?&U;LZQ;?\R_],"*Q9L)@HMR#?EV)*U,X:S&+
M)^P8]2*140HA<P=_CCF1L&N^S,YAY)BQ<C@V4'M_54OO+ 7M/DNU]-BBE$U!
MV6^:/KK[X@7XYZ"/DNO5I$]7(3J[%E0,8EH@O&T+L61!E(A!B+A$8R^BJ*6*
M/B,#:FVW/2N./+,43$>H:G<,^!@*,2+3]G(5&3(&N2;,62KUI\#>,(K*XC&F
M,HSC";:"9TQZN2E7XT2@N1*O$YEB&<:Y3A"#" IA?ACY$?%F%'J1+9'$BSS]
M6"R2+,P3( 9.D*S7:J#:<GQQU !5!8]/LIS.:*GE^GE?84&#U+\"89%=&P:,
M50(FV$B*!3>(3'Y@-+]PX>><1<  $HA^V%\"52)!P@K'TXU\3A,0C^96^[)@
MU9A2%3 HT!:^1\)'),%(0-\4W>Q35*3&5B 9*M:.$)]+/3K^&: ,?HX9#RO"
M@(A)TH63E89" Q?X09"B1(3PS0LQQOI9@9I4033'D 9KR!W;E"3?*/F .+!;
MQY%41+WI,#;G3G1T0-CC7<^NI01UE#TMQBP4.!X+1N6&;SG-A)J3!8T:&MO!
M0.)-N'I98A!2B\ <L L2LJ.D4)6B'1+6 T=BG,Q9+YOIT$(9+:D -XKZ05;2
M+SD>-TRE:Y22<OD1!M"L:@6+\1'3,*:*(C$':J?I=6(5.X&VBZJN<]\M-;2B
MZZJ8SEL%)KY*7W\X\^EPHJX8I9RITP8R&-R/UG8:. )4G?SDBFD34*\SQP9D
MGWZ7$2 ,%+OK"Q'U0;W^[OH<]/,VK;XG(:,=#Y XD)'HD,P!M#D/L-3*'[)K
MB>5KL P G=$;)(7:FTB3AM"NW9(J/MJP (*F1C:]!I8U8?D=GO?$_*VYW,$I
MK$J6\8ED 5P4IHY+Q(&+<*:*Y%8+7 X6G#+'8G0V >I3<KG$2[*1J54*]14P
MH?8U\KUB0AB3#50]FZCWT:"<^<:Y;6>>E&S+)>J&H=VDR!&4(<JD&N;;U>-;
MC93WWRU7&\,FR/L6DGLAM! -&.$M+#E%SJ4,.-I.-$MBJ2&:T,C;BB<(YV=+
MWHZX4BGV<P8"RMZS0LM\GJ770%<2Q0<0R2 S^0AX!HNSXEK$VEG!%1*LDI:C
M-/D&FOQ44$4G-DMH/U/;U%*HOB>9<6%I?9R/B/)YD-LF6')8:*O?OIU^7=-H
MA[PJ,.%WW$YUQ0)?6@"*C29Q60)MMJ_E216K[1>O6(V?@6)UH6XV?D:+D,0Z
MD0 @7"Y>)V49W6#4KH$ML,.ZL?Q(*92ZK"45XQ\*G9*B1W7=5'%50T[PMRB$
M,:O:$Y6173T%;$N()RHW$[M9QKJLJ!^5+2?D7-9\/(SEWR5KCT!(X+'QYG-J
MZI5/$V:H54K*I.FIN'4L*(+1;<K-[!3G1=./LJO@4[H&B#_U$=7%+JLGS7H&
MEJ4\'%W$*$\F$XQP(93<<>2'\P[UM5Q@ZQUK,<G28^IZZ#90M@=^PG'D8HIG
MA;\IR"?\-&>GJH'R7%SV9K-4^=)EF$2FJHWLQ?IR0F?SQOZD+%BQI_S4.$S'
MRWG&L0*49# G\[&6UW@UF']:@R[4;2EQSRKT93M6P[T!3M:C>\'B!$6+J:R]
M+6V'/*9*B<(*\^!;IV:*F?]!Z,044&D@.Q;!SQ7D#V;]_[[D2D;RHK&8DRQS
MZX"@B3@08YGD(2WK8Z0AA(]-3AZ&-P[C?U$%HDNJ>A2*2>DB5)(2U/^7J0Z^
MC'1TW'6R3C6#7Y:]=Q;J0E9MG2D2GO5E39?UM.<?L+#W+ ,6CN!\35$7O*#4
M7*YZ2/D_:TV<UE@NQ? SYZ:0@>S6%Z0JV'J.5=X4*1C36A3HGZKNQ(S?RDK&
M9.9.$=5H(BS4841N"QAB#)[%[U5J50LT#\GQB=-9>>"Y/U]XP1+]D.V*/#*;
M[C+^D;4@'96:)M5FO:6R7ZN6U<(/B^@@;QM5]YK$B$ $ZSN%G4:MQRRY$I?K
M!$+IF+S%RM0ZVQ&^\#F]#H\]"R(<R ??TREWSS4]J>Y1&%\FT:717(M9A/AP
MB0@49'"I=*M4()+)I0.;+J8,5?$+T282<$B7G%8IW=URY"T73  :DX4JH-%@
ME^"LH0'V[IOY^RGE*R$<(KR[C*AW=([*PM!.)KI;FB*U;%V%N;J$;NV,?>O%
M!2*^>99\_4S H,821TN+Z&MEZ46P$2IO&5()3M#3DHRK)$:"M*0 0V:2%8-S
M%RF.YL6<_LRH5Q+6(;00PZ3BK3%#)3,/^-(X<>E*5V5U 63Z)1.;B@8*(=AV
MH+I59UWA<BD#O(P=$#(H&\C@RAC&,4BLJ#I*_@X+PY;Z2:[792DKW1@,1+3%
M$]@:3M^77U'P#QQMV)AT)0$79=](@@,QCPDVE2:9"OASE,2,F"&-N24$L:[7
M9UD%R2K732VGB/.8+&54R1U^E$D@G!5K3*R)2I5.#PU(OJQR*>VZ:3(6P=(V
M\U:_2(Z1#0SV AX!!RI3$1EVLCDJ5^,TQ-B,83'/(,RLF1<HM:^.:P7PB&5-
M=]B$TN]HN/JT&R" 0D84=JCM-SA0F+8H/5=EFS*FJ=P%&ZAG!:\>R5>'<(.6
M_['L#'LO3!S9?Z;B2";2RV*2_OI3(QQL%;10Q\392&8/<\)8(4LB$G/VG<%0
M(E&29))ECJR.38LI39;%CV]"+"PK)9H9I,YAHMFQLASR*@-=CE+$,I82C:[4
M1R;<92R;#PI@R1F(3M&J"I11('>DP.?<\(EKU8@*&$AILU5J^0VY7K2 A"+K
M -O2&E@F'<:752D I>[1!II:0+D3M,UR=3KX:[Y@"RQ#\#CV<MQAF#"Y@)3K
M5CTWD7'"F:L,:L[=RGV)-8\.#1F*Q6'7>#$9<I:%*1W5[6#0'K2O/59XE JK
ME27UJR.]\K1(H6T5HTV6F'OJ2!D[DO;2LENW)BO7M@9W*(H7DX.Q]4NXS@'^
MK0]EQ[/.(];46[$1"3_&2;SA9YG("+; G3[A%,&:"IHY)W+P0F&!>[8+6#)Q
M+- G[[- C-#!J?1E<"'Z:FN?;$8-,-/'5!U;9>)SG"X%TYOT%ACID[0!^5P1
M<)B]3Y4EQWR=4E"J[$B[6%-Z3.4Z4IT&=PDGRU0>ZRH"A088X\_@D $, KI*
MT?49:V==(;.&MT3[V=B[&8]Q*X0\7"D>@Z7V+SC#M;$E;J2):_4TO#0)X.!9
M2@!'(D5,:J]OJ.BZ^7Z!1A(AJPU^UFCHUS+*IL)2G-3,JP&1:"0F6.$1ALU6
MX-7XA9 (!XWNX.[9%A4Q0=O=W=[3!Z,^Q0;0S/:W#W;V-[?>;&UN[3V'5-?'
MS0T@5G8<DFTN8+'N' 2"]=*FH1./T;D;J^UXK;"-@B$:DS*:7R#GAQ%\J&BX
MH;HD262V:Z9:R.IPM6^XJ=Q>QJ&=IN<ZX8P%:1"OTBF0H)MB%SNRO/4XF8]@
ME^_:2S;'^)J;NT%!K15>MEEFS!@M@ZJ8LV-)BHCFY;&_0 XGEY3DID %6M7V
M4=A(,A(J"ZVVW++)KH[Q&%?U,LI#.)L2O!*(HUW2&^8+"D/. JM=AD"6G;UY
M/:PE#N<87@,B;+2RX\XYVUOI'G"B$@JF>O@^1P((O+ Z[7I]6G#-&<AO;\>V
MP-:A*P#/?@G<1(^*4A)-?<_R-%6D6AIP0J!2IA6^D3D7.'Y.;+325JT\21J[
MN7BI4_Z@8ZG1TJ\KO:OA1$&AFT%8Z#HC@17?PN^J"HS3B<QUME0SJ5?S5.@M
M\FA.$@G5<O.APW%0N:= ZH]4Y,5*U=3I:Z-EAM<U\U0DOCT%>69 M]#+?'/?
MO-VE&"9G9\U &,YNHNI$6)JQLTI9Z2A5GB(\1JFD1#]XGLSO*L>4-5FFHYF,
M"F1RYSL%YQL2V+S7)!GF62:,/JH,\SE-O#,_]T&,,13F.<LOFE)R@B,1/TEI
MBPP$Z7.<D(4CQ *3TBVJBQ0PSPDI!"00(R F2**D)&.9<%9>RS(&^FZMFF*G
M%,AL/*/LIJ.J!(I M)408VR35RH6A1 -1NR!I/';6%CND$Q8N-U_NZ-E%TIV
M<0R?:(3+R3'L>($;J)':I[4!6FC'<PY 21;TK61;K6^VQFTV(,IDN@KASDFR
M,QBOEL1@L$F$+FIX7%$KB5'U.*^AB"!_E2RC@$4$JSG)<Z'1T ESFOEH%XV"
MVPEI_A@MG\;VH= DKS&"*%LD(Z"HQ  [KZ$<L]0QP=F5L=DX5E,&S0KKKTF1
M ,W40$R694LM%VG1U5<2"\P$;:.QR;\^=F0WE)Y@0>/$D7/46QW3- LGQMPK
MGZPC9GZJ0EDL.$WMSC$(-@D=LU>O_JM7_]DL_\.G>=]:*%V_C;QN[4JDY8?8
M\T/;Z[W7 .SF!6 [R8T%(: J;\H5+73-,T>\8-E!QKF%CBL<\Z.%SDN\'_>M
M"XV34>-WE81DDC\M0"O1Z&0C$0N0U;#&IE,K%:?L,EDWJ.^F/MK&U6XP<,LO
M:<&.Q"I<ZI%8D:M=\6\>8#'@?$G%<QC4(<2\QA #184I#ZI37]2P#%H"?52C
MXDW$-7VTC5QGJG>C<KU539R7;!)Y]%3O1S6)O(?6_#EG7ET8[)(U&T7N: @A
M.X8='LR&Q(R:F MRILA4["0*@\I47@KT(2I).IB;3!P60E$6G.9&5(04SF5Z
MR2DG#*0HS29U0R),EU(W1(2Y](E;FE-FJE'@&QHM*$LGB441;,8'RI2&K)>F
M@N.GK4<R96JQS;BTR*I4Z837R43HT#>MJYF@818J9),UQ9Y NV,K;*X72/8A
M%6<G;W?.2J8?>[N;?U+;<IGD7+WRR@#>N"T6]J]8RTPII(6L\,P*8^I(P/A,
MLA4>(B&NLTF\P[8CNUD\0\OYG#%-Y4B,30HQY54]=NY8V_HMJ[5EKJI+K@8N
MDD[]./RW_ ;T89Z\_B9;P/V!#:*)CF="FO3Q>DQI#&V%J."<L2OD4*-5>6VD
M\0*F9?8#)_XC>X*YF["^.C&4E]DZM,Z]<AQ%A99LLX3&;2HUIZJY=ZK+VY)9
M"&1U*0E(5*?BK*A5N2;5;@JK2_9]7-9?]2I/:2E 3"X/^8^B##-<&%9&7T3[
MQM;$Q&$,J'*?1'1.01C**<L'7K)N-1M*>.M-6%Y'6TAQ@41:M/,6$SSJ?3+7
MV,<L<[ Q#(+4Y(_@A[:$TUK9%L%&VF-K>&8C3+.D09@"%;24->,M*QJZ+(E6
MBZ2/MG-]+%?'7"^)'47QW&', +;7'3*LYYG;1EGRVU:YB77L<S(>4WEM*[.[
M;H;AA) N_(":[5Q#1FI:X)D96-YKW;$MJ4F,9340XR(-Y1GO4)CN7 :8X[B8
MZ2CP.IH>,MV$3<_,G_#7"B"O=F-#Z/H1D$I$1X;K;[F;&G!!*BK$DA"G2_RL
MZL_2'65 E5I=LQC2AH]>?!,;36JXPY67<<2X:^WK&\M44@/=L*(P) U4F0%9
M"S%&QH]%LLST"<)7J3=USW4YI:+;PN9'5A$]@EJ2T0!M<\%00K'Z4QF-=%64
M."7I$9M!)!/ Z':#T*A]I%4+[:R9Y0VDR4OQC /468!VQ8NV2KK$R\D4\#8X
M?'0GZW;$SSIUJ03H59DF)'3H.D..\TO&MU=008M,T(QMR"VKZ+!3#_FZ8D8>
M^N5X\K!%8>2G$0?ZKY3W%7,\8P?7$@4;/TJF>'1(%JCE+ZN%Z"*Z/LY<ZVK.
M"N@Z=APP1<TUS%W3\+*^=8M/@KZ^8^9<JN!%1)^O\:[1"Y@2+$D**7/9K&-]
M_D1HI]2050R"=-""**CI4>4KVN09KM'B4*R,_.J9>G4,KGOYU[0(.A"_J>3.
MA:62^6.@6T<4KV"5UC#E@1GI F,]&=WF9G'G6O&F.HA1"SM(ZJR<2JVU.)+.
M#7I+,_P'M_)0OY8NOJ_?('C6?@,W(6R=WH+S"M7"=^.6I=A>J[A7W?<#>J60
M]Z:=ERK[D^/5A?I@C(M$%5!B8M^SE1I@C\O);2_TI00U4_13*6\UG=\<)FZL
M--GU?6-L'FO$]183,X_;R/BZ A[J-A4K:P>Q,YV].:]6AQ'24)M7/VCGQ=,P
M\:QIV)$?C15ZTCHI6!]NY]@:BZW)&W+D G%*DA8+O.&(HR4V9O!:*@)T8T[(
M/3B6GBC[P2M0^B3&?L$;UKUCWOF:2I$\Q0;M=/=__&Y,GO7=D.7*X20U) O]
M2[7YGT+(:U*4W ODHN,1)D2F468U>@T^H] @:NJLZJH=,M^KR Z)WTV3)$ 4
MZWQ6:P9D1)$2?@RAN(D%X=4[A3XRD9.GDD./*CK51D^/"GX[<">*MU8D\NO?
M5'Q[2I:["D&BPF]XZVQ_A]:T.XC.AXD=2EIP[(M3-N^FLLAL8:J<>YS-V,,%
MBQN(W \C%CI\=+Q:V"%%D2O$,K09HH;0@2ILM7M&"#%$[[:R :.%:['29Z^(
M+%RLU1('!0.V53#% 41NFORR]0>(W9J^$!I]E*0+[ +$ZLMU$VJ,WKI%ZIH3
M)Q*V48^)N#R1DPML\K6*B6;2).U8G_E)[5QVL9.+^?P6R:P)PX&^ISAX0AV>
MW"M%[=KX&!T6,\I"4+)2%3>FD:38I+Y #P[:R@56[LA4B-K*BC>B#9@O(J[:
MC ZW!$@MSMB*JI$MP6A40$Z=\T G]%HCX5B9: D/IRO<#:JE0@L5A;\O=5@=
MK$[(6N!RH=G/!%AA*:J'C?\=3T8)J83NF(^U<G3)LY4I]V!5'5TTKA'P+$K'
ML$88W(Q 6XOE")8!%HS*4AB'ONL KJNR%>O[58HTPHH9 HMB(_-H]3;A_"*,
MA%-2SL++4M5\TU**<ZQ3JE2 %H<G"UD@&,92!&^ 9F3MF4(4.#1_F>2B5&&C
M./JWM3GUS$)UZ0T'DU6M!I^<0)!Y0&7-&4^Z/U$_,# :.6AEK)BF4G(5W8+@
M2B1@>ZW5)]"46$-(4.#W'>G+VN^3::X8_30NIE/6-<$ZH1-28@/I44//ZCK5
M3?0V5\N4M*Z-ULBL4,U@?:!JNT4KT/,'5>MM/D]4->7N42K0.H6DHL$4;@_7
M>\*'?$IGE915GGC\/B4)P:%Z:$TE#'7'W97/TF0YG5WGZ^IJ9]<76V^KAY!W
M;W,^NP;1E*M(6E'D#OPC\8<"5(DB8]LMO]TZ:"N&8846],<$K6JE^_J9C'/,
M#E^!NU\]^8U=_L5M=7=8F*W]WE/',NUN=W=Z3?'N_\W['^\W[^^M_L:[]D_]
M?W 0TV&#O.%WV<S>UOYC;N9^MU?<2P1D/%B?A:8JYG;\]F^:TU!!X>QZWN$4
M*'%XSEO-S'ZK:I&K#]>V6]2)5"BOJT&01W$D*+94<=,G2#5_G..W^:C'K^EQ
MD>JP]*L.2T4UYX7*3BN#C2B[10,C%-=_#M#/W>1S8)5D=T#^W, &A4OE1"9@
MU>ZWJ#@_5PK0VWGL6,'BSN]T]][L-63G%05X5T4!BL$VQ>K4A>"2QE5TOU7,
M,MH:#AYSNYMTT=^SZ1TK>1#!/EL";>_M[) ';QE-R?:F(BN*NF4'\[%",@5B
M0E;0X2>S'-VXY"0=?XN3JT@$4]*OI:VT OG<LE[>)M34-BI76.),2IQ,SPW<
MVM<F'T151X23'"8&#*LN%*S0Q1@8'KK48>(VD73DHRMDA+#O8:R+E$ ++5T_
MPJYY.8=?E>$SC)<LV%$9!0KK NXK,WY4M8H<E$WMH64'CG+'*[A2B37""]AN
MY.6SB;)MZ+-H\B-3Y.U&W]&A%0C(Q4YFUX#CC3CF(>(KA7=HG9O^]/6X7EIY
M4)C2<S0<?W3!&!M@/KY;G$@%(>KM=+?V]Q[HF+YI4I3(5G=_]\UN;W-K<W?[
M8'OW8'/OQZ-$'KUPP\/$@E0[% K^@Y*#H<KB7\B(KD_[5\+'37!EN@6'OG-1
MU.O<".C*S*3Z#=) _:,3B5 @(\?DX U F?)N8*1)94B[S8@ZCH"%3E]=YYIC
MSTQ0RF=9'^UJAMCN==!JCCF!'?PC*_H^,#&!17RZ24&HU=E(VZU NTD&RM-"
M@JP9!*9J7E&ZKA7I?R.([10E,>6//N@>'/RIL3@#G_SOX7PYQUW 6&=_ND:B
MK"$&[CD$1&O!/#9),[,E2,#6N-YTM]_\J.3R](NB"@X4;+-VM<:;RY54 '51
M];:*VH/XNTL:.AJ.P+[V!B#%O?.RDDI0"77DXC380RI>N:*61C-]7G3$-%]!
M#W0\3\UJ2<"RZQ>-#"SV]A=0:S3/N-N&<]$*"X+2CVWVX^>5*)ZZ7*2ABP7V
M([PRM;$RJVB1R"D=8Z(IU85,L.3CB.MZ)EVO:*!P62G',9-S6QDBS86Y^9:4
M\"-2RM2/[]P03B$5( "-&3S*:WUWT*W,F9HG64ZX%+#V,+>YU]O<^%^\;NK#
M7S4V)R'B,*I%QX,K8!]5RUI0CO%1B""M51NKBB,RF>Q1QB+Y<0P'8<Q16V6
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MS\*G4N:& CZ5K"9(N?/&07'K;-7"V+1J/)(U0A.9/Q_+DI,4"4'IMWG1;%(
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MSRUG.D<RR4BD"_YF*7@AC9UG^,%D$(FQ0#UI"P-$&K S?+D%#C.T"T8QR2G
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M>Z<C"F4#-E9@4-0ZAW\6\?;^_CZC7D<6"3A^/!%6X<PIEI^H+OBX%J^2>"W
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MV@!%!>2:4/]B*/[6QROKBSO.<S-JXO!W:0\.ML+P<HC(DRFB/V&'36(%4+
MQ;D5)I8)=E7Q%%!Y;"P(L$<AJJRBS1U=,E56^;+EX&<7@TM?7034NK+"W:7.
MJ5C(>KFQ(=519[O87":\=0B?*X"@NJIF\?+"RW/$>PX?+-%Y@I.RX/<8>9-@
MF:>!TD6IJ_UX*F>WO,7X:J/-+?_,Z<?4PLOJ!ROL5&]4HJ4XIO");[N1O"L3
M;XZA\:F9)3H9JQ]"8CFLI'TB.0(PSM-&_&XO@YCV71T3?ZXH?ZXH[]R*\G"+
M?NG\^)?#+?Z-]/\ 4$L! A0#%     @ 1(0X6/'5U>: (0  HOP  !$
M         ( !     &%C970M,C R-# Q,C(N:'1M4$L! A0#%     @ 1(0X
M6(_>>F*G"   S&$  !$              ( !KR$  &%C970M,C R-# Q,C(N
M>'-D4$L! A0#%     @ 1(0X6&"4 <R4/P$ \=X)  X              ( !
MA2H  &%C970M97@Q7S$N:'1M4$L! A0#%     @ 1(0X6$4AZ48?/@  !L !
M  X              ( !16H! &%C970M97@T7S$N:'1M4$L! A0#%     @
M1(0X6".$H96N"@  &4D   X              ( !D*@! &%C970M97@U7S$N
M:'1M4$L! A0#%     @ 1(0X6#J\W<BI"0  MB,   \              ( !
M:K,! &%C970M97@Y.5\Q+FAT;5!+ 0(4 Q0    ( $2$.%CN7]J*/PH  "HM
M   /              "  4"] 0!A8V5T+65X.3E?,BYH=&U02P4&      <
,!P"L 0  K,<!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
